1	Production	production	NN	_	0	ROOT
2	and	and	CC	_	1	COORD
3	characterization	characterization	NN	_	2	CONJ
4	of	of	IN	_	1	NMOD
5	murine	murine	JJ	_	6	NMOD
6	models	model	NNS	_	4	PMOD
7	of	of	IN	_	6	NMOD
8	classic	classic	JJ	_	14	NMOD
9	and	and	CC	_	8	COORD
10	intermediate	intermediate	JJ	_	9	CONJ
11	maple	maple	NN	_	12	NMOD
12	syrup	syrup	NN	_	14	NMOD
13	urine	urine	NN	_	14	NMOD
14	disease	disease	NN	_	7	PMOD

1	Abstract	abstract	NN	_	0	ROOT

1	Background	background	NN	_	0	ROOT

1	Maple	maple	NN	_	2	NMOD
2	Syrup	syrup	NN	_	4	NMOD
3	Urine	urine	NN	_	4	NMOD
4	Disease	disease	NN	_	6	NMOD
5	(	(	-LRB-	_	6	P
6	MSUD	msud	NN	_	8	SBJ
7	)	)	-RRB-	_	8	P
8	is	be	VBZ	_	0	ROOT
9	an	an	DT	_	11	NMOD
10	inborn	inborn	JJ	_	11	NMOD
11	error	error	NN	_	8	PRD
12	of	of	IN	_	11	NMOD
13	metabolism	metabolism	NN	_	12	PMOD
14	caused	cause	VBN	_	11	NMOD
15	by	by	IN	_	14	LGS
16	a	a	DT	_	17	NMOD
17	deficiency	deficiency	NN	_	15	PMOD
18	of	of	IN	_	17	NMOD
19	branched	branch	VBN	_	21	NMOD
20	-	-	HYPH	_	19	P
21	chain	chain	NN	_	24	NMOD
22	keto	keto	NN	_	23	NMOD
23	acid	acid	NN	_	24	NMOD
24	dehydrogenase	dehydrogenase	NN	_	18	PMOD
25	.	.	.	_	8	P

1	MSUD	msud	NN	_	2	SBJ
2	has	have	VBZ	_	0	ROOT
3	several	several	JJ	_	5	NMOD
4	clinical	clinical	JJ	_	5	NMOD
5	phenotypes	phenotype	NNS	_	2	OBJ
6	depending	depend	VBG	_	2	ADV
7	on	on	IN	_	6	PMOD
8	the	the	DT	_	9	NMOD
9	degree	degree	NN	_	7	PMOD
10	of	of	IN	_	9	NMOD
11	enzyme	enzyme	NN	_	12	NMOD
12	deficiency	deficiency	NN	_	10	PMOD
13	.	.	.	_	2	P

1	Current	current	JJ	_	2	NMOD
2	treatments	treatment	NNS	_	3	SBJ
3	are	be	VBP	_	0	ROOT
4	not	not	RB	_	3	ADV
5	satisfactory	satisfactory	JJ	_	3	PRD
6	and	and	CC	_	3	COORD
7	require	require	VBP	_	6	CONJ
8	new	new	JJ	_	9	NMOD
9	approaches	approach	NNS	_	7	OBJ
10	to	to	TO	_	7	PRP
11	combat	combat	VB	_	10	IM
12	this	this	DT	_	13	NMOD
13	disease	disease	NN	_	11	OBJ
14	.	.	.	_	3	P

1	A	a	DT	_	3	NMOD
2	major	major	JJ	_	3	NMOD
3	hurdle	hurdle	NN	_	8	SBJ
4	in	in	IN	_	3	NMOD
5	developing	develop	VBG	_	4	PMOD
6	new	new	JJ	_	7	NMOD
7	treatments	treatment	NNS	_	5	OBJ
8	has	have	VBZ	_	0	ROOT
9	been	be	VBN	_	8	VC
10	the	the	DT	_	11	NMOD
11	lack	lack	NN	_	9	PRD
12	of	of	IN	_	11	NMOD
13	a	a	DT	_	16	NMOD
14	suitable	suitable	JJ	_	16	NMOD
15	animal	animal	NN	_	16	NMOD
16	model	model	NN	_	12	PMOD
17	.	.	.	_	8	P

1	Methods	method	NNS	_	0	ROOT

1	To	to	TO	_	11	PRP
2	create	create	VB	_	1	IM
3	a	a	DT	_	5	NMOD
4	murine	murine	JJ	_	5	NMOD
5	model	model	NN	_	2	OBJ
6	of	of	IN	_	5	NMOD
7	classic	classic	JJ	_	8	NMOD
8	MSUD	msud	NN	_	6	PMOD
9	,	,	,	_	11	P
10	we	we	PRP	_	11	SBJ
11	used	use	VBD	_	0	ROOT
12	gene	gene	NN	_	13	NMOD
13	targeting	targeting	NN	_	11	OBJ
14	and	and	CC	_	13	COORD
15	embryonic	embryonic	JJ	_	17	NMOD
16	stem	stem	NN	_	17	NMOD
17	cell	cell	NN	_	18	NMOD
18	technologies	technology	NNS	_	14	CONJ
19	to	to	TO	_	11	PRP
20	create	create	VB	_	19	IM
21	a	a	DT	_	23	NMOD
22	mouse	mouse	NN	_	23	NMOD
23	line	line	NN	_	20	OBJ
24	that	that	WDT	_	25	SBJ
25	lacked	lack	VBD	_	23	NMOD
26	a	a	DT	_	30	NMOD
27	functional	functional	JJ	_	30	NMOD
28	E2	e0	NN	_	30	NMOD
29	subunit	subunit	NN	_	30	NMOD
30	gene	gene	NN	_	25	OBJ
31	of	of	IN	_	30	NMOD
32	branched	branch	VBN	_	34	NMOD
33	-	-	HYPH	_	32	P
34	chain	chain	NN	_	37	NMOD
35	keto	keto	NN	_	36	NMOD
36	acid	acid	NN	_	37	NMOD
37	dehydrogenase	dehydrogenase	NN	_	31	PMOD
38	.	.	.	_	11	P

1	To	to	TO	_	11	PRP
2	create	create	VB	_	1	IM
3	a	a	DT	_	5	NMOD
4	murine	murine	JJ	_	5	NMOD
5	model	model	NN	_	2	OBJ
6	of	of	IN	_	5	NMOD
7	intermediate	intermediate	JJ	_	8	NMOD
8	MSUD	msud	NN	_	6	PMOD
9	,	,	,	_	11	P
10	we	we	PRP	_	11	SBJ
11	used	use	VBD	_	0	ROOT
12	transgenic	transgenic	JJ	_	13	NMOD
13	technology	technology	NN	_	11	OBJ
14	to	to	TO	_	11	PRP
15	express	express	VB	_	14	IM
16	a	a	DT	_	19	NMOD
17	human	human	JJ	_	19	NMOD
18	E2	e0	NN	_	19	NMOD
19	cDNA	cdna	NN	_	15	OBJ
20	on	on	IN	_	19	NMOD
21	the	the	DT	_	23	NMOD
22	knockout	knockout	NN	_	23	NMOD
23	background	background	NN	_	20	PMOD
24	.	.	.	_	11	P

1	Mice	mouse	NNS	_	5	SBJ
2	of	of	IN	_	1	NMOD
3	both	both	DT	_	4	NMOD
4	models	model	NNS	_	2	PMOD
5	were	be	VBD	_	0	ROOT
6	characterized	characterize	VBN	_	5	VC
7	at	at	IN	_	6	ADV
8	the	the	DT	_	16	NMOD
9	molecular	molecular	JJ	_	16	NMOD
10	,	,	,	_	9	P
11	biochemical	biochemical	JJ	_	9	CONJ
12	,	,	,	_	11	P
13	and	and	CC	_	11	COORD
14	whole	whole	JJ	_	15	NMOD
15	animal	animal	NN	_	13	CONJ
16	levels	level	NNS	_	7	PMOD
17	.	.	.	_	5	P

1	Results	result	NNS	_	0	ROOT

1	By	by	IN	_	16	MNR
2	disrupting	disrupt	VBG	_	1	PMOD
3	the	the	DT	_	6	NMOD
4	E2	e0	NN	_	6	NMOD
5	subunit	subunit	NN	_	6	NMOD
6	gene	gene	NN	_	2	OBJ
7	of	of	IN	_	6	NMOD
8	branched	branch	VBN	_	10	NMOD
9	-	-	HYPH	_	8	P
10	chain	chain	NN	_	13	NMOD
11	keto	keto	NN	_	12	NMOD
12	acid	acid	NN	_	13	NMOD
13	dehydrogenase	dehydrogenase	NN	_	7	PMOD
14	,	,	,	_	16	P
15	we	we	PRP	_	16	SBJ
16	created	create	VBD	_	0	ROOT
17	a	a	DT	_	21	NMOD
18	gene	gene	NN	_	19	NMOD
19	knockout	knockout	NN	_	21	NMOD
20	mouse	mouse	NN	_	21	NMOD
21	model	model	NN	_	16	OBJ
22	of	of	IN	_	21	NMOD
23	classic	classic	JJ	_	24	NMOD
24	MSUD	msud	NN	_	22	PMOD
25	.	.	.	_	16	P

1	The	the	DT	_	4	NMOD
2	homozygous	homozygous	JJ	_	4	NMOD
3	knockout	knockout	NN	_	4	NMOD
4	mice	mouse	NNS	_	5	SBJ
5	lacked	lack	VBD	_	0	ROOT
6	branched	branch	VBN	_	8	NMOD
7	-	-	HYPH	_	6	P
8	chain	chain	NN	_	11	NMOD
9	keto	keto	NN	_	10	NMOD
10	acid	acid	NN	_	11	NMOD
11	dehydrogenase	dehydrogenase	NN	_	12	NMOD
12	activity	activity	NN	_	5	OBJ
13	,	,	,	_	12	P
14	E2	e0	NN	_	15	NMOD
15	immunoreactivity	immunoreactivity	NN	_	12	APPO
16	,	,	,	_	5	P
17	and	and	CC	_	5	COORD
18	had	have	VBD	_	17	CONJ
19	a	a	DT	_	23	NMOD
20	3	0	CD	_	23	NMOD
21	-	-	HYPH	_	20	P
22	fold	fold	JJ	_	20	QMOD
23	increase	increase	NN	_	18	OBJ
24	in	in	IN	_	23	NMOD
25	circulating	circulate	VBG	_	30	NMOD
26	branched	branch	VBN	_	28	NMOD
27	-	-	HYPH	_	26	P
28	chain	chain	NN	_	30	NMOD
29	amino	amino	NN	_	30	NMOD
30	acids	acid	NNS	_	24	PMOD
31	.	.	.	_	5	P

1	These	these	DT	_	3	NMOD
2	metabolic	metabolic	JJ	_	3	NMOD
3	derangements	derangement	NNS	_	4	SBJ
4	resulted	result	VBD	_	0	ROOT
5	in	in	IN	_	4	ADV
6	neonatal	neonatal	JJ	_	7	NMOD
7	lethality	lethality	NN	_	5	PMOD
8	.	.	.	_	4	P

1	Transgenic	transgenic	JJ	_	2	NMOD
2	expression	expression	NN	_	16	SBJ
3	of	of	IN	_	2	NMOD
4	a	a	DT	_	7	NMOD
5	human	human	JJ	_	7	NMOD
6	E2	e0	NN	_	7	NMOD
7	cDNA	cdna	NN	_	3	PMOD
8	in	in	IN	_	2	LOC
9	the	the	DT	_	10	NMOD
10	liver	liver	NN	_	8	PMOD
11	of	of	IN	_	10	NMOD
12	the	the	DT	_	15	NMOD
13	E2	e0	NN	_	15	NMOD
14	knockout	knockout	NN	_	15	NMOD
15	animals	animal	NNS	_	11	PMOD
16	produced	produce	VBD	_	0	ROOT
17	a	a	DT	_	18	NMOD
18	model	model	NN	_	16	OBJ
19	of	of	IN	_	18	NMOD
20	intermediate	intermediate	JJ	_	21	NMOD
21	MSUD	msud	NN	_	19	PMOD
22	.	.	.	_	16	P

1	Branched	branch	VBN	_	3	NMOD
2	-	-	HYPH	_	1	P
3	chain	chain	NN	_	6	NMOD
4	keto	keto	NN	_	5	NMOD
5	acid	acid	NN	_	6	NMOD
6	dehydrogenase	dehydrogenase	NN	_	7	NMOD
7	activity	activity	NN	_	8	SBJ
8	was	be	VBD	_	0	ROOT
9	5	0	CD	_	12	NMOD
10	–	–	SYM	_	9	P
11	6	0	CD	_	9	QMOD
12	%	%	NN	_	8	PRD
13	of	of	IN	_	12	NMOD
14	normal	normal	JJ	_	13	PMOD
15	and	and	CC	_	8	COORD
16	was	be	VBD	_	15	CONJ
17	sufficient	sufficient	JJ	_	16	PRD
18	to	to	TO	_	17	AMOD
19	allow	allow	VB	_	18	IM
20	survival	survival	NN	_	19	OBJ
21	,	,	,	_	8	P
22	but	but	CC	_	8	COORD
23	was	be	VBD	_	22	CONJ
24	insufficient	insufficient	JJ	_	23	PRD
25	to	to	TO	_	24	AMOD
26	normalize	normalize	VB	_	25	IM
27	circulating	circulate	VBG	_	26	VC
28	branched	branch	VBN	_	30	NMOD
29	-	-	HYPH	_	28	P
30	chain	chain	NN	_	32	NMOD
31	amino	amino	NN	_	32	NMOD
32	acids	acid	NNS	_	33	NMOD
33	levels	level	NNS	_	27	OBJ
34	,	,	,	_	33	P
35	which	which	WDT	_	36	SBJ
36	were	be	VBD	_	33	NMOD
37	intermediate	intermediate	JJ	_	36	PRD
38	between	between	IN	_	36	ADV
39	wildtype	wildtype	NN	_	38	PMOD
40	and	and	CC	_	39	COORD
41	the	the	DT	_	45	NMOD
42	classic	classic	JJ	_	45	NMOD
43	MSUD	msud	NN	_	45	NMOD
44	mouse	mouse	NN	_	45	NMOD
45	model	model	NN	_	40	CONJ
46	.	.	.	_	8	P

1	Conclusion	conclusion	NN	_	0	ROOT

1	These	these	DT	_	2	NMOD
2	mice	mouse	NNS	_	3	SBJ
3	represent	represent	VBP	_	0	ROOT
4	important	important	JJ	_	6	NMOD
5	animal	animal	NN	_	6	NMOD
6	models	model	NNS	_	3	OBJ
7	that	that	WDT	_	9	SBJ
8	closely	closely	RB	_	9	ADV
9	approximate	approximate	VBP	_	6	NMOD
10	the	the	DT	_	11	NMOD
11	phenotype	phenotype	NN	_	9	OBJ
12	of	of	IN	_	11	NMOD
13	humans	human	NNS	_	12	PMOD
14	with	with	IN	_	13	NMOD
15	the	the	DT	_	19	NMOD
16	classic	classic	JJ	_	19	NMOD
17	and	and	CC	_	16	COORD
18	intermediate	intermediate	JJ	_	17	CONJ
19	forms	form	NNS	_	14	PMOD
20	of	of	IN	_	19	NMOD
21	MSUD	msud	NN	_	20	PMOD
22	.	.	.	_	3	P

1	These	these	DT	_	2	NMOD
2	animals	animal	NNS	_	3	SBJ
3	provide	provide	VBP	_	0	ROOT
4	useful	useful	JJ	_	5	NMOD
5	models	model	NNS	_	3	OBJ
6	to	to	TO	_	5	NMOD
7	further	far	RB	_	6	ADV
8	characterize	characterize	VB	_	6	IM
9	the	the	DT	_	10	NMOD
10	pathogenesis	pathogenesis	NN	_	8	OBJ
11	of	of	IN	_	10	NMOD
12	MSUD	msud	NN	_	11	PMOD
13	,	,	,	_	5	P
14	as	as	RB	_	16	ADV
15	well	well	RB	_	16	ADV
16	as	as	IN	_	5	COORD
17	models	model	NNS	_	16	CONJ
18	to	to	TO	_	17	NMOD
19	test	test	VB	_	18	IM
20	novel	novel	JJ	_	22	NMOD
21	therapeutic	therapeutic	JJ	_	22	NMOD
22	strategies	strategy	NNS	_	19	OBJ
23	,	,	,	_	22	P
24	such	such	JJ	_	25	PMOD
25	as	as	IN	_	22	NMOD
26	gene	gene	NN	_	29	NMOD
27	and	and	CC	_	26	COORD
28	cellular	cellular	JJ	_	27	CONJ
29	therapies	therapy	NNS	_	25	PMOD
30	,	,	,	_	29	P
31	to	to	TO	_	29	NMOD
32	treat	treat	VB	_	31	IM
33	this	this	DT	_	36	NMOD
34	devastating	devastate	VBG	_	36	NMOD
35	metabolic	metabolic	JJ	_	36	NMOD
36	disease	disease	NN	_	32	OBJ
37	.	.	.	_	3	P

1	Background	background	NN	_	0	ROOT

1	Maple	maple	NN	_	2	NMOD
2	Syrup	syrup	NN	_	4	NMOD
3	Urine	urine	NN	_	4	NMOD
4	Disease	disease	NN	_	6	NMOD
5	(	(	-LRB-	_	6	P
6	MSUD	msud	NN	_	8	SBJ
7	)	)	-RRB-	_	8	P
8	is	be	VBZ	_	0	ROOT
9	a	a	DT	_	11	NMOD
10	genetic	genetic	JJ	_	11	NMOD
11	disorder	disorder	NN	_	8	PRD
12	caused	cause	VBN	_	11	NMOD
13	by	by	IN	_	12	LGS
14	a	a	DT	_	15	NMOD
15	deficiency	deficiency	NN	_	30	NMOD
16	of	of	IN	_	15	NMOD
17	branched	branch	VBN	_	19	NMOD
18	-	-	HYPH	_	17	P
19	chain	chain	NN	_	22	NMOD
20	keto	keto	NN	_	21	NMOD
21	acid	acid	NN	_	22	NMOD
22	dehydrogenase	dehydrogenase	NN	_	24	NMOD
23	(	(	-LRB-	_	24	P
24	BCKDH	bckdh	NN	_	16	PMOD
25	)	)	-RRB-	_	30	P
26	,	,	,	_	30	P
27	a	a	DT	_	30	NMOD
28	mitochondrial	mitochondrial	JJ	_	30	NMOD
29	multienzyme	multienzyme	NN	_	30	NMOD
30	complex	complex	NN	_	13	PMOD
31	responsible	responsible	JJ	_	30	NMOD
32	for	for	IN	_	31	AMOD
33	the	the	DT	_	35	NMOD
34	oxidative	oxidative	JJ	_	35	NMOD
35	decarboxylation	decarboxylation	NN	_	32	PMOD
36	of	of	IN	_	35	NMOD
37	branched	branch	VBN	_	39	NMOD
38	-	-	HYPH	_	37	P
39	chain	chain	NN	_	41	NMOD
40	keto	keto	NN	_	41	NMOD
41	acids	acid	NNS	_	36	PMOD
42	derived	derive	VBN	_	41	NMOD
43	from	from	IN	_	42	ADV
44	branched	branch	VBN	_	46	NMOD
45	-	-	HYPH	_	44	P
46	chain	chain	NN	_	48	NMOD
47	amino	amino	NN	_	48	NMOD
48	acids	acid	NNS	_	50	NMOD
49	(	(	-LRB-	_	50	P
50	BCAA	bcaa	NN	_	43	PMOD
51	)	)	-RRB-	_	50	P
52	,	,	,	_	50	P
53	leucine	leucine	NN	_	50	CONJ
54	,	,	,	_	53	P
55	isoleucine	isoleucine	NN	_	53	CONJ
56	and	and	CC	_	55	COORD
57	valine	valine	NN	_	56	CONJ
58	(	(	-LRB-	_	62	P
59	for	for	IN	_	62	ADV
60	review	review	NN	_	59	PMOD
61	,	,	,	_	62	P
62	see	see	VB	_	8	PRN
63	:	:	:	_	62	P
64	[	[	-LRB-	_	62	P
65	1	0	CD	_	62	OBJ
66	]	]	-RRB-	_	62	P
67	)	)	-RRB-	_	62	P
68	.	.	.	_	8	P

1	Patients	patient	NNS	_	10	SBJ
2	with	with	IN	_	1	NMOD
3	MSUD	msud	NN	_	2	PMOD
4	,	,	,	_	10	P
5	depending	depend	VBG	_	10	ADV
6	on	on	IN	_	5	PMOD
7	the	the	DT	_	8	NMOD
8	mutation	mutation	NN	_	6	PMOD
9	,	,	,	_	10	P
10	show	show	VBP	_	0	ROOT
11	variable	variable	JJ	_	12	NMOD
12	degrees	degree	NNS	_	10	OBJ
13	of	of	IN	_	12	NMOD
14	enzyme	enzyme	NN	_	15	NMOD
15	deficiency	deficiency	NN	_	13	PMOD
16	leading	lead	VBG	_	15	NMOD
17	to	to	IN	_	16	ADV
18	several	several	JJ	_	21	NMOD
19	different	different	JJ	_	21	NMOD
20	clinical	clinical	JJ	_	21	NMOD
21	phenotypes	phenotype	NNS	_	17	PMOD
22	[	[	-LRB-	_	23	P
23	1	0	CD	_	10	PRN
24	]	]	-RRB-	_	23	P
25	.	.	.	_	10	P

1	Approximately	approximately	RB	_	2	QMOD
2	75	0	CD	_	3	NMOD
3	%	%	NN	_	7	SBJ
4	of	of	IN	_	3	NMOD
5	MSUD	msud	NN	_	6	NMOD
6	patients	patient	NNS	_	4	PMOD
7	have	have	VBP	_	0	ROOT
8	the	the	DT	_	10	NMOD
9	classic	classic	JJ	_	10	NMOD
10	form	form	NN	_	7	OBJ
11	of	of	IN	_	10	NMOD
12	the	the	DT	_	13	NMOD
13	disease	disease	NN	_	11	PMOD
14	with	with	IN	_	10	NMOD
15	BCKDH	bckdh	NN	_	16	NMOD
16	activity	activity	NN	_	14	PMOD
17	in	in	IN	_	16	NMOD
18	the	the	DT	_	19	NMOD
19	range	range	NN	_	17	PMOD
20	of	of	IN	_	19	NMOD
21	0	0	CD	_	24	NMOD
22	–	–	SYM	_	21	P
23	2	0	CD	_	21	QMOD
24	%	%	NN	_	20	PMOD
25	of	of	IN	_	24	NMOD
26	normal	normal	JJ	_	25	PMOD
27	[	[	-LRB-	_	28	P
28	1	0	CD	_	7	PRN
29	]	]	-RRB-	_	28	P
30	.	.	.	_	7	P

1	These	these	DT	_	2	NMOD
2	patients	patient	NNS	_	3	SBJ
3	show	show	VBP	_	0	ROOT
4	markedly	markedly	RB	_	5	AMOD
5	elevated	elevate	VBN	_	6	NMOD
6	levels	level	NNS	_	3	OBJ
7	of	of	IN	_	6	NMOD
8	BCAA	bcaa	NN	_	7	PMOD
9	in	in	IN	_	3	LOC
10	blood	blood	NN	_	9	PMOD
11	and	and	CC	_	10	COORD
12	other	other	JJ	_	14	NMOD
13	body	body	NN	_	14	NMOD
14	fluids	fluid	NNS	_	11	CONJ
15	[	[	-LRB-	_	16	P
16	1	0	CD	_	3	PRN
17	]	]	-RRB-	_	16	P
18	.	.	.	_	3	P

1	Besides	besides	IN	_	7	ADV
2	the	the	DT	_	4	NMOD
3	classic	classic	JJ	_	4	NMOD
4	form	form	NN	_	1	PMOD
5	,	,	,	_	7	P
6	there	there	EX	_	7	SBJ
7	are	be	VBP	_	0	ROOT
8	other	other	JJ	_	9	NMOD
9	variants	variant	NNS	_	7	PRD
10	of	of	IN	_	9	NMOD
11	the	the	DT	_	12	NMOD
12	disease	disease	NN	_	10	PMOD
13	.	.	.	_	7	P

1	Patients	patient	NNS	_	9	SBJ
2	with	with	IN	_	1	NMOD
3	the	the	DT	_	5	NMOD
4	intermediate	intermediate	JJ	_	5	NMOD
5	form	form	NN	_	2	PMOD
6	of	of	IN	_	5	NMOD
7	the	the	DT	_	8	NMOD
8	disease	disease	NN	_	6	PMOD
9	show	show	VBP	_	0	ROOT
10	BCKDH	bckdh	NN	_	11	NMOD
11	activity	activity	NN	_	9	OBJ
12	in	in	IN	_	11	NMOD
13	the	the	DT	_	14	NMOD
14	range	range	NN	_	12	PMOD
15	of	of	IN	_	14	NMOD
16	3	0	CD	_	19	NMOD
17	–	–	SYM	_	16	P
18	30	0	CD	_	16	QMOD
19	%	%	NN	_	15	PMOD
20	of	of	IN	_	19	NMOD
21	normal	normal	JJ	_	20	PMOD
22	.	.	.	_	9	P

1	In	in	IN	_	9	LOC
2	such	such	JJ	_	3	NMOD
3	patients	patient	NNS	_	1	PMOD
4	the	the	DT	_	5	NMOD
5	onset	onset	NN	_	9	SBJ
6	of	of	IN	_	5	NMOD
7	the	the	DT	_	8	NMOD
8	disease	disease	NN	_	6	PMOD
9	is	be	VBZ	_	0	ROOT
10	delayed	delay	VBN	_	9	VC
11	,	,	,	_	9	P
12	but	but	CC	_	9	COORD
13	there	there	EX	_	14	SBJ
14	are	be	VBP	_	12	CONJ
15	persistently	persistently	RB	_	16	AMOD
16	elevated	elevate	VBN	_	17	NMOD
17	levels	level	NNS	_	14	PRD
18	of	of	IN	_	17	NMOD
19	BCAA	bcaa	NN	_	18	PMOD
20	[	[	-LRB-	_	21	P
21	1	0	CD	_	14	PRN
22	]	]	-RRB-	_	21	P
23	.	.	.	_	9	P

1	Patients	patient	NNS	_	8	SBJ
2	with	with	IN	_	1	NMOD
3	the	the	DT	_	5	NMOD
4	intermittent	intermittent	JJ	_	5	NMOD
5	form	form	NN	_	2	PMOD
6	of	of	IN	_	5	NMOD
7	MSUD	msud	NN	_	6	PMOD
8	show	show	VBP	_	0	ROOT
9	BCKDH	bckdh	NN	_	10	NMOD
10	activity	activity	NN	_	8	OBJ
11	in	in	IN	_	8	ADV
12	the	the	DT	_	13	NMOD
13	range	range	NN	_	11	PMOD
14	of	of	IN	_	13	NMOD
15	5	0	CD	_	18	NMOD
16	–	–	SYM	_	15	P
17	20	0	CD	_	15	QMOD
18	%	%	NN	_	14	PMOD
19	and	and	CC	_	8	COORD
20	during	during	IN	_	28	TMP
21	the	the	DT	_	23	NMOD
22	asymptomatic	asymptomatic	JJ	_	23	NMOD
23	phase	phase	NN	_	20	PMOD
24	the	the	DT	_	27	NMOD
25	blood	blood	NN	_	27	NMOD
26	BCAA	bcaa	NN	_	27	NMOD
27	levels	level	NNS	_	28	SBJ
28	are	be	VBP	_	19	CONJ
29	normal	normal	JJ	_	28	PRD
30	[	[	-LRB-	_	31	P
31	1	0	CD	_	28	PRN
32	]	]	-RRB-	_	31	P
33	.	.	.	_	8	P

1	The	the	DT	_	3	NMOD
2	overall	overall	JJ	_	3	NMOD
3	incidence	incidence	NN	_	10	SBJ
4	of	of	IN	_	3	NMOD
5	MSUD	msud	NN	_	4	PMOD
6	in	in	IN	_	3	NMOD
7	the	the	DT	_	9	NMOD
8	general	general	JJ	_	9	NMOD
9	population	population	NN	_	6	PMOD
10	is	be	VBZ	_	0	ROOT
11	1	0	CD	_	13	NMOD
12	:	:	SYM	_	13	P
13	185,000	0	CD	_	10	PRD
14	[	[	-LRB-	_	15	P
15	1	0	CD	_	10	PRN
16	]	]	-RRB-	_	15	P
17	,	,	,	_	10	P
18	and	and	CC	_	10	COORD
19	in	in	IN	_	32	ADV
20	certain	certain	JJ	_	22	NMOD
21	population	population	NN	_	22	NMOD
22	groups	group	NNS	_	19	PMOD
23	,	,	,	_	22	P
24	such	such	JJ	_	25	PMOD
25	as	as	IN	_	22	NMOD
26	Mennonites	mennonite	NNS	_	25	PMOD
27	of	of	IN	_	26	NMOD
28	Pennsylvania	pennsylvania	NNP	_	27	PMOD
29	,	,	,	_	32	P
30	the	the	DT	_	31	NMOD
31	incidence	incidence	NN	_	32	SBJ
32	is	be	VBZ	_	18	CONJ
33	estimated	estimate	VBN	_	32	VC
34	to	to	TO	_	33	OPRD
35	be	be	VB	_	34	IM
36	as	as	IN	_	35	PRD
37	high	high	JJ	_	36	PMOD
38	as	as	IN	_	37	AMOD
39	1	0	CD	_	41	NMOD
40	:	:	SYM	_	41	P
41	176	0	CD	_	38	PMOD
42	[	[	-LRB-	_	43	P
43	2	0	CD	_	33	PRN
44	]	]	-RRB-	_	43	P
45	.	.	.	_	10	P

1	The	the	DT	_	3	NMOD
2	BCKDH	bckdh	NN	_	3	NMOD
3	complex	complex	NN	_	11	SBJ
4	,	,	,	_	3	P
5	the	the	DT	_	7	NMOD
6	deficient	deficient	JJ	_	7	NMOD
7	enzyme	enzyme	NN	_	3	APPO
8	in	in	IN	_	7	NMOD
9	MSUD	msud	NN	_	8	PMOD
10	,	,	,	_	11	P
11	consists	consist	VBZ	_	0	ROOT
12	of	of	IN	_	11	ADV
13	three	three	CD	_	15	NMOD
14	catalytic	catalytic	JJ	_	15	NMOD
15	proteins	protein	NNS	_	12	PMOD
16	,	,	,	_	15	P
17	a	a	DT	_	18	NMOD
18	decarboxylase	decarboxylase	NN	_	15	APPO
19	(	(	-LRB-	_	20	P
20	E1	e0	NN	_	18	PRN
21	)	)	-RRB-	_	20	P
22	,	,	,	_	18	P
23	a	a	DT	_	25	NMOD
24	dihydrolipoyl	dihydrolipoyl	NN	_	25	NMOD
25	transacylase	transacylase	NN	_	18	CONJ
26	(	(	-LRB-	_	27	P
27	E2	e0	NN	_	25	PRN
28	)	)	-RRB-	_	27	P
29	,	,	,	_	25	P
30	and	and	CC	_	25	COORD
31	a	a	DT	_	33	NMOD
32	dihydrolipoyl	dihydrolipoyl	NN	_	33	NMOD
33	dehydrogenase	dehydrogenase	NN	_	30	CONJ
34	(	(	-LRB-	_	35	P
35	E3	e0	NN	_	33	PRN
36	)	)	-RRB-	_	35	P
37	.	.	.	_	11	P

1	The	the	DT	_	3	NMOD
2	E1	e0	NN	_	3	NMOD
3	component	component	NN	_	4	SBJ
4	is	be	VBZ	_	0	ROOT
5	a	a	DT	_	6	NMOD
6	heterotetramer	heterotetramer	NN	_	4	PRD
7	composed	compose	VBN	_	6	NMOD
8	of	of	IN	_	7	ADV
9	two	two	CD	_	10	NMOD
10	α	α	NN	_	14	NMOD
11	and	and	CC	_	10	COORD
12	two	two	CD	_	13	NMOD
13	β	β	NN	_	11	CONJ
14	subunits	subunit	NNS	_	8	PMOD
15	[	[	-LRB-	_	16	P
16	3	0	CD	_	4	PRN
17	]	]	-RRB-	_	16	P
18	.	.	.	_	4	P

1	The	the	DT	_	5	NMOD
2	E1	e0	NN	_	5	NMOD
3	and	and	CC	_	2	COORD
4	E2	e0	NN	_	3	CONJ
5	components	component	NNS	_	6	SBJ
6	are	be	VBP	_	0	ROOT
7	specific	specific	JJ	_	6	PRD
8	to	to	IN	_	7	AMOD
9	BCKDH	bckdh	NN	_	8	PMOD
10	,	,	,	_	6	P
11	whereas	whereas	IN	_	6	ADV
12	E3	e0	NN	_	13	SBJ
13	is	be	VBZ	_	11	SUB
14	also	also	RB	_	13	ADV
15	used	use	VBN	_	13	VC
16	by	by	IN	_	15	LGS
17	pyruvate	pyruvate	NN	_	23	NMOD
18	and	and	CC	_	17	COORD
19	α	α	NN	_	21	NMOD
20	-	-	HYPH	_	19	P
21	ketoglutarate	ketoglutarate	NN	_	18	CONJ
22	dehydrogenase	dehydrogenase	NN	_	23	NMOD
23	complexes	complex	NNS	_	16	PMOD
24	[	[	-LRB-	_	25	P
25	3	0	CD	_	23	PRN
26	]	]	-RRB-	_	25	P
27	and	and	CC	_	23	COORD
28	the	the	DT	_	31	NMOD
29	glycine	glycine	NN	_	30	NMOD
30	cleavage	cleavage	NN	_	31	NMOD
31	system	system	NN	_	27	CONJ
32	[	[	-LRB-	_	33	P
33	4	0	CD	_	31	PRN
34	]	]	-RRB-	_	33	P
35	.	.	.	_	6	P

1	BCKDH	bckdh	NN	_	2	SBJ
2	is	be	VBZ	_	0	ROOT
3	also	also	RB	_	2	ADV
4	associated	associate	VBN	_	2	VC
5	with	with	IN	_	4	ADV
6	two	two	CD	_	8	NMOD
7	regulatory	regulatory	JJ	_	8	NMOD
8	proteins	protein	NNS	_	5	PMOD
9	,	,	,	_	8	P
10	a	a	DT	_	12	NMOD
11	specific	specific	JJ	_	12	NMOD
12	kinase	kinase	NN	_	8	APPO
13	and	and	CC	_	12	COORD
14	a	a	DT	_	15	NMOD
15	phosphatase	phosphatase	NN	_	13	CONJ
16	which	which	WDT	_	17	SBJ
17	regulate	regulate	VBP	_	8	NMOD
18	the	the	DT	_	19	NMOD
19	activity	activity	NN	_	17	OBJ
20	of	of	IN	_	19	NMOD
21	this	this	DT	_	22	NMOD
22	enzyme	enzyme	NN	_	20	PMOD
23	through	through	IN	_	17	MNR
24	a	a	DT	_	34	NMOD
25	phosphorylation	phosphorylation	NN	_	34	NMOD
26	(	(	-LRB-	_	27	P
27	inactivation	inactivation	NN	_	25	PRN
28	)	)	-RRB-	_	27	P
29	and	and	CC	_	25	COORD
30	dephosphorylation	dephosphorylation	NN	_	29	CONJ
31	(	(	-LRB-	_	32	P
32	activation	activation	NN	_	30	PRN
33	)	)	-RRB-	_	32	P
34	cycle	cycle	NN	_	23	PMOD
35	of	of	IN	_	34	NMOD
36	the	the	DT	_	39	NMOD
37	E1	e0	NN	_	39	NMOD
38	α	α	NN	_	39	NMOD
39	subunit	subunit	NN	_	35	PMOD
40	[	[	-LRB-	_	43	P
41	5	0	CD	_	43	NMOD
42	,	,	,	_	43	P
43	6	0	CD	_	4	PRN
44	]	]	-RRB-	_	43	P
45	.	.	.	_	2	P

1	Mutations	mutation	NNS	_	13	SBJ
2	in	in	IN	_	1	NMOD
3	the	the	DT	_	4	NMOD
4	genes	gene	NNS	_	2	PMOD
5	of	of	IN	_	4	NMOD
6	the	the	DT	_	10	NMOD
7	E1	e0	NN	_	10	NMOD
8	and	and	CC	_	7	COORD
9	E2	e0	NN	_	8	CONJ
10	subunits	subunit	NNS	_	5	PMOD
11	of	of	IN	_	10	NMOD
12	BCKDH	bckdh	NN	_	11	PMOD
13	have	have	VBP	_	27	DEP
14	been	be	VBN	_	13	VC
15	described	describe	VBN	_	14	VC
16	,	,	,	_	27	P
17	however	however	RB	_	27	ADV
18	,	,	,	_	27	P
19	the	the	DT	_	20	NMOD
20	majority	majority	NN	_	27	SBJ
21	of	of	IN	_	20	NMOD
22	MSUD	msud	NN	_	23	NMOD
23	mutations	mutation	NNS	_	21	PMOD
24	identified	identify	VBN	_	23	NMOD
25	thus	thus	RB	_	26	AMOD
26	far	far	RB	_	24	ADV
27	are	be	VBP	_	0	ROOT
28	in	in	IN	_	27	PRD
29	the	the	DT	_	31	NMOD
30	E2	e0	NN	_	31	NMOD
31	subunit	subunit	NN	_	28	PMOD
32	[	[	-LRB-	_	35	P
33	1	0	CD	_	35	NMOD
34	,	,	,	_	35	P
35	7	0	CD	_	27	PRN
36	]	]	-RRB-	_	35	P
37	.	.	.	_	27	P

1	To	to	IN	_	7	TMP
2	date	date	NN	_	1	PMOD
3	,	,	,	_	7	P
4	cases	case	NNS	_	7	SBJ
5	of	of	IN	_	4	NMOD
6	MSUD	msud	NN	_	5	PMOD
7	have	have	VBP	_	0	ROOT
8	not	not	RB	_	7	ADV
9	been	be	VBN	_	7	VC
10	associated	associate	VBN	_	9	VC
11	with	with	IN	_	10	ADV
12	defects	defect	NNS	_	11	PMOD
13	in	in	IN	_	12	NMOD
14	the	the	DT	_	16	NMOD
15	regulatory	regulatory	JJ	_	16	NMOD
16	kinase	kinase	NN	_	13	PMOD
17	and	and	CC	_	16	COORD
18	phosphatase	phosphatase	NN	_	17	CONJ
19	[	[	-LRB-	_	20	P
20	1	0	CD	_	10	PRN
21	]	]	-RRB-	_	20	P
22	.	.	.	_	7	P

1	Current	current	JJ	_	2	NMOD
2	management	management	NN	_	6	SBJ
3	of	of	IN	_	2	NMOD
4	MSUD	msud	NN	_	5	NMOD
5	patients	patient	NNS	_	3	PMOD
6	relies	rely	VBZ	_	0	ROOT
7	on	on	IN	_	6	ADV
8	a	a	DT	_	12	NMOD
9	strict	strict	JJ	_	12	NMOD
10	lifelong	lifelong	JJ	_	12	NMOD
11	dietary	dietary	JJ	_	12	NMOD
12	restriction	restriction	NN	_	7	PMOD
13	of	of	IN	_	12	NMOD
14	protein	protein	NN	_	13	PMOD
15	or	or	CC	_	14	COORD
16	BCAA	bcaa	NN	_	15	CONJ
17	[	[	-LRB-	_	20	P
18	1	0	CD	_	20	NMOD
19	,	,	,	_	20	P
20	8	0	CD	_	6	PRN
21	]	]	-RRB-	_	20	P
22	.	.	.	_	6	P

1	Such	such	PDT	_	4	NMOD
2	a	a	DT	_	4	NMOD
3	dietary	dietary	JJ	_	4	NMOD
4	management	management	NN	_	11	SBJ
5	of	of	IN	_	4	NMOD
6	the	the	DT	_	7	NMOD
7	disease	disease	NN	_	5	PMOD
8	,	,	,	_	11	P
9	however	however	RB	_	11	ADV
10	,	,	,	_	11	P
11	is	be	VBZ	_	0	ROOT
12	not	not	RB	_	11	ADV
13	entirely	entirely	RB	_	14	AMOD
14	satisfactory	satisfactory	JJ	_	11	PRD
15	especially	especially	RB	_	16	PMOD
16	in	in	IN	_	11	TMP
17	times	time	NNS	_	16	PMOD
18	of	of	IN	_	17	NMOD
19	metabolic	metabolic	JJ	_	20	NMOD
20	decompensation	decompensation	NN	_	18	PMOD
21	due	due	IN	_	20	NMOD
22	to	to	IN	_	21	PMOD
23	infection	infection	NN	_	21	PMOD
24	,	,	,	_	23	P
25	injuries	injury	NNS	_	23	CONJ
26	and	and	CC	_	25	COORD
27	other	other	JJ	_	28	NMOD
28	stressors	stressor	NNS	_	26	CONJ
29	.	.	.	_	11	P

1	In	in	IN	_	8	ADV
2	spite	spite	NN	_	1	PMOD
3	of	of	IN	_	2	NMOD
4	dietary	dietary	JJ	_	5	NMOD
5	intervention	intervention	NN	_	3	PMOD
6	,	,	,	_	8	P
7	there	there	EX	_	8	SBJ
8	is	be	VBZ	_	0	ROOT
9	significant	significant	JJ	_	10	NMOD
10	mortality	mortality	NN	_	8	PRD
11	associated	associate	VBN	_	10	NMOD
12	with	with	IN	_	11	ADV
13	MSUD	msud	NN	_	12	PMOD
14	and	and	CC	_	8	COORD
15	there	there	EX	_	16	SBJ
16	is	be	VBZ	_	14	CONJ
17	a	a	DT	_	19	NMOD
18	high	high	JJ	_	19	NMOD
19	incidence	incidence	NN	_	16	PRD
20	of	of	IN	_	19	NMOD
21	mental	mental	JJ	_	22	NMOD
22	retardation	retardation	NN	_	20	PMOD
23	in	in	IN	_	16	LOC
24	survivors	survivor	NNS	_	23	PMOD
25	[	[	-LRB-	_	26	P
26	9	0	CD	_	16	PRN
27	]	]	-RRB-	_	26	P
28	.	.	.	_	8	P

1	Because	because	IN	_	35	PRP
2	of	of	IN	_	1	PMOD
3	the	the	DT	_	5	NMOD
4	central	central	JJ	_	5	NMOD
5	role	role	NN	_	1	PMOD
6	of	of	IN	_	5	NMOD
7	the	the	DT	_	8	NMOD
8	liver	liver	NN	_	6	PMOD
9	in	in	IN	_	5	NMOD
10	amino	amino	NN	_	11	NMOD
11	acid	acid	NN	_	12	NMOD
12	metabolism	metabolism	NN	_	9	PMOD
13	and	and	CC	_	5	COORD
14	moderate	moderate	JJ	_	16	AMOD
15	/	/	SYM	_	16	P
16	high	high	JJ	_	17	NMOD
17	levels	level	NNS	_	13	CONJ
18	of	of	IN	_	17	NMOD
19	BCKDH	bckdh	NN	_	20	NMOD
20	activity	activity	NN	_	18	PMOD
21	in	in	IN	_	20	LOC
22	human	human	JJ	_	23	NMOD
23	liver	liver	NN	_	21	PMOD
24	[	[	-LRB-	_	25	P
25	10	0	CD	_	5	PRN
26	-	-	SYM	_	27	P
27	12	0	CD	_	25	NMOD
28	]	]	-RRB-	_	25	P
29	,	,	,	_	35	P
30	a	a	DT	_	32	NMOD
31	few	few	JJ	_	32	NMOD
32	cases	case	NNS	_	35	SBJ
33	of	of	IN	_	32	NMOD
34	MSUD	msud	NN	_	33	PMOD
35	have	have	VBP	_	0	ROOT
36	recently	recently	RB	_	35	TMP
37	been	be	VBN	_	35	VC
38	treated	treat	VBN	_	37	VC
39	by	by	IN	_	38	MNR
40	liver	liver	NN	_	41	NMOD
41	transplantation	transplantation	NN	_	39	PMOD
42	[	[	-LRB-	_	43	P
43	13	0	CD	_	38	PRN
44	-	-	SYM	_	45	P
45	16	0	CD	_	43	NMOD
46	]	]	-RRB-	_	43	P
47	.	.	.	_	35	P

1	While	while	IN	_	20	ADV
2	the	the	DT	_	6	NMOD
3	short	short	JJ	_	5	NMOD
4	-	-	HYPH	_	3	P
5	term	term	NN	_	6	NMOD
6	outcome	outcome	NN	_	10	SBJ
7	of	of	IN	_	6	NMOD
8	liver	liver	NN	_	9	NMOD
9	transplantation	transplantation	NN	_	7	PMOD
10	is	be	VBZ	_	1	SUB
11	encouraging	encouraging	JJ	_	10	PRD
12	,	,	,	_	20	P
13	long	long	JJ	_	15	NMOD
14	-	-	HYPH	_	13	P
15	term	term	NN	_	16	NMOD
16	effects	effect	NNS	_	20	SBJ
17	of	of	IN	_	16	NMOD
18	this	this	DT	_	19	NMOD
19	approach	approach	NN	_	17	PMOD
20	are	be	VBP	_	0	ROOT
21	not	not	RB	_	20	ADV
22	known	know	VBN	_	20	VC
23	.	.	.	_	20	P

1	However	however	RB	_	5	ADV
2	,	,	,	_	5	P
3	these	these	DT	_	4	NMOD
4	patients	patient	NNS	_	5	SBJ
5	are	be	VBP	_	0	ROOT
6	now	now	RB	_	5	TMP
7	required	require	VBN	_	5	VC
8	to	to	TO	_	7	OPRD
9	take	take	VB	_	8	IM
10	immunosuppressant	immunosuppressant	NN	_	11	NMOD
11	drugs	drug	NNS	_	9	OBJ
12	for	for	IN	_	9	TMP
13	the	the	DT	_	14	NMOD
14	rest	rest	NN	_	12	PMOD
15	of	of	IN	_	14	NMOD
16	their	their	PRP$	_	17	NMOD
17	lives	life	NNS	_	15	PMOD
18	,	,	,	_	9	P
19	often	often	RB	_	20	TMP
20	with	with	IN	_	9	ADV
21	undesirable	undesirable	JJ	_	23	NMOD
22	side	side	NN	_	23	NMOD
23	effects	effect	NNS	_	20	PMOD
24	.	.	.	_	5	P

1	Moreover	moreover	RB	_	15	ADV
2	,	,	,	_	15	P
3	the	the	DT	_	4	NMOD
4	cost	cost	NN	_	15	SBJ
5	associated	associate	VBN	_	4	NMOD
6	with	with	IN	_	5	ADV
7	liver	liver	NN	_	8	NMOD
8	transplantation	transplantation	NN	_	6	PMOD
9	and	and	CC	_	4	COORD
10	the	the	DT	_	11	NMOD
11	availability	availability	NN	_	9	CONJ
12	of	of	IN	_	11	NMOD
13	donor	donor	NN	_	14	NMOD
14	livers	liver	NNS	_	12	PMOD
15	are	be	VBP	_	0	ROOT
16	additional	additional	JJ	_	18	NMOD
17	limiting	limit	VBG	_	18	NMOD
18	factors	factor	NNS	_	15	PRD
19	for	for	IN	_	18	NMOD
20	the	the	DT	_	21	NMOD
21	practicality	practicality	NN	_	19	PMOD
22	of	of	IN	_	21	NMOD
23	treatment	treatment	NN	_	22	PMOD
24	of	of	IN	_	23	NMOD
25	this	this	DT	_	26	NMOD
26	disease	disease	NN	_	24	PMOD
27	.	.	.	_	15	P

1	Because	because	IN	_	14	PRP
2	of	of	IN	_	1	PMOD
3	the	the	DT	_	6	NMOD
4	current	current	JJ	_	6	NMOD
5	unsatisfactory	unsatisfactory	JJ	_	6	NMOD
6	options	option	NNS	_	1	PMOD
7	for	for	IN	_	6	NMOD
8	the	the	DT	_	9	NMOD
9	treatment	treatment	NN	_	7	PMOD
10	of	of	IN	_	9	NMOD
11	MSUD	msud	NN	_	10	PMOD
12	,	,	,	_	14	P
13	there	there	EX	_	14	SBJ
14	is	be	VBZ	_	0	ROOT
15	a	a	DT	_	16	NMOD
16	need	need	NN	_	14	PRD
17	for	for	IN	_	16	NMOD
18	improved	improve	VBN	_	19	NMOD
19	therapies	therapy	NNS	_	17	PMOD
20	to	to	TO	_	19	NMOD
21	combat	combat	VB	_	20	IM
22	this	this	DT	_	23	NMOD
23	disease	disease	NN	_	21	OBJ
24	.	.	.	_	14	P

1	An	an	DT	_	2	NMOD
2	obstacle	obstacle	NN	_	9	SBJ
3	to	to	IN	_	2	NMOD
4	developing	develop	VBG	_	3	PMOD
5	novel	novel	JJ	_	6	NMOD
6	treatments	treatment	NNS	_	4	OBJ
7	for	for	IN	_	6	NMOD
8	MSUD	msud	NN	_	7	PMOD
9	has	have	VBZ	_	0	ROOT
10	been	be	VBN	_	9	VC
11	the	the	DT	_	12	NMOD
12	lack	lack	NN	_	10	PRD
13	of	of	IN	_	12	NMOD
14	a	a	DT	_	17	NMOD
15	suitable	suitable	JJ	_	17	NMOD
16	animal	animal	NN	_	17	NMOD
17	model	model	NN	_	13	PMOD
18	to	to	TO	_	17	NMOD
19	perform	perform	VB	_	18	IM
20	necessary	necessary	JJ	_	22	NMOD
21	preclinical	preclinical	JJ	_	22	NMOD
22	studies	study	NNS	_	19	OBJ
23	.	.	.	_	9	P

1	Although	although	IN	_	19	ADV
2	a	a	DT	_	5	NMOD
3	Hereford	hereford	NNP	_	4	NMOD
4	calf	calf	NN	_	5	NMOD
5	model	model	NN	_	8	SBJ
6	with	with	IN	_	5	NMOD
7	MSUD	msud	NN	_	6	PMOD
8	has	have	VBZ	_	1	SUB
9	been	be	VBN	_	8	VC
10	described	describe	VBN	_	9	VC
11	[	[	-LRB-	_	14	P
12	17	0	CD	_	14	DEP
13	-	-	SYM	_	14	P
14	19	0	CD	_	10	PRN
15	]	]	-RRB-	_	14	P
16	,	,	,	_	19	P
17	this	this	DT	_	18	NMOD
18	model	model	NN	_	19	SBJ
19	is	be	VBZ	_	0	ROOT
20	neither	neither	CC	_	22	COORD
21	readily	readily	RB	_	22	AMOD
22	available	available	JJ	_	19	PRD
23	nor	nor	CC	_	22	COORD
24	practical	practical	JJ	_	23	CONJ
25	to	to	TO	_	24	AMOD
26	perform	perform	VB	_	25	IM
27	preclinical	preclinical	JJ	_	28	NMOD
28	studies	study	NNS	_	26	OBJ
29	.	.	.	_	19	P

1	Furthermore	furthermore	RB	_	11	ADV
2	,	,	,	_	11	P
3	comparison	comparison	NN	_	11	SBJ
4	of	of	IN	_	3	NMOD
5	this	this	DT	_	7	NMOD
6	animal	animal	NN	_	7	NMOD
7	model	model	NN	_	4	PMOD
8	with	with	IN	_	7	NMOD
9	human	human	JJ	_	10	NMOD
10	MSUD	msud	NN	_	8	PMOD
11	has	have	VBZ	_	0	ROOT
12	shown	show	VBN	_	11	VC
13	some	some	DT	_	14	NMOD
14	differences	difference	NNS	_	12	OBJ
15	in	in	IN	_	14	NMOD
16	the	the	DT	_	17	NMOD
17	pathology	pathology	NN	_	15	PMOD
18	of	of	IN	_	17	NMOD
19	the	the	DT	_	20	NMOD
20	disease	disease	NN	_	18	PMOD
21	[	[	-LRB-	_	22	P
22	1	0	CD	_	12	PRN
23	]	]	-RRB-	_	22	P
24	,	,	,	_	12	P
25	making	make	VBG	_	12	ADV
26	this	this	DT	_	27	NMOD
27	animal	animal	NN	_	25	OBJ
28	a	a	DT	_	31	NMOD
29	less	less	RBR	_	30	AMOD
30	desirable	desirable	JJ	_	31	NMOD
31	model	model	NN	_	27	OPRD
32	for	for	IN	_	31	NMOD
33	the	the	DT	_	35	NMOD
34	human	human	JJ	_	35	NMOD
35	disease	disease	NN	_	32	PMOD
36	.	.	.	_	11	P

1	Recently	recently	RB	_	23	TMP
2	,	,	,	_	23	P
3	a	a	DT	_	10	NMOD
4	N	n	NN	_	6	NMOD
5	-	-	HYPH	_	4	P
6	ethyl	ethyl	NN	_	10	NMOD
7	-	-	HYPH	_	6	P
8	N	n	NN	_	10	NMOD
9	-	-	HYPH	_	8	P
10	nitrosourea	nitrosourea	NN	_	12	NMOD
11	(	(	-LRB-	_	12	P
12	ENU	enu	NN	_	15	AMOD
13	)	)	-RRB-	_	15	P
14	-	-	HYPH	_	12	P
15	induced	induce	VBN	_	17	NMOD
16	mutant	mutant	NN	_	17	NMOD
17	mouse	mouse	NN	_	23	SBJ
18	that	that	WDT	_	20	SBJ
19	phenotypically	phenotypically	RB	_	20	ADV
20	resembles	resemble	VBZ	_	17	NMOD
21	human	human	JJ	_	22	NMOD
22	MSUD	msud	NN	_	20	OBJ
23	has	have	VBZ	_	0	ROOT
24	been	be	VBN	_	23	VC
25	described	describe	VBN	_	24	VC
26	[	[	-LRB-	_	27	P
27	20	0	CD	_	25	PRN
28	]	]	-RRB-	_	27	P
29	.	.	.	_	23	P

1	However	however	RB	_	8	ADV
2	,	,	,	_	8	P
3	the	the	DT	_	4	NMOD
4	mutation	mutation	NN	_	8	SBJ
5	in	in	IN	_	4	NMOD
6	this	this	DT	_	7	NMOD
7	model	model	NN	_	5	PMOD
8	disrupts	disrupt	VBZ	_	0	ROOT
9	a	a	DT	_	11	NMOD
10	splice	splice	NN	_	11	NMOD
11	site	site	NN	_	8	OBJ
12	in	in	IN	_	11	LOC
13	the	the	DT	_	20	NMOD
14	mitochondrial	mitochondrial	JJ	_	20	NMOD
15	branched	branch	VBN	_	17	NMOD
16	-	-	HYPH	_	15	P
17	chain	chain	NN	_	18	NMOD
18	aminotransferase	aminotransferase	NN	_	20	NMOD
19	(	(	-LRB-	_	20	P
20	BCAT	bcat	NN	_	22	NMOD
21	)	)	-RRB-	_	22	P
22	gene	gene	NN	_	12	PMOD
23	,	,	,	_	12	P
24	not	not	RB	_	12	PMOD
25	in	in	IN	_	12	PMOD
26	BCKDH	bckdh	NN	_	25	PMOD
27	,	,	,	_	26	P
28	the	the	DT	_	30	NMOD
29	deficient	deficient	JJ	_	30	NMOD
30	enzyme	enzyme	NN	_	26	APPO
31	in	in	IN	_	30	NMOD
32	MSUD	msud	NN	_	31	PMOD
33	.	.	.	_	8	P

1	Because	because	IN	_	20	PRP
2	the	the	DT	_	3	NMOD
3	mutation	mutation	NN	_	4	SBJ
4	is	be	VBZ	_	1	SUB
5	not	not	RB	_	4	ADV
6	in	in	IN	_	4	LOC
7	BCKDH	bckdh	NN	_	6	PMOD
8	,	,	,	_	20	P
9	the	the	DT	_	10	NMOD
10	validity	validity	NN	_	20	SBJ
11	of	of	IN	_	10	NMOD
12	this	this	DT	_	15	NMOD
13	mutant	mutant	NN	_	15	NMOD
14	mouse	mouse	NN	_	15	NMOD
15	line	line	NN	_	11	PMOD
16	for	for	IN	_	10	NMOD
17	modeling	model	VBG	_	19	NMOD
18	human	human	JJ	_	19	NMOD
19	MSUD	msud	NN	_	16	PMOD
20	is	be	VBZ	_	0	ROOT
21	questionable	questionable	JJ	_	20	PRD
22	.	.	.	_	20	P

1	The	the	DT	_	2	NMOD
2	objective	objective	NN	_	7	SBJ
3	of	of	IN	_	2	NMOD
4	the	the	DT	_	6	NMOD
5	present	present	JJ	_	6	NMOD
6	study	study	NN	_	3	PMOD
7	was	be	VBD	_	0	ROOT
8	to	to	TO	_	7	PRD
9	create	create	VB	_	8	IM
10	genetically	genetically	RB	_	11	AMOD
11	engineered	engineer	VBN	_	13	NMOD
12	murine	murine	JJ	_	13	NMOD
13	models	model	NNS	_	9	OBJ
14	of	of	IN	_	13	NMOD
15	MSUD	msud	NN	_	14	PMOD
16	that	that	WDT	_	17	SBJ
17	mimic	mimic	VBP	_	13	NMOD
18	the	the	DT	_	19	NMOD
19	pathology	pathology	NN	_	17	OBJ
20	of	of	IN	_	19	NMOD
21	the	the	DT	_	26	NMOD
22	classic	classic	JJ	_	26	NMOD
23	and	and	CC	_	22	COORD
24	intermediate	intermediate	JJ	_	23	CONJ
25	variant	variant	JJ	_	26	NMOD
26	forms	form	NNS	_	20	PMOD
27	of	of	IN	_	26	NMOD
28	the	the	DT	_	30	NMOD
29	human	human	JJ	_	30	NMOD
30	disease	disease	NN	_	27	PMOD
31	.	.	.	_	7	P

1	The	the	DT	_	3	NMOD
2	classic	classic	JJ	_	3	NMOD
3	model	model	NN	_	4	SBJ
4	was	be	VBD	_	0	ROOT
5	created	create	VBN	_	4	VC
6	by	by	IN	_	5	MNR
7	targeted	target	VBN	_	8	NMOD
8	inactivation	inactivation	NN	_	6	PMOD
9	of	of	IN	_	8	NMOD
10	the	the	DT	_	12	NMOD
11	E2	e0	NN	_	12	NMOD
12	subunit	subunit	NN	_	9	PMOD
13	of	of	IN	_	12	NMOD
14	BCKDH	bckdh	NN	_	13	PMOD
15	by	by	IN	_	8	NMOD
16	homologous	homologous	JJ	_	17	NMOD
17	recombination	recombination	NN	_	15	PMOD
18	in	in	IN	_	8	NMOD
19	embryonic	embryonic	JJ	_	22	NMOD
20	stem	stem	NN	_	22	NMOD
21	(	(	-LRB-	_	22	P
22	ES	e	NN	_	24	NMOD
23	)	)	-RRB-	_	24	P
24	cells	cell	NNS	_	18	PMOD
25	.	.	.	_	4	P

1	The	the	DT	_	2	NMOD
2	model	model	NN	_	6	SBJ
3	of	of	IN	_	2	NMOD
4	intermediate	intermediate	JJ	_	5	NMOD
5	MSUD	msud	NN	_	3	PMOD
6	was	be	VBD	_	0	ROOT
7	created	create	VBN	_	6	VC
8	by	by	IN	_	7	MNR
9	partial	partial	JJ	_	11	NMOD
10	transgenic	transgenic	JJ	_	11	NMOD
11	rescue	rescue	NN	_	8	PMOD
12	of	of	IN	_	11	NMOD
13	the	the	DT	_	16	NMOD
14	E2	e0	NN	_	16	NMOD
15	gene	gene	NN	_	16	NMOD
16	knockout	knockout	NN	_	12	PMOD
17	.	.	.	_	6	P

1	This	this	DT	_	2	NMOD
2	report	report	NN	_	3	SBJ
3	describes	describe	VBZ	_	0	ROOT
4	the	the	DT	_	5	NMOD
5	generation	generation	NN	_	3	OBJ
6	and	and	CC	_	5	COORD
7	characterization	characterization	NN	_	6	CONJ
8	of	of	IN	_	5	NMOD
9	these	these	DT	_	11	NMOD
10	murine	murine	JJ	_	11	NMOD
11	models	model	NNS	_	8	PMOD
12	of	of	IN	_	11	NMOD
13	MSUD	msud	NN	_	12	PMOD
14	.	.	.	_	3	P

1	These	these	DT	_	2	NMOD
2	models	model	NNS	_	3	SBJ
3	will	will	MD	_	0	ROOT
4	allow	allow	VB	_	3	VC
5	for	for	IN	_	4	ADV
6	the	the	DT	_	7	NMOD
7	development	development	NN	_	5	PMOD
8	of	of	IN	_	7	NMOD
9	novel	novel	JJ	_	11	NMOD
10	treatment	treatment	NN	_	11	NMOD
11	approaches	approach	NNS	_	8	PMOD
12	,	,	,	_	11	P
13	such	such	JJ	_	14	PMOD
14	as	as	IN	_	11	NMOD
15	gene	gene	NN	_	19	NMOD
16	or	or	CC	_	15	COORD
17	stem	stem	NN	_	18	NMOD
18	cell	cell	NN	_	16	CONJ
19	therapies	therapy	NNS	_	14	PMOD
20	,	,	,	_	4	P
21	to	to	TO	_	4	PRP
22	ultimately	ultimately	RB	_	21	ADV
23	cure	cure	VB	_	21	IM
24	MSUD	msud	NN	_	23	OBJ
25	.	.	.	_	3	P

1	Methods	method	NNS	_	0	ROOT

1	All	all	DT	_	2	NMOD
2	studies	study	NNS	_	5	SBJ
3	involving	involve	VBG	_	2	NMOD
4	animals	animal	NNS	_	3	OBJ
5	were	be	VBD	_	0	ROOT
6	reviewed	review	VBN	_	5	VC
7	and	and	CC	_	6	COORD
8	approved	approve	VBN	_	7	CONJ
9	by	by	IN	_	6	LGS
10	the	the	DT	_	11	NMOD
11	University	university	NNP	_	9	PMOD
12	of	of	IN	_	11	NMOD
13	Pittsburgh	pittsburgh	NNP	_	20	NMOD
14	's	's	POS	_	13	NMOD
15	Institutional	institutional	NNP	_	16	NMOD
16	Animal	animal	NNP	_	17	NMOD
17	Care	care	NNP	_	20	NMOD
18	and	and	CC	_	17	COORD
19	Use	use	NNP	_	18	CONJ
20	Committee	committee	NNP	_	12	PMOD
21	.	.	.	_	5	P

1	Gene	gene	NN	_	2	NMOD
2	knockout	knockout	NN	_	3	NMOD
3	production	production	NN	_	0	ROOT

1	A	a	DT	_	4	NMOD
2	genomic	genomic	JJ	_	4	NMOD
3	DNA	dna	NN	_	4	NMOD
4	subclone	subclone	NN	_	27	SBJ
5	of	of	IN	_	4	NMOD
6	Strain	strain	NN	_	10	NMOD
7	129	0	CD	_	9	NMOD
8	/	/	HYPH	_	7	P
9	SvJ	svj	NN	_	10	NMOD
10	DNA	dna	NN	_	5	PMOD
11	that	that	WDT	_	12	SBJ
12	contained	contain	VBD	_	4	NMOD
13	a	a	DT	_	14	NMOD
14	portion	portion	NN	_	12	OBJ
15	of	of	IN	_	14	NMOD
16	Exons	exon	NNS	_	17	NMOD
17	4	0	CD	_	15	PMOD
18	and	and	CC	_	17	COORD
19	5	0	CD	_	18	CONJ
20	of	of	IN	_	17	NMOD
21	the	the	DT	_	23	NMOD
22	E2	e0	NN	_	23	NMOD
23	gene	gene	NN	_	20	PMOD
24	and	and	CC	_	23	COORD
25	flanking	flanking	NN	_	26	NMOD
26	DNA	dna	NN	_	24	CONJ
27	was	be	VBD	_	0	ROOT
28	obtained	obtain	VBN	_	27	VC
29	from	from	IN	_	28	ADV
30	a	a	DT	_	33	NMOD
31	P1	p0	NN	_	32	NMOD
32	phage	phage	NN	_	33	NMOD
33	library	library	NN	_	29	PMOD
34	from	from	IN	_	33	NMOD
35	Genome	genome	NNP	_	38	NMOD
36	Systems	system	NNP	_	38	NMOD
37	,	,	,	_	38	P
38	Inc.	inc.	NNP	_	34	PMOD
39	,	,	,	_	38	P
40	(	(	-LRB-	_	53	P
41	St.	st.	NNP	_	42	NMOD
42	Louis	louis	NNP	_	53	DEP
43	,	,	,	_	42	P
44	MO	mo	NNP	_	42	APPO
45	;	;	:	_	53	P
46	'	'	SYM	_	53	P
47	3	0	CD	_	49	NMOD
48	-	-	HYPH	_	47	P
49	Hit	hit	NN	_	52	NMOD
50	Mouse	mouse	NNP	_	51	NMOD
51	ES	e	NNP	_	52	NMOD
52	Library	library	NNP	_	53	DEP
53	'	'	POS	_	38	PRN
54	)	)	-RRB-	_	53	P
55	.	.	.	_	27	P

1	A	a	DT	_	9	NMOD
2	positive	positive	JJ	_	4	AMOD
3	/	/	HYPH	_	2	P
4	negative	negative	JJ	_	9	NMOD
5	replacement	replacement	NN	_	6	NMOD
6	type	type	NN	_	9	NMOD
7	gene	gene	NN	_	8	NMOD
8	targeting	targeting	NN	_	9	NMOD
9	vector	vector	NN	_	13	SBJ
10	[	[	-LRB-	_	11	P
11	21	0	CD	_	9	PRN
12	]	]	-RRB-	_	11	P
13	was	be	VBD	_	0	ROOT
14	created	create	VBN	_	13	VC
15	by	by	IN	_	14	MNR
16	replacing	replace	VBG	_	15	PMOD
17	a	a	DT	_	23	NMOD
18	1.67	0	CD	_	19	NMOD
19	kb	kb	NN	_	23	NMOD
20	EcoRV	ecorv	NN	_	22	NMOD
21	-	-	HYPH	_	20	P
22	Smal	smal	NN	_	23	NMOD
23	fragment	fragment	NN	_	16	OBJ
24	that	that	WDT	_	25	SBJ
25	included	include	VBD	_	23	NMOD
26	a	a	DT	_	27	NMOD
27	portion	portion	NN	_	25	OBJ
28	of	of	IN	_	27	NMOD
29	Exon	exon	NN	_	28	PMOD
30	4	0	CD	_	29	NMOD
31	and	and	CC	_	27	COORD
32	all	all	DT	_	31	CONJ
33	of	of	IN	_	32	NMOD
34	Exon	exon	NN	_	33	PMOD
35	5	0	CD	_	34	NMOD
36	with	with	IN	_	27	NMOD
37	the	the	DT	_	40	NMOD
38	PGKneo	pgkneo	NN	_	40	NMOD
39	marker	marker	NN	_	40	NMOD
40	gene	gene	NN	_	36	PMOD
41	(	(	-LRB-	_	42	P
42	See	see	VB	_	40	PRN
43	Fig.	fig.	NN	_	44	NMOD
44	1A	0a	NN	_	42	OBJ
45	)	)	-RRB-	_	42	P
46	from	from	IN	_	40	NMOD
47	the	the	DT	_	49	NMOD
48	pPNT	ppnt	NN	_	49	NMOD
49	vector	vector	NN	_	46	PMOD
50	[	[	-LRB-	_	51	P
51	22	0	CD	_	25	PRN
52	]	]	-RRB-	_	51	P
53	.	.	.	_	13	P

1	The	the	DT	_	3	NMOD
2	targeting	targeting	NN	_	3	NMOD
3	construct	construct	NN	_	4	SBJ
4	was	be	VBD	_	0	ROOT
5	linearized	linearize	VBN	_	4	VC
6	with	with	IN	_	5	ADV
7	NotI	noti	NN	_	6	PMOD
8	and	and	CC	_	5	COORD
9	electroporated	electroporated	VBN	_	8	CONJ
10	into	into	IN	_	9	ADV
11	R1	r0	NN	_	13	NMOD
12	ES	e	NN	_	13	NMOD
13	cells	cell	NNS	_	10	PMOD
14	[	[	-LRB-	_	15	P
15	23	0	CD	_	13	PRN
16	]	]	-RRB-	_	15	P
17	under	under	IN	_	9	ADV
18	conditions	condition	NNS	_	17	PMOD
19	described	describe	VBN	_	18	NMOD
20	previously	previously	RB	_	19	TMP
21	[	[	-LRB-	_	22	P
22	24	0	CD	_	19	PRN
23	]	]	-RRB-	_	22	P
24	.	.	.	_	4	P

1	ES	e	NN	_	2	NMOD
2	cells	cell	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	selected	select	VBN	_	3	VC
5	with	with	IN	_	4	ADV
6	G418	g0	NN	_	5	PMOD
7	(	(	-LRB-	_	15	P
8	300	0	CD	_	9	NMOD
9	μg	μg	NN	_	15	DEP
10	/	/	SYM	_	11	P
11	ml	ml	NN	_	9	NMOD
12	;	;	:	_	15	P
13	Life	life	NNP	_	15	NMOD
14	Technologies	technology	NNPS	_	15	NMOD
15	Inc.	inc.	NNP	_	6	PRN
16	,	,	,	_	15	P
17	Gaithersburg	gaithersburg	NNP	_	15	APPO
18	,	,	,	_	17	P
19	MD	md	NNP	_	17	APPO
20	)	)	-RRB-	_	15	P
21	and	and	CC	_	6	COORD
22	gancyclovir	gancyclovir	NN	_	21	CONJ
23	(	(	-LRB-	_	22	P
24	2	0	CD	_	25	NMOD
25	μM	μm	NN	_	22	NMOD
26	;	;	:	_	22	P
27	gift	gift	NN	_	22	NMOD
28	of	of	IN	_	27	NMOD
29	Syntex	syntex	NNP	_	28	PMOD
30	,	,	,	_	29	P
31	Palo	palo	NNP	_	32	NMOD
32	Alto	alto	NNP	_	29	APPO
33	,	,	,	_	32	P
34	CA	ca	NNP	_	32	APPO
35	)	)	-RRB-	_	22	P
36	.	.	.	_	3	P

1	Doubly	doubly	RB	_	2	AMOD
2	resistant	resistant	JJ	_	3	NMOD
3	clones	clone	NNS	_	4	SBJ
4	were	be	VBD	_	0	ROOT
5	screened	screen	VBN	_	4	VC
6	for	for	IN	_	5	PRP
7	gene	gene	NN	_	8	NMOD
8	targeting	targeting	NN	_	6	PMOD
9	by	by	IN	_	5	MNR
10	Southern	southern	NNP	_	11	NMOD
11	blot	blot	NN	_	12	NMOD
12	analysis	analysis	NN	_	9	PMOD
13	of	of	IN	_	12	NMOD
14	BglI	bgli	NN	_	17	NMOD
15	digested	digest	VBN	_	17	NMOD
16	genomic	genomic	JJ	_	17	NMOD
17	DNA	dna	NN	_	13	PMOD
18	.	.	.	_	4	P

1	Blots	blot	NNS	_	2	SBJ
2	were	be	VBD	_	0	ROOT
3	hybridized	hybridize	VBN	_	2	VC
4	with	with	IN	_	3	MNR
5	an	an	DT	_	9	NMOD
6	Exon	exon	NN	_	8	AMOD
7	6	0	CD	_	6	NMOD
8	specific	specific	JJ	_	9	NMOD
9	probe	probe	NN	_	4	PMOD
10	that	that	WDT	_	11	SBJ
11	was	be	VBD	_	9	NMOD
12	external	external	JJ	_	11	PRD
13	to	to	IN	_	12	AMOD
14	the	the	DT	_	17	NMOD
15	gene	gene	NN	_	16	NMOD
16	targeting	targeting	NN	_	17	NMOD
17	construct	construct	NN	_	13	PMOD
18	.	.	.	_	2	P

1	Correctly	correctly	RB	_	2	AMOD
2	targeted	target	VBN	_	4	NMOD
3	ES	e	NN	_	4	NMOD
4	cells	cell	NNS	_	5	SBJ
5	were	be	VBD	_	0	ROOT
6	injected	inject	VBN	_	5	VC
7	into	into	IN	_	6	ADV
8	C57BL	c0bl	NN	_	10	NMOD
9	/	/	HYPH	_	8	P
10	6J	0j	NN	_	11	NMOD
11	blastocysts	blastocyst	NNS	_	7	PMOD
12	to	to	TO	_	6	PRP
13	produce	produce	VB	_	12	IM
14	chimeric	chimeric	JJ	_	15	NMOD
15	mice	mouse	NNS	_	13	OBJ
16	using	use	VBG	_	13	MNR
17	standard	standard	JJ	_	18	NMOD
18	procedures	procedure	NNS	_	16	OBJ
19	.	.	.	_	5	P

1	Heterozygous	heterozygous	JJ	_	2	NMOD
2	offspring	offspring	NN	_	7	SBJ
3	from	from	IN	_	2	NMOD
4	germline	germline	NN	_	5	AMOD
5	competent	competent	JJ	_	6	NMOD
6	chimeras	chimera	NNS	_	3	PMOD
7	were	be	VBD	_	0	ROOT
8	intercrossed	intercrossed	VBN	_	7	VC
9	to	to	TO	_	8	PRP
10	produce	produce	VB	_	9	IM
11	wild	wild	JJ	_	12	NMOD
12	type	type	NN	_	27	NMOD
13	(	(	-LRB-	_	16	P
14	+	+	SYM	_	16	P
15	/	/	HYPH	_	16	P
16	+	+	SYM	_	12	PRN
17	)	)	-RRB-	_	16	P
18	,	,	,	_	12	P
19	heterozygous	heterozygous	JJ	_	12	CONJ
20	(	(	-LRB-	_	23	P
21	+	+	SYM	_	23	P
22	/	/	HYPH	_	23	P
23	-	-	SYM	_	19	PRN
24	)	)	-RRB-	_	23	P
25	and	and	CC	_	19	COORD
26	homozygous	homozygous	JJ	_	25	CONJ
27	knockout	knockout	NN	_	33	NMOD
28	(	(	-LRB-	_	31	P
29	-	-	SYM	_	31	P
30	/	/	HYPH	_	31	P
31	-	-	SYM	_	27	PRN
32	)	)	-RRB-	_	31	P
33	mice	mouse	NNS	_	10	OBJ
34	.	.	.	_	7	P

1	At	at	IN	_	10	ADV
2	all	all	DT	_	3	NMOD
3	generations	generation	NNS	_	1	PMOD
4	,	,	,	_	10	P
5	+	+	SYM	_	7	P
6	/	/	HYPH	_	7	P
7	-	-	SYM	_	9	NMOD
8	breeding	breed	VBG	_	9	NMOD
9	pairs	pair	NNS	_	10	SBJ
10	were	be	VBD	_	0	ROOT
11	used	use	VBN	_	10	VC
12	.	.	.	_	10	P

1	Results	result	NNS	_	4	SBJ
2	presented	present	VBN	_	1	NMOD
3	here	here	RB	_	2	ADV
4	are	be	VBP	_	0	ROOT
5	from	from	IN	_	4	PRD
6	mice	mouse	NNS	_	5	PMOD
7	derived	derive	VBN	_	6	NMOD
8	from	from	IN	_	7	ADV
9	the	the	DT	_	12	NMOD
10	F2	f0	NN	_	12	NMOD
11	+	+	SYM	_	10	P
12	generations	generation	NNS	_	8	PMOD
13	.	.	.	_	4	P

1	All	all	DT	_	2	NMOD
2	animals	animal	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	of	of	IN	_	3	PRD
5	a	a	DT	_	16	NMOD
6	mixed	mix	VBN	_	16	NMOD
7	C57BL	c0bl	NN	_	9	NMOD
8	/	/	HYPH	_	7	P
9	6J	0j	NN	_	14	NMOD
10	×	×	SYM	_	14	P
11	Strain	strain	NN	_	14	NMOD
12	129Sv	0sv	NN	_	14	NMOD
13	/	/	HYPH	_	12	P
14	SvJ	svj	NN	_	16	NMOD
15	genetic	genetic	JJ	_	16	NMOD
16	background	background	NN	_	4	PMOD
17	.	.	.	_	3	P

1	Figure	figure	NN	_	0	ROOT
2	1	0	CD	_	1	NMOD

1	E2	e0	NN	_	5	NMOD
2	gene	gene	NN	_	3	NMOD
3	knockout	knockout	NN	_	5	NMOD
4	mouse	mouse	NN	_	5	NMOD
5	production	production	NN	_	0	ROOT
6	.	.	.	_	5	P

1	A	a	LS	_	5	NMOD
2	,	,	,	_	5	P
3	Gene	gene	NN	_	4	NMOD
4	targeting	targeting	NN	_	5	NMOD
5	strategy	strategy	NN	_	0	ROOT
6	used	use	VBN	_	5	NMOD
7	for	for	IN	_	6	PRP
8	targeting	target	VBG	_	7	PMOD
9	the	the	DT	_	11	NMOD
10	E2	e0	NN	_	11	NMOD
11	locus	locus	NN	_	8	OBJ
12	in	in	IN	_	6	LOC
13	mouse	mouse	NN	_	15	NMOD
14	ES	e	NN	_	15	NMOD
15	cells	cell	NNS	_	12	PMOD
16	.	.	.	_	5	P

1	The	the	DT	_	3	NMOD
2	targeting	targeting	NN	_	3	NMOD
3	construct	construct	NN	_	4	SBJ
4	was	be	VBD	_	0	ROOT
5	designed	design	VBN	_	4	VC
6	to	to	TO	_	5	PRP
7	delete	delete	VB	_	6	IM
8	1.67	0	CD	_	9	NMOD
9	kb	kb	NN	_	7	OBJ
10	of	of	IN	_	9	NMOD
11	sequence	sequence	NN	_	10	PMOD
12	between	between	IN	_	7	ADV
13	an	an	DT	_	15	NMOD
14	EcoRV	ecorv	NN	_	15	NMOD
15	site	site	NN	_	12	PMOD
16	in	in	IN	_	15	LOC
17	Exon	exon	NN	_	16	PMOD
18	4	0	CD	_	17	NMOD
19	and	and	CC	_	15	COORD
20	a	a	DT	_	22	NMOD
21	Smal	smal	NN	_	22	NMOD
22	site	site	NN	_	19	CONJ
23	in	in	IN	_	22	LOC
24	intron	intron	NN	_	23	PMOD
25	5	0	CD	_	24	NMOD
26	.	.	.	_	4	P

1	The	the	DT	_	5	NMOD
2	wild	wild	JJ	_	3	NMOD
3	type	type	NN	_	5	NMOD
4	E2	e0	NN	_	5	NMOD
5	gene	gene	NN	_	6	SBJ
6	contains	contain	VBZ	_	0	ROOT
7	an	an	DT	_	13	NMOD
8	~	~	SYM	_	9	P
9	16	0	CD	_	10	NMOD
10	kb	kb	NN	_	13	NMOD
11	BglI	bgli	NN	_	13	NMOD
12	restriction	restriction	NN	_	13	NMOD
13	fragment	fragment	NN	_	6	OBJ
14	that	that	WDT	_	15	SBJ
15	hybridizes	hybridize	VBZ	_	13	NMOD
16	to	to	IN	_	15	ADV
17	the	the	DT	_	21	NMOD
18	Exon	exon	NN	_	20	AMOD
19	6	0	CD	_	18	NMOD
20	specific	specific	JJ	_	21	NMOD
21	probe	probe	NN	_	16	PMOD
22	.	.	.	_	6	P

1	A	a	DT	_	5	NMOD
2	correctly	correctly	RB	_	3	AMOD
3	targeted	target	VBN	_	5	NMOD
4	E2	e0	NN	_	5	NMOD
5	locus	locus	NN	_	6	SBJ
6	harbors	harbor	VBZ	_	0	ROOT
7	an	an	DT	_	13	NMOD
8	~	~	SYM	_	9	P
9	11	0	CD	_	10	NMOD
10	kb	kb	NN	_	13	NMOD
11	BglI	bgli	NN	_	13	NMOD
12	restriction	restriction	NN	_	13	NMOD
13	fragment	fragment	NN	_	6	OBJ
14	that	that	WDT	_	15	SBJ
15	hybridizes	hybridize	VBZ	_	13	NMOD
16	to	to	IN	_	15	ADV
17	the	the	DT	_	19	NMOD
18	same	same	JJ	_	19	NMOD
19	probe	probe	NN	_	16	PMOD
20	.	.	.	_	6	P

1	Note	note	VB	_	0	ROOT
2	that	that	IN	_	1	OBJ
3	the	the	DT	_	4	NMOD
4	probe	probe	NN	_	5	SBJ
5	will	will	MD	_	2	SUB
6	not	not	RB	_	5	ADV
7	detect	detect	VB	_	5	VC
8	random	random	JJ	_	9	NMOD
9	integration	integration	NN	_	7	OBJ
10	of	of	IN	_	9	NMOD
11	the	the	DT	_	13	NMOD
12	targeting	targeting	NN	_	13	NMOD
13	vector	vector	NN	_	10	PMOD
14	because	because	IN	_	7	PRP
15	it	it	PRP	_	16	SBJ
16	is	be	VBZ	_	14	SUB
17	external	external	JJ	_	16	PRD
18	to	to	IN	_	17	AMOD
19	the	the	DT	_	21	NMOD
20	targeting	targeting	NN	_	21	NMOD
21	vector	vector	NN	_	18	PMOD
22	.	.	.	_	1	P

1	B	b	LS	_	5	NMOD
2	,	,	,	_	5	P
3	Southern	southern	NNP	_	4	NMOD
4	blot	blot	NN	_	5	NMOD
5	analysis	analysis	NN	_	0	ROOT
6	of	of	IN	_	5	NMOD
7	Bgll	bgll	NN	_	8	AMOD
8	digested	digest	VBN	_	10	NMOD
9	genomic	genomic	JJ	_	10	NMOD
10	DNA	dna	NN	_	6	PMOD
11	derived	derive	VBN	_	10	NMOD
12	from	from	IN	_	11	ADV
13	the	the	DT	_	19	NMOD
14	parental	parental	JJ	_	19	NMOD
15	wild	wild	JJ	_	16	NMOD
16	type	type	NN	_	19	NMOD
17	ES	e	NN	_	18	NMOD
18	cell	cell	NN	_	19	NMOD
19	line	line	NN	_	12	PMOD
20	(	(	-LRB-	_	21	P
21	R1	r0	NN	_	19	PRN
22	)	)	-RRB-	_	21	P
23	,	,	,	_	19	P
24	a	a	DT	_	29	NMOD
25	heterozygous	heterozygous	JJ	_	29	NMOD
26	targeted	target	VBN	_	29	NMOD
27	ES	e	NN	_	28	NMOD
28	cell	cell	NN	_	29	NMOD
29	line	line	NN	_	19	APPO
30	(	(	-LRB-	_	31	P
31	362	0	CD	_	29	PRN
32	)	)	-RRB-	_	31	P
33	,	,	,	_	12	P
34	and	and	CC	_	12	COORD
35	from	from	IN	_	34	CONJ
36	wild	wild	JJ	_	37	NMOD
37	type	type	NN	_	52	NMOD
38	(	(	-LRB-	_	41	P
39	+	+	SYM	_	41	P
40	/	/	HYPH	_	41	P
41	+	+	SYM	_	37	PRN
42	)	)	-RRB-	_	41	P
43	,	,	,	_	37	P
44	heterozygous	heterozygous	JJ	_	37	CONJ
45	(	(	-LRB-	_	48	P
46	+	+	SYM	_	48	P
47	/	/	HYPH	_	48	P
48	-	-	SYM	_	44	PRN
49	)	)	-RRB-	_	48	P
50	and	and	CC	_	44	COORD
51	homozygous	homozygous	JJ	_	50	CONJ
52	knockout	knockout	NN	_	58	NMOD
53	(	(	-LRB-	_	56	P
54	-	-	SYM	_	56	P
55	/	/	HYPH	_	56	P
56	-	-	SYM	_	52	PRN
57	)	)	-RRB-	_	56	P
58	mice	mouse	NNS	_	35	PMOD
59	.	.	.	_	5	P

1	The	the	DT	_	2	NMOD
2	blot	blot	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	hybridized	hybridize	VBN	_	3	VC
5	with	with	IN	_	4	MNR
6	an	an	DT	_	10	NMOD
7	Exon	exon	NN	_	9	AMOD
8	6	0	CD	_	7	NMOD
9	specific	specific	JJ	_	10	NMOD
10	probe	probe	NN	_	5	PMOD
11	.	.	.	_	3	P

1	C	c	LS	_	4	NMOD
2	,	,	,	_	4	P
3	Immunohistochemical	immunohistochemical	JJ	_	4	NMOD
4	analysis	analysis	NN	_	0	ROOT
5	of	of	IN	_	4	NMOD
6	fresh	fresh	JJ	_	7	AMOD
7	frozen	freeze	VBN	_	9	NMOD
8	liver	liver	NN	_	9	NMOD
9	sections	section	NNS	_	5	PMOD
10	from	from	IN	_	9	NMOD
11	control	control	NN	_	19	NMOD
12	(	(	-LRB-	_	15	P
13	+	+	SYM	_	15	P
14	/	/	HYPH	_	15	P
15	+	+	SYM	_	11	PRN
16	)	)	-RRB-	_	15	P
17	and	and	CC	_	11	COORD
18	E2	e0	NN	_	17	CONJ
19	knockout	knockout	NN	_	29	NMOD
20	(	(	-LRB-	_	23	P
21	-	-	SYM	_	23	P
22	/	/	HYPH	_	23	P
23	-	-	SYM	_	19	PRN
24	)	)	-RRB-	_	23	P
25	postnatal	postnatal	JJ	_	26	NMOD
26	day	day	NN	_	29	NMOD
27	1	0	CD	_	26	NMOD
28	mouse	mouse	NN	_	29	NMOD
29	pups	pup	NNS	_	10	PMOD
30	.	.	.	_	4	P

1	Sections	section	NNS	_	2	SBJ
2	were	be	VBD	_	0	ROOT
3	stained	stain	VBN	_	2	VC
4	for	for	IN	_	3	ADV
5	E2	e0	NN	_	4	PMOD
6	using	use	VBG	_	3	MNR
7	an	an	DT	_	10	NMOD
8	E2	e0	NN	_	9	AMOD
9	specific	specific	JJ	_	10	NMOD
10	antibody	antibody	NN	_	6	OBJ
11	(	(	-LRB-	_	12	P
12	green	green	JJ	_	10	PRN
13	)	)	-RRB-	_	12	P
14	and	and	CC	_	10	COORD
15	a	a	DT	_	17	NMOD
16	nuclear	nuclear	JJ	_	17	NMOD
17	stain	stain	NN	_	14	CONJ
18	(	(	-LRB-	_	19	P
19	blue	blue	JJ	_	17	PRN
20	)	)	-RRB-	_	19	P
21	.	.	.	_	2	P

1	Note	note	VB	_	0	ROOT
2	the	the	DT	_	4	NMOD
3	complete	complete	JJ	_	4	NMOD
4	absence	absence	NN	_	1	OBJ
5	of	of	IN	_	4	NMOD
6	E2	e0	NN	_	7	NMOD
7	immunoreactivity	immunoreactivity	NN	_	5	PMOD
8	in	in	IN	_	1	LOC
9	the	the	DT	_	10	NMOD
10	section	section	NN	_	8	PMOD
11	from	from	IN	_	10	NMOD
12	the	the	DT	_	14	NMOD
13	knockout	knockout	NN	_	14	NMOD
14	mouse	mouse	NN	_	11	PMOD
15	.	.	.	_	1	P

1	D	d	LS	_	5	DEP
2	,	,	,	_	5	P
3	Similar	similar	JJ	_	4	NMOD
4	results	result	NNS	_	5	SBJ
5	were	be	VBD	_	0	ROOT
6	observed	observe	VBN	_	5	VC
7	upon	upon	IN	_	6	ADV
8	immunohistochemical	immunohistochemical	JJ	_	9	NMOD
9	analysis	analysis	NN	_	7	PMOD
10	of	of	IN	_	9	NMOD
11	primary	primary	JJ	_	16	NMOD
12	mouse	mouse	NN	_	14	NMOD
13	embryonic	embryonic	JJ	_	14	NMOD
14	fibroblasts	fibroblast	NNS	_	16	NMOD
15	(	(	-LRB-	_	16	P
16	MEFs	mefs	NNS	_	10	PMOD
17	)	)	-RRB-	_	5	P
18	.	.	.	_	5	P

1	Note	note	VB	_	0	ROOT
2	that	that	IN	_	1	OBJ
3	the	the	DT	_	6	NMOD
4	readily	readily	RB	_	5	AMOD
5	detectable	detectable	JJ	_	6	NMOD
6	signal	signal	NN	_	13	SBJ
7	for	for	IN	_	6	NMOD
8	E2	e0	NN	_	7	PMOD
9	in	in	IN	_	6	LOC
10	the	the	DT	_	12	NMOD
11	control	control	NN	_	12	NMOD
12	cells	cell	NNS	_	9	PMOD
13	was	be	VBD	_	2	SUB
14	present	present	JJ	_	13	PRD
15	in	in	IN	_	14	AMOD
16	a	a	DT	_	17	NMOD
17	pattern	pattern	NN	_	15	PMOD
18	characteristic	characteristic	JJ	_	17	NMOD
19	of	of	IN	_	18	AMOD
20	mitochondria	mitochondrion	NNS	_	19	PMOD
21	,	,	,	_	20	P
22	the	the	DT	_	24	NMOD
23	subcellular	subcellular	JJ	_	24	NMOD
24	location	location	NN	_	20	APPO
25	of	of	IN	_	24	NMOD
26	BCKDH	bckdh	NN	_	25	PMOD
27	.	.	.	_	1	P

1	Production	production	NN	_	0	ROOT
2	of	of	IN	_	1	NMOD
3	transgenic	transgenic	JJ	_	4	NMOD
4	mice	mouse	NNS	_	2	PMOD

1	Standard	standard	JJ	_	3	NMOD
2	molecular	molecular	JJ	_	3	NMOD
3	techniques	technique	NNS	_	4	SBJ
4	were	be	VBD	_	0	ROOT
5	used	use	VBN	_	4	VC
6	to	to	TO	_	5	PRP
7	assemble	assemble	VB	_	6	IM
8	the	the	DT	_	10	NMOD
9	transgenic	transgenic	JJ	_	10	NMOD
10	construct	construct	NN	_	7	OBJ
11	,	,	,	_	10	P
12	pTRE	ptre	NN	_	14	NMOD
13	-	-	HYPH	_	12	P
14	E2	e0	NN	_	10	APPO
15	.	.	.	_	4	P

1	This	this	DT	_	2	NMOD
2	transgene	transgene	NN	_	3	SBJ
3	contains	contain	VBZ	_	0	ROOT
4	the	the	DT	_	11	NMOD
5	tetracycline	tetracycline	NN	_	11	NMOD
6	responsive	responsive	JJ	_	11	NMOD
7	hCMV	hcmv	NN	_	11	NMOD
8	*	*	SYM	_	7	P
9	-	-	HYPH	_	7	P
10	1	0	CD	_	7	NMOD
11	promoter	promoter	NN	_	3	OBJ
12	[	[	-LRB-	_	11	P
13	consisting	consist	VBG	_	11	NMOD
14	of	of	IN	_	13	ADV
15	the	the	DT	_	20	NMOD
16	tetracycline	tetracycline	NN	_	18	NMOD
17	responsive	responsive	JJ	_	18	NMOD
18	element	element	NN	_	20	NMOD
19	(	(	-LRB-	_	20	P
20	TRE	tre	NN	_	14	PMOD
21	)	)	-RRB-	_	20	P
22	and	and	CC	_	20	COORD
23	a	a	DT	_	26	NMOD
24	minimal	minimal	JJ	_	26	NMOD
25	hCMV	hcmv	NN	_	26	NMOD
26	promoter	promoter	NN	_	22	CONJ
27	]	]	-RRB-	_	26	P
28	[	[	-LRB-	_	29	P
29	25	0	CD	_	26	PRN
30	]	]	-RRB-	_	29	P
31	from	from	IN	_	26	NMOD
32	pTRE2	ptre0	NN	_	31	PMOD
33	(	(	-LRB-	_	35	P
34	Clontech	clontech	NNP	_	35	NMOD
35	Inc.	inc.	NNP	_	26	PRN
36	,	,	,	_	35	P
37	Mt.	mt.	NNP	_	38	NMOD
38	View	view	NNP	_	35	APPO
39	,	,	,	_	38	P
40	CA	ca	NNP	_	38	APPO
41	)	)	-RRB-	_	35	P
42	,	,	,	_	11	P
43	a	a	DT	_	45	NMOD
44	chimeric	chimeric	JJ	_	45	NMOD
45	intron	intron	NN	_	11	CONJ
46	from	from	IN	_	45	NMOD
47	pCI	pci	NN	_	46	PMOD
48	(	(	-LRB-	_	49	P
49	Promega	promega	NNP	_	45	PRN
50	)	)	-RRB-	_	49	P
51	to	to	TO	_	45	NMOD
52	increase	increase	VB	_	51	IM
53	message	message	NN	_	54	NMOD
54	stability	stability	NN	_	52	OBJ
55	and	and	CC	_	54	COORD
56	expression	expression	NN	_	55	CONJ
57	[	[	-LRB-	_	60	P
58	26	0	CD	_	60	NMOD
59	,	,	,	_	60	P
60	27	0	CD	_	52	PRN
61	]	]	-RRB-	_	60	P
62	,	,	,	_	45	P
63	a	a	DT	_	66	NMOD
64	Kozak	kozak	NN	_	66	NMOD
65	consensus	consensus	NN	_	66	NMOD
66	sequence	sequence	NN	_	45	CONJ
67	at	at	IN	_	66	LOC
68	the	the	DT	_	70	NMOD
69	initiation	initiation	NN	_	70	NMOD
70	codon	codon	NN	_	67	PMOD
71	to	to	TO	_	66	NMOD
72	optimize	optimize	VB	_	71	IM
73	translation	translation	NN	_	72	OBJ
74	[	[	-LRB-	_	75	P
75	28	0	CD	_	72	PRN
76	]	]	-RRB-	_	75	P
77	,	,	,	_	66	P
78	the	the	DT	_	81	NMOD
79	human	human	JJ	_	81	NMOD
80	E2	e0	NN	_	81	NMOD
81	cDNA	cdna	NN	_	66	CONJ
82	which	which	WDT	_	83	SBJ
83	has	have	VBZ	_	81	NMOD
84	been	be	VBN	_	83	VC
85	modified	modify	VBN	_	84	VC
86	to	to	TO	_	85	PRP
87	contain	contain	VB	_	86	IM
88	a	a	DT	_	92	NMOD
89	4	0	CD	_	92	NMOD
90	×	×	SYM	_	89	P
91	alanine	alanine	NN	_	92	NMOD
92	linker	linker	NN	_	87	OBJ
93	followed	follow	VBN	_	92	NMOD
94	by	by	IN	_	93	LGS
95	a	a	DT	_	100	NMOD
96	c	c	NN	_	98	NMOD
97	-	-	HYPH	_	96	P
98	myc	myc	NN	_	100	NMOD
99	epitope	epitope	NN	_	100	NMOD
100	tag	tag	NN	_	94	PMOD
101	at	at	IN	_	100	LOC
102	the	the	DT	_	104	NMOD
103	carboxy	carboxy	NN	_	104	NMOD
104	terminus	terminus	NN	_	101	PMOD
105	to	to	TO	_	100	NMOD
106	facilitate	facilitate	VB	_	105	IM
107	detection	detection	NN	_	106	OBJ
108	,	,	,	_	81	P
109	and	and	CC	_	81	COORD
110	an	an	DT	_	114	NMOD
111	SV40	sv0	NN	_	114	NMOD
112	late	late	JJ	_	114	NMOD
113	polyadenylation	polyadenylation	NN	_	114	NMOD
114	sequence	sequence	NN	_	109	CONJ
115	from	from	IN	_	114	NMOD
116	pCI	pci	NN	_	115	PMOD
117	for	for	IN	_	114	NMOD
118	enhanced	enhance	VBN	_	120	NMOD
119	mRNA	mrna	NN	_	120	NMOD
120	stability	stability	NN	_	117	PMOD
121	and	and	CC	_	120	COORD
122	translation	translation	NN	_	121	CONJ
123	.	.	.	_	3	P

1	The	the	DT	_	7	NMOD
2	2.48	0	CD	_	3	NMOD
3	kb	kb	NN	_	7	NMOD
4	TRE	tre	NN	_	6	NMOD
5	-	-	HYPH	_	4	P
6	E2	e0	NN	_	7	NMOD
7	transgene	transgene	NN	_	8	SBJ
8	was	be	VBD	_	0	ROOT
9	purified	purify	VBN	_	8	VC
10	from	from	IN	_	9	ADV
11	vector	vector	NN	_	12	NMOD
12	sequences	sequence	NNS	_	10	PMOD
13	following	follow	VBG	_	9	ADV
14	digestion	digestion	NN	_	13	PMOD
15	with	with	IN	_	14	NMOD
16	XhoI	xhoi	NN	_	15	PMOD
17	and	and	CC	_	16	COORD
18	BamHI	bamhi	NN	_	17	CONJ
19	and	and	CC	_	9	COORD
20	injected	inject	VBN	_	19	CONJ
21	into	into	IN	_	20	ADV
22	C57BL	c0bl	NN	_	24	NMOD
23	/	/	HYPH	_	22	P
24	6J	0j	NN	_	30	NMOD
25	or	or	CC	_	24	COORD
26	C57BL	c0bl	NN	_	28	NMOD
27	/	/	HYPH	_	26	P
28	6J	0j	NN	_	25	CONJ
29	×	×	SYM	_	30	P
30	Strain	strain	NN	_	33	NMOD
31	129SvEv	0svev	NN	_	33	NMOD
32	mouse	mouse	NN	_	33	NMOD
33	embryos	embryo	NNS	_	21	PMOD
34	at	at	IN	_	9	LOC
35	the	the	DT	_	38	NMOD
36	transgenic	transgenic	JJ	_	38	NMOD
37	core	core	NN	_	38	NMOD
38	facilities	facility	NNS	_	34	PMOD
39	of	of	IN	_	38	NMOD
40	the	the	DT	_	41	NMOD
41	University	university	NNP	_	39	PMOD
42	of	of	IN	_	41	NMOD
43	Pittsburgh	pittsburgh	NNP	_	42	PMOD
44	and	and	CC	_	41	COORD
45	the	the	DT	_	46	NMOD
46	University	university	NNP	_	44	CONJ
47	of	of	IN	_	46	NMOD
48	Cincinnati	cincinnati	NNP	_	47	PMOD
49	,	,	,	_	9	P
50	respectively	respectively	RB	_	9	ADV
51	.	.	.	_	8	P

1	Genomic	genomic	JJ	_	2	NMOD
2	DNA	dna	NN	_	8	SBJ
3	from	from	IN	_	2	NMOD
4	the	the	DT	_	5	NMOD
5	tail	tail	NN	_	3	PMOD
6	of	of	IN	_	5	NMOD
7	mice	mouse	NNS	_	6	PMOD
8	was	be	VBD	_	0	ROOT
9	screened	screen	VBN	_	8	VC
10	by	by	IN	_	9	MNR
11	Southern	southern	NNP	_	12	NMOD
12	blot	blot	NN	_	13	NMOD
13	analysis	analysis	NN	_	10	PMOD
14	following	follow	VBG	_	9	ADV
15	digestion	digestion	NN	_	14	PMOD
16	with	with	IN	_	15	NMOD
17	EcoRI	ecori	NN	_	16	PMOD
18	and	and	CC	_	15	COORD
19	hybridization	hybridization	NN	_	18	CONJ
20	to	to	IN	_	19	NMOD
21	an	an	DT	_	25	NMOD
22	~	~	SYM	_	23	P
23	400	0	CD	_	24	NMOD
24	bp	bp	NN	_	25	NMOD
25	probe	probe	NN	_	20	PMOD
26	derived	derive	VBN	_	25	NMOD
27	from	from	IN	_	26	ADV
28	the	the	DT	_	30	NMOD
29	SV40	sv0	NN	_	30	NMOD
30	portion	portion	NN	_	27	PMOD
31	of	of	IN	_	30	NMOD
32	the	the	DT	_	36	NMOD
33	TRE	tre	NN	_	35	NMOD
34	-	-	HYPH	_	33	P
35	E2	e0	NN	_	36	NMOD
36	transgene	transgene	NN	_	31	PMOD
37	.	.	.	_	8	P

1	Production	production	NN	_	0	ROOT
2	of	of	IN	_	1	NMOD
3	intermediate	intermediate	JJ	_	6	NMOD
4	MSUD	msud	NN	_	6	NMOD
5	murine	murine	JJ	_	6	NMOD
6	model	model	NN	_	2	PMOD

1	The	the	DT	_	7	NMOD
2	various	various	JJ	_	7	NMOD
3	TRE	tre	NN	_	5	NMOD
4	-	-	HYPH	_	3	P
5	E2	e0	NN	_	7	NMOD
6	transgenic	transgenic	JJ	_	7	NMOD
7	lines	line	NNS	_	9	SBJ
8	produced	produce	VBN	_	7	NMOD
9	were	be	VBD	_	0	ROOT
10	mated	mate	VBN	_	9	VC
11	independently	independently	RB	_	10	ADV
12	to	to	IN	_	10	ADV
13	mice	mouse	NNS	_	12	PMOD
14	that	that	WDT	_	15	SBJ
15	were	be	VBD	_	13	NMOD
16	heterozygous	heterozygous	JJ	_	15	PRD
17	for	for	IN	_	16	AMOD
18	both	both	CC	_	21	COORD
19	the	the	DT	_	21	NMOD
20	E2	e0	NN	_	21	NMOD
21	knockout	knockout	NN	_	17	PMOD
22	and	and	CC	_	21	COORD
23	the	the	DT	_	27	NMOD
24	LAP	lap	NN	_	26	NMOD
25	-	-	HYPH	_	24	P
26	tTA	tta	NN	_	27	NMOD
27	transgene	transgene	NN	_	22	CONJ
28	[	[	-LRB-	_	56	P
29	Tg	tg	NN	_	37	NMOD
30	(	(	-LRB-	_	31	P
31	tTALap	ttalap	NN	_	37	PRN
32	)	)	-RRB-	_	31	P
33	Bjd	bjd	NN	_	35	NMOD
34	/	/	HYPH	_	33	P
35	J	j	NN	_	37	NMOD
36	;	;	:	_	37	P
37	Stock	stock	NN	_	56	DEP
38	3272	0	CD	_	37	NMOD
39	;	;	:	_	56	P
40	The	the	DT	_	42	NMOD
41	Jackson	jackson	NNP	_	42	NMOD
42	Laboratory	laboratory	NNP	_	56	DEP
43	,	,	,	_	42	P
44	Bar	bar	NNP	_	45	NMOD
45	Harbor	harbor	NNP	_	42	APPO
46	,	,	,	_	45	P
47	ME	me	NNP	_	45	APPO
48	;	;	:	_	56	P
49	NMRI	nmri	NN	_	55	NMOD
50	×	×	SYM	_	55	P
51	FVB	fvb	NN	_	55	NMOD
52	×	×	SYM	_	55	P
53	C57BL	c0bl	NN	_	55	NMOD
54	/	/	HYPH	_	53	P
55	6J	0j	NN	_	56	NMOD
56	background	background	NN	_	10	PRN
57	]	]	-RRB-	_	56	P
58	.	.	.	_	9	P

1	Interbreeding	interbreeding	NN	_	13	SBJ
2	of	of	IN	_	1	NMOD
3	animals	animal	NNS	_	2	PMOD
4	that	that	WDT	_	5	SBJ
5	were	be	VBD	_	3	NMOD
6	heterozygous	heterozygous	JJ	_	5	PRD
7	for	for	IN	_	6	AMOD
8	both	both	DT	_	9	NMOD
9	transgenes	transgene	NNS	_	7	PMOD
10	and	and	CC	_	9	COORD
11	the	the	DT	_	12	NMOD
12	knockout	knockout	NN	_	10	CONJ
13	resulted	result	VBD	_	0	ROOT
14	in	in	IN	_	13	ADV
15	the	the	DT	_	16	NMOD
16	production	production	NN	_	14	PMOD
17	of	of	IN	_	16	NMOD
18	mice	mouse	NNS	_	17	PMOD
19	with	with	IN	_	18	NMOD
20	a	a	DT	_	21	NMOD
21	variety	variety	NN	_	19	PMOD
22	of	of	IN	_	21	NMOD
23	genotypes	genotype	NNS	_	22	PMOD
24	including	include	VBG	_	18	NMOD
25	some	some	DT	_	26	NMOD
26	animals	animal	NNS	_	24	PMOD
27	that	that	WDT	_	28	SBJ
28	were	be	VBD	_	26	NMOD
29	homozygous	homozygous	JJ	_	28	PRD
30	for	for	IN	_	29	AMOD
31	the	the	DT	_	32	NMOD
32	knockout	knockout	NN	_	30	PMOD
33	and	and	CC	_	28	COORD
34	were	be	VBD	_	33	CONJ
35	positive	positive	JJ	_	34	PRD
36	for	for	IN	_	35	AMOD
37	both	both	DT	_	38	NMOD
38	transgenes	transgene	NNS	_	36	PMOD
39	(	(	-LRB-	_	41	P
40	we	we	PRP	_	41	SBJ
41	refer	refer	VBP	_	34	PRN
42	to	to	IN	_	41	ADV
43	this	this	DT	_	44	NMOD
44	genotype	genotype	NN	_	42	PMOD
45	as	as	IN	_	41	ADV
46	the	the	DT	_	50	NMOD
47	``	``	``	_	50	P
48	rescue	rescue	NN	_	50	NMOD
49	''	''	''	_	50	P
50	genotype	genotype	NN	_	45	PMOD
51	)	)	-RRB-	_	41	P
52	.	.	.	_	13	P

1	If	if	IN	_	25	ADV
2	our	our	PRP$	_	3	NMOD
3	strategy	strategy	NN	_	13	SBJ
4	for	for	IN	_	3	NMOD
5	rescuing	rescue	VBG	_	4	PMOD
6	the	the	DT	_	9	NMOD
7	neonatal	neonatal	JJ	_	9	NMOD
8	lethal	lethal	JJ	_	9	NMOD
9	phenotype	phenotype	NN	_	5	OBJ
10	of	of	IN	_	9	NMOD
11	the	the	DT	_	12	NMOD
12	knockout	knockout	NN	_	10	PMOD
13	were	be	VBD	_	1	SUB
14	successful	successful	JJ	_	13	PRD
15	,	,	,	_	25	P
16	then	then	RB	_	25	ADV
17	those	those	DT	_	20	NMOD
18	homozygous	homozygous	JJ	_	20	NMOD
19	knockout	knockout	NN	_	20	NMOD
20	animals	animal	NNS	_	25	SBJ
21	that	that	WDT	_	22	SBJ
22	had	have	VBD	_	20	NMOD
23	both	both	DT	_	24	NMOD
24	transgenes	transgene	NNS	_	22	OBJ
25	would	would	MD	_	0	ROOT
26	survive	survive	VB	_	25	VC
27	beyond	beyond	IN	_	26	TMP
28	the	the	DT	_	30	NMOD
29	neonatal	neonatal	JJ	_	30	NMOD
30	period	period	NN	_	27	PMOD
31	.	.	.	_	25	P

1	Genotyping	genotyping	NN	_	0	ROOT

1	All	all	DT	_	2	NMOD
2	mice	mouse	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	genotyped	genotyped	VBN	_	3	VC
5	by	by	IN	_	4	MNR
6	Southern	southern	NNP	_	7	NMOD
7	blot	blot	NN	_	8	NMOD
8	analysis	analysis	NN	_	5	PMOD
9	.	.	.	_	3	P

1	Genomic	genomic	JJ	_	2	NMOD
2	DNAs	dna	NNS	_	7	SBJ
3	prepared	prepare	VBN	_	2	NMOD
4	from	from	IN	_	3	MNR
5	tail	tail	NN	_	6	NMOD
6	snips	snip	NNS	_	4	PMOD
7	were	be	VBD	_	0	ROOT
8	digested	digest	VBN	_	7	VC
9	with	with	IN	_	8	MNR
10	an	an	DT	_	13	NMOD
11	appropriate	appropriate	JJ	_	13	NMOD
12	restriction	restriction	NN	_	13	NMOD
13	enzyme	enzyme	NN	_	9	PMOD
14	,	,	,	_	8	P
15	size	size	NN	_	16	DEP
16	fractionated	fractionate	VBN	_	8	CONJ
17	by	by	IN	_	16	MNR
18	agarose	agarose	NN	_	19	NMOD
19	gel	gel	NN	_	20	NMOD
20	electrophoresis	electrophoresis	NN	_	17	PMOD
21	,	,	,	_	16	P
22	blotted	blot	VBN	_	16	CONJ
23	to	to	IN	_	22	ADV
24	nylon	nylon	NN	_	23	PMOD
25	,	,	,	_	22	P
26	and	and	CC	_	22	COORD
27	probed	probe	VBN	_	26	CONJ
28	using	use	VBG	_	27	MNR
29	standard	standard	JJ	_	30	NMOD
30	procedures	procedure	NNS	_	28	OBJ
31	.	.	.	_	7	P

1	Immunohistochemistry	immunohistochemistry	NN	_	0	ROOT

1	Primary	primary	JJ	_	4	NMOD
2	mouse	mouse	NN	_	4	NMOD
3	embryonic	embryonic	JJ	_	4	NMOD
4	fibroblasts	fibroblast	NNS	_	5	SBJ
5	were	be	VBD	_	0	ROOT
6	prepared	prepare	VBN	_	5	VC
7	from	from	IN	_	6	MNR
8	embryonic	embryonic	JJ	_	14	NMOD
9	day	day	NN	_	11	NMOD
10	~	~	SYM	_	11	P
11	16.5	0	CD	_	14	NMOD
12	–	–	SYM	_	13	P
13	18.5	0	CD	_	11	NMOD
14	fetuses	fetus	NNS	_	7	PMOD
15	as	as	IN	_	6	ADV
16	described	describe	VBN	_	15	SUB
17	[	[	-LRB-	_	18	P
18	29	0	CD	_	6	PRN
19	]	]	-RRB-	_	18	P
20	.	.	.	_	5	P

1	Fibroblasts	fibroblast	NNS	_	2	SBJ
2	were	be	VBD	_	0	ROOT
3	passed	pass	VBN	_	2	VC
4	onto	onto	IN	_	3	ADV
5	glass	glass	NN	_	4	PMOD
6	,	,	,	_	3	P
7	fixed	fix	VBN	_	3	CONJ
8	in	in	IN	_	7	MNR
9	2	0	CD	_	10	NMOD
10	%	%	NN	_	11	NMOD
11	paraformaldehyde	paraformaldehyde	NN	_	8	PMOD
12	in	in	IN	_	7	MNR
13	PBS	pb	NN	_	12	PMOD
14	for	for	IN	_	7	TMP
15	10	0	CD	_	16	NMOD
16	minutes	minute	NNS	_	14	PMOD
17	,	,	,	_	7	P
18	permeabilized	permeabilized	VBN	_	7	CONJ
19	in	in	IN	_	18	MNR
20	2	0	CD	_	21	NMOD
21	%	%	NN	_	22	NMOD
22	paraformaldehyde	paraformaldehyde	NN	_	19	PMOD
23	containing	contain	VBG	_	22	NMOD
24	0.1	0	CD	_	25	NMOD
25	%	%	NN	_	27	NMOD
26	Triton	triton	NN	_	27	NMOD
27	X100	x0	NN	_	23	OBJ
28	for	for	IN	_	18	TMP
29	10	0	CD	_	30	NMOD
30	minutes	minute	NNS	_	28	PMOD
31	and	and	CC	_	18	COORD
32	washed	wash	VBD	_	31	CONJ
33	three	three	CD	_	34	NMOD
34	times	time	NNS	_	32	TMP
35	in	in	IN	_	32	MNR
36	PBS	pb	NN	_	35	PMOD
37	containing	contain	VBG	_	36	NMOD
38	0.5	0	CD	_	39	NMOD
39	%	%	NN	_	40	NMOD
40	BSA	bsa	NN	_	37	OBJ
41	and	and	CC	_	40	COORD
42	0.15	0	CD	_	43	NMOD
43	%	%	NN	_	44	NMOD
44	glycine	glycine	NN	_	41	CONJ
45	,	,	,	_	37	P
46	pH	ph	NN	_	37	ADV
47	7.4	0	CD	_	46	NMOD
48	(	(	-LRB-	_	50	P
49	Buffer	buffer	NN	_	50	NMOD
50	A	a	NN	_	37	PRN
51	)	)	-RRB-	_	50	P
52	.	.	.	_	2	P

1	Following	follow	VBG	_	29	ADV
2	a	a	DT	_	5	NMOD
3	30	0	CD	_	4	NMOD
4	min	min	NN	_	5	NMOD
5	incubation	incubation	NN	_	1	PMOD
6	with	with	IN	_	5	NMOD
7	purified	purify	VBN	_	9	NMOD
8	goat	goat	NN	_	9	NMOD
9	IgG	igg	NN	_	6	PMOD
10	(	(	-LRB-	_	13	P
11	50	0	CD	_	13	NMOD
12	(	(	-LRB-	_	13	P
13	μg	μg	NN	_	9	PRN
14	/	/	SYM	_	15	P
15	ml	ml	NN	_	13	NMOD
16	)	)	-RRB-	_	13	P
17	at	at	IN	_	5	NMOD
18	25	0	CD	_	19	NMOD
19	°C	°c	NN	_	17	PMOD
20	and	and	CC	_	5	COORD
21	three	three	CD	_	23	NMOD
22	additional	additional	JJ	_	23	NMOD
23	washes	wash	NNS	_	20	CONJ
24	with	with	IN	_	23	NMOD
25	Buffer	buffer	NN	_	26	NMOD
26	A	a	NN	_	24	PMOD
27	,	,	,	_	29	P
28	cells	cell	NNS	_	29	SBJ
29	were	be	VBD	_	0	ROOT
30	incubated	incubate	VBN	_	29	VC
31	for	for	IN	_	30	TMP
32	60	0	CD	_	33	NMOD
33	min	min	NN	_	31	PMOD
34	with	with	IN	_	30	ADV
35	E2	e0	NN	_	37	AMOD
36	-	-	HYPH	_	35	P
37	specific	specific	JJ	_	38	NMOD
38	antiserum	antiserum	NN	_	34	PMOD
39	[	[	-LRB-	_	40	P
40	30	0	CD	_	38	PRN
41	]	]	-RRB-	_	40	P
42	at	at	IN	_	38	NMOD
43	1	0	CD	_	44	NMOD
44	μg	μg	NN	_	42	PMOD
45	/	/	SYM	_	46	P
46	ml	ml	NN	_	44	NMOD
47	followed	follow	VBN	_	30	OPRD
48	by	by	IN	_	47	LGS
49	three	three	CD	_	50	NMOD
50	washes	wash	NNS	_	48	PMOD
51	in	in	IN	_	50	NMOD
52	Buffer	buffer	NN	_	53	NMOD
53	A	a	NN	_	51	PMOD
54	and	and	CC	_	50	COORD
55	60	0	CD	_	56	NMOD
56	minute	minute	NN	_	57	NMOD
57	incubation	incubation	NN	_	54	CONJ
58	in	in	IN	_	57	NMOD
59	fluorescently	fluorescently	RB	_	60	AMOD
60	labeled	label	VBN	_	62	NMOD
61	second	$#ORD#$	JJ	_	62	NMOD
62	antibody	antibody	NN	_	58	PMOD
63	(	(	-LRB-	_	67	P
64	1	0	CD	_	67	NMOD
65	–	–	SYM	_	64	P
66	2	0	CD	_	64	QMOD
67	μg	μg	NN	_	30	PRN
68	/	/	SYM	_	69	P
69	ml	ml	NN	_	67	NMOD
70	)	)	-RRB-	_	67	P
71	.	.	.	_	29	P

1	The	the	DT	_	2	NMOD
2	cells	cell	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	then	then	RB	_	3	ADV
5	washed	wash	VBN	_	3	VC
6	six	six	CD	_	7	NMOD
7	times	time	NNS	_	5	TMP
8	(	(	-LRB-	_	10	P
9	5	0	CD	_	10	NMOD
10	min	min	NN	_	7	PRN
11	/	/	SYM	_	12	P
12	wash	wash	NN	_	10	NMOD
13	)	)	-RRB-	_	10	P
14	in	in	IN	_	5	MNR
15	Buffer	buffer	NN	_	16	NMOD
16	A	a	NN	_	14	PMOD
17	and	and	CC	_	5	COORD
18	then	then	RB	_	19	ADV
19	mounted	mount	VBN	_	17	CONJ
20	in	in	IN	_	19	MNR
21	gelvatol	gelvatol	NN	_	20	PMOD
22	(	(	-LRB-	_	23	P
23	Monsanto	monsanto	NNP	_	21	PRN
24	,	,	,	_	23	P
25	St	st	NNP	_	26	NMOD
26	Louis	louis	NNP	_	23	APPO
27	)	)	-RRB-	_	23	P
28	.	.	.	_	3	P

1	When	when	WRB	_	7	TMP
2	livers	liver	NNS	_	6	SBJ
3	from	from	IN	_	2	NMOD
4	newborn	newborn	JJ	_	5	NMOD
5	pups	pup	NNS	_	3	PMOD
6	were	be	VBD	_	10	TMP
7	examined	examine	VBN	_	6	VC
8	,	,	,	_	10	P
9	fixation	fixation	NN	_	10	SBJ
10	was	be	VBD	_	0	ROOT
11	by	by	IN	_	10	PRD
12	immersion	immersion	NN	_	11	PMOD
13	in	in	IN	_	12	NMOD
14	2	0	CD	_	15	NMOD
15	%	%	NN	_	16	NMOD
16	paraformaldehyde	paraformaldehyde	NN	_	13	PMOD
17	followed	follow	VBN	_	12	NMOD
18	by	by	IN	_	17	LGS
19	cryoprotection	cryoprotection	NN	_	18	PMOD
20	and	and	CC	_	19	COORD
21	shock	shock	NN	_	22	NMOD
22	freezing	freezing	NN	_	20	CONJ
23	in	in	IN	_	19	NMOD
24	liquid	liquid	JJ	_	25	NMOD
25	nitrogen	nitrogen	NN	_	26	AMOD
26	cooled	cool	VBN	_	27	NMOD
27	isopentane	isopentane	NN	_	23	PMOD
28	and	and	CC	_	19	COORD
29	sectioning	sectioning	NN	_	28	CONJ
30	(	(	-LRB-	_	32	P
31	5	0	CD	_	32	NMOD
32	microns	micron	NNS	_	29	PRN
33	)	)	-RRB-	_	32	P
34	.	.	.	_	10	P

1	Otherwise	otherwise	RB	_	3	ADV
2	processing	processing	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	as	as	IN	_	3	PRD
5	for	for	IN	_	4	PMOD
6	the	the	DT	_	7	NMOD
7	cells	cell	NNS	_	5	PMOD
8	above	above	RB	_	7	NMOD
9	(	(	-LRB-	_	3	P
10	without	without	IN	_	3	ADV
11	the	the	DT	_	15	NMOD
12	fixation	fixation	NN	_	15	NMOD
13	and	and	CC	_	12	COORD
14	permabilization	permabilization	NN	_	13	CONJ
15	steps	step	NNS	_	10	PMOD
16	)	)	-RRB-	_	3	P
17	.	.	.	_	3	P

1	Amino	amino	NN	_	2	NMOD
2	acid	acid	NN	_	3	NMOD
3	analysis	analysis	NN	_	0	ROOT

1	Blood	blood	NN	_	2	SBJ
2	was	be	VBD	_	0	ROOT
3	collected	collect	VBN	_	2	VC
4	from	from	IN	_	3	ADV
5	the	the	DT	_	10	NMOD
6	retroorbital	retroorbital	JJ	_	10	NMOD
7	sinus	sinus	NN	_	10	NMOD
8	or	or	CC	_	7	COORD
9	tail	tail	NN	_	8	CONJ
10	vein	vein	NN	_	4	PMOD
11	of	of	IN	_	10	NMOD
12	mice	mouse	NNS	_	11	PMOD
13	and	and	CC	_	3	COORD
14	spotted	spot	VBN	_	13	CONJ
15	on	on	IN	_	14	MNR
16	a	a	DT	_	18	NMOD
17	filter	filter	NN	_	18	NMOD
18	paper	paper	NN	_	15	PMOD
19	routinely	routinely	RB	_	20	ADV
20	used	use	VBN	_	18	NMOD
21	for	for	IN	_	20	PRP
22	blood	blood	NN	_	25	NMOD
23	amino	amino	NN	_	24	NMOD
24	acid	acid	NN	_	25	NMOD
25	analysis	analysis	NN	_	21	PMOD
26	for	for	IN	_	25	NMOD
27	prenatal	prenatal	JJ	_	28	NMOD
28	screening	screening	NN	_	26	PMOD
29	.	.	.	_	2	P

1	Concentrations	concentration	NNS	_	10	SBJ
2	of	of	IN	_	1	NMOD
3	BCAA	bcaa	NN	_	2	PMOD
4	and	and	CC	_	3	COORD
5	other	other	JJ	_	7	NMOD
6	amino	amino	NN	_	7	NMOD
7	acids	acid	NNS	_	4	CONJ
8	in	in	IN	_	1	NMOD
9	blood	blood	NN	_	8	PMOD
10	were	be	VBD	_	0	ROOT
11	determined	determine	VBN	_	10	VC
12	by	by	IN	_	11	MNR
13	tandem	tandem	JJ	_	15	NMOD
14	mass	mass	NN	_	15	NMOD
15	spectrometry	spectrometry	NN	_	12	PMOD
16	(	(	-LRB-	_	18	P
17	Pediatrix	pediatrix	NNP	_	18	NMOD
18	Screening	screening	NNP	_	15	PRN
19	,	,	,	_	18	P
20	Bridgeville	bridgeville	NNP	_	18	APPO
21	,	,	,	_	20	P
22	PA	pa	NNP	_	20	APPO
23	)	)	-RRB-	_	18	P
24	.	.	.	_	10	P

1	Assay	assay	NN	_	0	ROOT
2	of	of	IN	_	1	NMOD
3	BCKDH	bckdh	NN	_	4	NMOD
4	activity	activity	NN	_	2	PMOD

1	Livers	liver	NNS	_	2	SBJ
2	were	be	VBD	_	0	ROOT
3	removed	remove	VBN	_	2	VC
4	,	,	,	_	3	P
5	frozen	freeze	VBN	_	3	CONJ
6	in	in	IN	_	5	MNR
7	liquid	liquid	JJ	_	8	NMOD
8	nitrogen	nitrogen	NN	_	6	PMOD
9	,	,	,	_	5	P
10	and	and	CC	_	5	COORD
11	stored	store	VBN	_	10	CONJ
12	at	at	IN	_	11	ADV
13	-	-	HYPH	_	14	P
14	80	0	CD	_	15	NMOD
15	°C	°c	NN	_	12	PMOD
16	.	.	.	_	2	P

1	At	at	IN	_	9	TMP
2	the	the	DT	_	3	NMOD
3	time	time	NN	_	1	PMOD
4	of	of	IN	_	3	NMOD
5	enzyme	enzyme	NN	_	6	NMOD
6	assay	assay	NN	_	4	PMOD
7	,	,	,	_	9	P
8	livers	liver	NNS	_	9	SBJ
9	were	be	VBD	_	0	ROOT
10	thawed	thaw	VBN	_	9	VC
11	,	,	,	_	10	P
12	and	and	CC	_	10	COORD
13	homogenized	homogenize	VBN	_	12	CONJ
14	(	(	-LRB-	_	21	P
15	1	0	CD	_	17	NMOD
16	:	:	SYM	_	17	P
17	9	0	CD	_	21	DEP
18	,	,	,	_	21	P
19	w	w	NN	_	21	NMOD
20	/	/	HYPH	_	19	P
21	v	v	NN	_	13	PRN
22	)	)	-RRB-	_	21	P
23	in	in	IN	_	13	MNR
24	0.25	0	CD	_	25	NMOD
25	M	m	NN	_	26	NMOD
26	sucrose	sucrose	NN	_	23	PMOD
27	,	,	,	_	26	P
28	10	0	CD	_	29	NMOD
29	mM	mm	NN	_	32	NMOD
30	Tris	tris	NN	_	32	NMOD
31	-	-	HYPH	_	30	P
32	HC1	hc0	NN	_	26	APPO
33	,	,	,	_	32	P
34	pH	ph	NN	_	32	APPO
35	7.4	0	CD	_	34	NMOD
36	.	.	.	_	9	P

1	Liver	liver	NN	_	2	NMOD
2	homogenates	homogenate	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	centrifuged	centrifuge	VBN	_	3	VC
5	at	at	IN	_	4	MNR
6	600	0	CD	_	8	NMOD
7	×	×	SYM	_	6	P
8	g	g	NN	_	5	PMOD
9	for	for	IN	_	4	TMP
10	10	0	CD	_	11	NMOD
11	min	min	NN	_	9	PMOD
12	at	at	IN	_	4	MNR
13	4	0	CD	_	14	NMOD
14	°C	°c	NN	_	12	PMOD
15	and	and	CC	_	3	COORD
16	the	the	DT	_	18	NMOD
17	supernatant	supernatant	NN	_	18	NMOD
18	fraction	fraction	NN	_	19	SBJ
19	was	be	VBD	_	15	CONJ
20	saved	save	VBN	_	19	VC
21	to	to	TO	_	20	PRP
22	determine	determine	VB	_	21	IM
23	the	the	DT	_	25	NMOD
24	BCKDH	bckdh	NN	_	25	NMOD
25	activity	activity	NN	_	22	OBJ
26	.	.	.	_	3	P

1	The	the	DT	_	2	NMOD
2	use	use	NN	_	6	SBJ
3	of	of	IN	_	2	NMOD
4	tissue	tissue	NN	_	5	NMOD
5	homogenates	homogenate	NNS	_	3	PMOD
6	was	be	VBD	_	0	ROOT
7	necessitated	necessitate	VBN	_	6	VC
8	by	by	IN	_	7	LGS
9	the	the	DT	_	11	NMOD
10	limited	limited	JJ	_	11	NMOD
11	availability	availability	NN	_	8	PMOD
12	of	of	IN	_	11	NMOD
13	liver	liver	NN	_	14	NMOD
14	tissue	tissue	NN	_	12	PMOD
15	,	,	,	_	14	P
16	particularly	particularly	RB	_	17	PMOD
17	from	from	IN	_	14	NMOD
18	newborn	newborn	JJ	_	19	NMOD
19	pups	pup	NNS	_	17	PMOD
20	.	.	.	_	6	P

1	BCKDH	bckdh	NN	_	2	NMOD
2	activity	activity	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	determined	determine	VBN	_	3	VC
5	by	by	IN	_	4	MNR
6	measuring	measure	VBG	_	5	PMOD
7	the	the	DT	_	8	NMOD
8	release	release	NN	_	6	OBJ
9	of	of	IN	_	8	NMOD
10	14CO2	0co0	NN	_	9	PMOD
11	from	from	IN	_	6	ADV
12	α	α	NN	_	14	NMOD
13	-	-	HYPH	_	12	P
14	keto	keto	NN	_	20	NMOD
15	[	[	-LRB-	_	16	P
16	1	0	CD	_	14	PRN
17	-	-	SYM	_	18	P
18	14C	0c	NN	_	16	NMOD
19	]	]	-RRB-	_	16	P
20	isocaproate	isocaproate	NN	_	11	PMOD
21	as	as	IN	_	4	ADV
22	described	describe	VBN	_	21	SUB
23	previously	previously	RB	_	22	TMP
24	[	[	-LRB-	_	25	P
25	31	0	CD	_	22	PRN
26	]	]	-RRB-	_	25	P
27	.	.	.	_	3	P

1	The	the	DT	_	4	NMOD
2	complete	complete	JJ	_	4	NMOD
3	reaction	reaction	NN	_	4	NMOD
4	mixture	mixture	NN	_	5	SBJ
5	contained	contain	VBD	_	0	ROOT
6	(	(	-LRB-	_	10	P
7	final	final	JJ	_	8	NMOD
8	volume	volume	NN	_	10	NMOD
9	1	0	CD	_	10	NMOD
10	ml	ml	NN	_	5	PRN
11	)	)	-RRB-	_	10	P
12	30	0	CD	_	13	NMOD
13	mM	mm	NN	_	16	NMOD
14	potassium	potassium	NN	_	15	NMOD
15	phosphate	phosphate	NN	_	16	NMOD
16	buffer	buffer	NN	_	5	OBJ
17	,	,	,	_	16	P
18	pH	ph	NN	_	16	APPO
19	7.4	0	CD	_	18	NMOD
20	,	,	,	_	16	P
21	0.20	0	CD	_	22	NMOD
22	mM	mm	NN	_	25	NMOD
23	α	α	NN	_	25	NMOD
24	-	-	HYPH	_	23	P
25	ketoisocaproate	ketoisocaproate	NN	_	16	CONJ
26	,	,	,	_	25	P
27	0.40	0	CD	_	28	NMOD
28	mM	mm	NN	_	29	NMOD
29	CoASH	coash	NN	_	25	CONJ
30	,	,	,	_	29	P
31	0.40	0	CD	_	32	NMOD
32	mM	mm	NN	_	34	NMOD
33	thiamin	thiamin	NN	_	34	NMOD
34	pyrophosphate	pyrophosphate	NN	_	29	CONJ
35	,	,	,	_	34	P
36	2	0	CD	_	37	NMOD
37	mM	mm	NN	_	38	NMOD
38	NAD	nad	NN	_	34	CONJ
39	+	+	SYM	_	38	P
40	,	,	,	_	38	P
41	2	0	CD	_	42	NMOD
42	mM	mm	NN	_	43	NMOD
43	dithiothreitol	dithiothreitol	NN	_	38	CONJ
44	,	,	,	_	43	P
45	5	0	CD	_	46	NMOD
46	mM	mm	NN	_	47	NMOD
47	Mg2	mg0	NN	_	43	CONJ
48	+	+	SYM	_	47	P
49	,	,	,	_	47	P
50	approximately	approximately	RB	_	51	QMOD
51	250,000	0	CD	_	52	NMOD
52	DPM	dpm	NN	_	47	CONJ
53	of	of	IN	_	52	NMOD
54	α	α	NN	_	56	NMOD
55	-	-	HYPH	_	54	P
56	keto	keto	NN	_	62	NMOD
57	[	[	-LRB-	_	58	P
58	1	0	CD	_	56	PRN
59	-	-	SYM	_	60	P
60	14C	0c	NN	_	58	NMOD
61	]	]	-RRB-	_	58	P
62	isocaproate	isocaproate	NN	_	53	PMOD
63	,	,	,	_	52	P
64	and	and	CC	_	52	COORD
65	0.10	0	CD	_	66	NMOD
66	ml	ml	NN	_	64	CONJ
67	of	of	IN	_	66	NMOD
68	liver	liver	NN	_	69	NMOD
69	homogenate	homogenate	NN	_	67	PMOD
70	(	(	-LRB-	_	75	P
71	2	0	CD	_	74	NMOD
72	–	–	SYM	_	71	P
73	3	0	CD	_	71	QMOD
74	mg	mg	NN	_	75	NMOD
75	protein	protein	NN	_	69	PRN
76	)	)	-RRB-	_	75	P
77	.	.	.	_	5	P

1	Assays	assay	NNS	_	2	SBJ
2	were	be	VBD	_	0	ROOT
3	carried	carry	VBN	_	2	VC
4	out	out	RP	_	3	PRT
5	for	for	IN	_	3	TMP
6	15	0	CD	_	7	NMOD
7	min	min	NN	_	5	PMOD
8	at	at	IN	_	3	MNR
9	37	0	CD	_	10	NMOD
10	°C	°c	NN	_	8	PMOD
11	,	,	,	_	2	P
12	14CO2	0co0	NN	_	13	SBJ
13	was	be	VBD	_	2	CONJ
14	trapped	trap	VBN	_	13	VC
15	in	in	IN	_	14	LOC
16	hydroxide	hydroxide	NN	_	15	PMOD
17	of	of	IN	_	16	NMOD
18	Hyamine	hyamine	NN	_	17	PMOD
19	,	,	,	_	13	P
20	and	and	CC	_	13	COORD
21	radioactivity	radioactivity	NN	_	22	SBJ
22	was	be	VBD	_	20	CONJ
23	determined	determine	VBN	_	22	VC
24	by	by	IN	_	23	MNR
25	liquid	liquid	JJ	_	26	NMOD
26	scintillation	scintillation	NN	_	27	NMOD
27	spectrometry	spectrometry	NN	_	24	PMOD
28	.	.	.	_	2	P

1	Western	western	NNP	_	2	NMOD
2	blot	blot	NN	_	3	NMOD
3	analysis	analysis	NN	_	0	ROOT

1	Protein	protein	NN	_	2	NMOD
2	extracts	extract	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	isolated	isolate	VBN	_	3	VC
5	from	from	IN	_	4	ADV
6	homogenized	homogenize	VBN	_	7	NMOD
7	liver	liver	NN	_	5	PMOD
8	(	(	-LRB-	_	7	P
9	freshly	freshly	RB	_	10	ADV
10	harvested	harvest	VBN	_	7	NMOD
11	and	and	CC	_	10	COORD
12	flash	flash	NN	_	13	DEP
13	frozen	freeze	VBN	_	11	CONJ
14	)	)	-RRB-	_	7	P
15	of	of	IN	_	7	NMOD
16	wildtype	wildtype	NN	_	24	AMOD
17	,	,	,	_	16	P
18	Line	line	NN	_	19	NMOD
19	525A	0a	NN	_	16	CONJ
20	,	,	,	_	19	P
21	and	and	CC	_	19	COORD
22	Line	line	NN	_	23	NMOD
23	A	a	NN	_	21	CONJ
24	transgenic	transgenic	JJ	_	25	NMOD
25	mice	mouse	NNS	_	15	PMOD
26	.	.	.	_	3	P

1	Protein	protein	NN	_	8	SBJ
2	(	(	-LRB-	_	4	P
3	25	0	CD	_	4	NMOD
4	μg	μg	NN	_	1	PRN
5	per	per	IN	_	4	NMOD
6	sample	sample	NN	_	5	PMOD
7	)	)	-RRB-	_	4	P
8	was	be	VBD	_	0	ROOT
9	analyzed	analyze	VBN	_	8	VC
10	by	by	IN	_	9	MNR
11	electrophoresis	electrophoresis	NN	_	10	PMOD
12	on	on	IN	_	9	MNR
13	a	a	DT	_	20	NMOD
14	10	0	CD	_	15	NMOD
15	%	%	NN	_	20	NMOD
16	SDS	sd	NN	_	18	NMOD
17	-	-	HYPH	_	16	P
18	PAGE	page	NN	_	20	NMOD
19	Ready	ready	JJ	_	20	NMOD
20	Gel	gel	NN	_	12	PMOD
21	(	(	-LRB-	_	28	P
22	Bio	bio	NNP	_	24	NMOD
23	-	-	HYPH	_	22	P
24	Rad	rad	NNP	_	28	DEP
25	,	,	,	_	28	P
26	Hercules	hercules	NNP	_	28	LOC
27	,	,	,	_	28	P
28	CA	ca	NNP	_	20	PRN
29	)	)	-RRB-	_	28	P
30	and	and	CC	_	9	COORD
31	transferred	transfer	VBN	_	30	CONJ
32	to	to	IN	_	31	ADV
33	PVDF	pvdf	NN	_	34	NMOD
34	membrane	membrane	NN	_	32	PMOD
35	(	(	-LRB-	_	42	P
36	Sequi	sequi	NNP	_	38	NMOD
37	-	-	HYPH	_	36	P
38	Blot	blot	NNP	_	42	DEP
39	;	;	:	_	42	P
40	Bio	bio	NNP	_	42	NMOD
41	-	-	HYPH	_	40	P
42	Rad	rad	NNP	_	34	PRN
43	)	)	-RRB-	_	42	P
44	via	via	IN	_	31	MNR
45	electroblotting	electroblotting	NN	_	44	PMOD
46	.	.	.	_	8	P

1	All	all	DT	_	2	NMOD
2	blots	blot	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	probed	probe	VBN	_	3	VC
5	for	for	IN	_	4	ADV
6	E2	e0	NN	_	7	NMOD
7	protein	protein	NN	_	5	PMOD
8	using	use	VBG	_	4	MNR
9	polyclonal	polyclonal	JJ	_	12	NMOD
10	rabbit	rabbit	NN	_	12	NMOD
11	E2	e0	NN	_	12	NMOD
12	antisera	antiserum	NNS	_	8	OBJ
13	(	(	-LRB-	_	16	P
14	1	0	CD	_	16	NMOD
15	:	:	SYM	_	16	P
16	5,000	0	CD	_	12	PRN
17	)	)	-RRB-	_	16	P
18	,	,	,	_	12	P
19	which	which	WDT	_	20	SBJ
20	detects	detect	VBZ	_	12	NMOD
21	both	both	CC	_	36	COORD
22	mouse	mouse	NN	_	36	NMOD
23	(	(	-LRB-	_	26	P
24	~	~	SYM	_	25	P
25	47	0	CD	_	26	NMOD
26	kD	kd	NN	_	22	PRN
27	)	)	-RRB-	_	26	P
28	and	and	CC	_	22	COORD
29	human	human	JJ	_	28	CONJ
30	(	(	-LRB-	_	33	P
31	~	~	SYM	_	32	P
32	54	0	CD	_	33	NMOD
33	kD	kd	NN	_	29	PRN
34	)	)	-RRB-	_	33	P
35	E2	e0	NN	_	36	NMOD
36	subunits	subunit	NNS	_	20	OBJ
37	(	(	-LRB-	_	42	P
38	[	[	-LRB-	_	42	P
39	30	0	CD	_	42	DEP
40	]	]	-RRB-	_	42	P
41	;	;	:	_	42	P
42	gift	gift	NN	_	36	PRN
43	from	from	IN	_	42	NMOD
44	Dr.	dr.	NNP	_	46	NMOD
45	Susan	susan	NNP	_	46	NMOD
46	Hutson	hutson	NNP	_	43	PMOD
47	,	,	,	_	46	P
48	Wake	wake	NNP	_	49	NMOD
49	Forest	forest	NNP	_	50	NMOD
50	University	university	NNP	_	46	APPO
51	)	)	-RRB-	_	42	P
52	.	.	.	_	3	P

1	Blots	blot	NNS	_	2	SBJ
2	were	be	VBD	_	0	ROOT
3	re-probed	re-probed	VBN	_	2	VC
4	with	with	IN	_	3	MNR
5	a	a	DT	_	11	NMOD
6	rabbit	rabbit	NN	_	11	NMOD
7	anti-c	anti-c	JJ	_	9	NMOD
8	-	-	HYPH	_	7	P
9	myc	myc	NN	_	11	NMOD
10	tag	tag	NN	_	11	NMOD
11	antibody	antibody	NN	_	4	PMOD
12	(	(	-LRB-	_	25	P
13	1	0	CD	_	15	NMOD
14	:	:	SYM	_	15	P
15	10,000	0	CD	_	25	DEP
16	;	;	:	_	25	P
17	abCam	abcam	NNP	_	25	DEP
18	,	,	,	_	17	P
19	Cambridge	cambridge	NNP	_	17	APPO
20	,	,	,	_	19	P
21	MA	ma	NNP	_	19	APPO
22	;	;	:	_	25	P
23	cat.	cat.	NN	_	25	NMOD
24	#	#	SYM	_	25	P
25	ab9106	ab0	NN	_	11	PRN
26	-	-	HYPH	_	25	P
27	100	0	CD	_	25	NMOD
28	)	)	-RRB-	_	25	P
29	.	.	.	_	2	P

1	Blots	blot	NNS	_	2	SBJ
2	were	be	VBD	_	0	ROOT
3	also	also	RB	_	2	ADV
4	re-probed	re-probed	VBN	_	2	VC
5	with	with	IN	_	4	MNR
6	an	an	DT	_	7	NMOD
7	antibody	antibody	NN	_	5	PMOD
8	for	for	IN	_	7	NMOD
9	β	β	NN	_	11	NMOD
10	-	-	HYPH	_	9	P
11	actin	actin	NN	_	8	PMOD
12	(	(	-LRB-	_	24	P
13	43	0	CD	_	14	NMOD
14	kD	kd	NN	_	24	DEP
15	;	;	:	_	24	P
16	1	0	CD	_	18	NMOD
17	:	:	SYM	_	18	P
18	10,000	0	CD	_	24	DEP
19	;	;	:	_	24	P
20	abCam	abcam	NN	_	24	DEP
21	;	;	:	_	24	P
22	cat.	cat.	NN	_	24	NMOD
23	#	#	SYM	_	24	P
24	ab8227	ab0	NN	_	11	PRN
25	-	-	HYPH	_	24	P
26	50	0	CD	_	24	NMOD
27	)	)	-RRB-	_	24	P
28	to	to	TO	_	4	PRP
29	allow	allow	VB	_	28	IM
30	for	for	IN	_	29	ADV
31	loading	loading	NN	_	32	NMOD
32	comparisons	comparison	NNS	_	30	PMOD
33	.	.	.	_	2	P

1	A	a	DT	_	5	NMOD
2	goat	goat	NN	_	5	NMOD
3	anti-rabbit	anti-rabbit	JJ	_	5	NMOD
4	secondary	secondary	JJ	_	5	NMOD
5	antibody	antibody	NN	_	27	SBJ
6	conjugated	conjugate	VBN	_	5	NMOD
7	to	to	IN	_	6	ADV
8	horseradish	horseradish	NN	_	9	NMOD
9	peroxidase	peroxidase	NN	_	7	PMOD
10	(	(	-LRB-	_	25	P
11	1	0	CD	_	13	NMOD
12	:	:	SYM	_	13	P
13	10,000	0	CD	_	25	DEP
14	;	;	:	_	25	P
15	Novus	novus	NNP	_	25	DEP
16	,	,	,	_	15	P
17	Littleton	littleton	NNP	_	15	APPO
18	,	,	,	_	17	P
19	CO	co	NNP	_	17	APPO
20	;	;	:	_	25	P
21	cat.	cat.	NN	_	25	NMOD
22	#	#	SYM	_	25	P
23	NB730	nb0	NN	_	25	NMOD
24	-	-	HYPH	_	23	P
25	H	h	NN	_	9	PRN
26	)	)	-RRB-	_	25	P
27	was	be	VBD	_	0	ROOT
28	used	use	VBN	_	27	VC
29	for	for	IN	_	28	PRP
30	detection	detection	NN	_	29	PMOD
31	using	use	VBG	_	28	MNR
32	the	the	DT	_	36	NMOD
33	Western	western	NNP	_	34	NMOD
34	Lightning	lightning	NNP	_	36	NMOD
35	chemiluminescence	chemiluminescence	NN	_	36	NMOD
36	reagent	reagent	NN	_	31	OBJ
37	(	(	-LRB-	_	39	P
38	Perkin	perkin	NNP	_	39	NMOD
39	Elmer	elmer	NNP	_	36	PRN
40	,	,	,	_	39	P
41	Boston	boston	NNP	_	39	APPO
42	,	,	,	_	41	P
43	MA	ma	NNP	_	41	APPO
44	)	)	-RRB-	_	39	P
45	and	and	CC	_	28	COORD
46	exposed	expose	VBN	_	45	CONJ
47	to	to	IN	_	46	ADV
48	X-ray	x-ray	NN	_	49	NMOD
49	film	film	NN	_	47	PMOD
50	.	.	.	_	27	P

1	Statistical	statistical	JJ	_	2	NMOD
2	analyses	analysis	NNS	_	0	ROOT

1	All	all	DT	_	7	NMOD
2	BCAA	bcaa	NN	_	7	NMOD
3	and	and	CC	_	2	COORD
4	BCKDH	bckdh	NN	_	3	CONJ
5	enzyme	enzyme	NN	_	7	NMOD
6	activity	activity	NN	_	7	NMOD
7	data	datum	NNS	_	8	SBJ
8	are	be	VBP	_	0	ROOT
9	presented	present	VBN	_	8	VC
10	as	as	IN	_	9	MNR
11	the	the	DT	_	12	NMOD
12	mean	mean	NN	_	10	PMOD
13	+	+	SYM	_	12	COORD
14	/	/	HYPH	_	13	P
15	-	-	SYM	_	13	P
16	the	the	DT	_	18	NMOD
17	standard	standard	JJ	_	18	NMOD
18	error	error	NN	_	23	NMOD
19	of	of	IN	_	18	NMOD
20	the	the	DT	_	21	NMOD
21	mean	mean	NN	_	19	PMOD
22	(	(	-LRB-	_	23	P
23	S.E.M.	s.e.m.	NN	_	13	CONJ
24	)	)	-RRB-	_	8	P
25	.	.	.	_	8	P

1	Differences	difference	NNS	_	4	SBJ
2	between	between	IN	_	1	NMOD
3	genotypes	genotype	NNS	_	2	PMOD
4	were	be	VBD	_	0	ROOT
5	compared	compare	VBN	_	4	VC
6	by	by	IN	_	5	ADV
7	Student	student	NNP	_	10	NMOD
8	's	's	POS	_	7	NMOD
9	t	t	NN	_	10	NMOD
10	test	test	NN	_	6	PMOD
11	[	[	-LRB-	_	12	P
12	32	0	CD	_	5	PRN
13	]	]	-RRB-	_	12	P
14	.	.	.	_	4	P

1	Results	result	NNS	_	0	ROOT

1	Production	production	NN	_	0	ROOT
2	of	of	IN	_	1	NMOD
3	E2	e0	NN	_	6	NMOD
4	gene	gene	NN	_	5	NMOD
5	knockout	knockout	NN	_	6	NMOD
6	mice	mouse	NNS	_	2	PMOD

1	To	to	TO	_	8	PRP
2	create	create	VB	_	1	IM
3	E2	e0	NN	_	5	NMOD
4	knockout	knockout	NN	_	5	NMOD
5	mice	mouse	NNS	_	2	OBJ
6	,	,	,	_	8	P
7	we	we	PRP	_	8	SBJ
8	used	use	VBD	_	0	ROOT
9	gene	gene	NN	_	10	NMOD
10	targeting	targeting	NN	_	8	OBJ
11	in	in	IN	_	8	LOC
12	mouse	mouse	NN	_	14	NMOD
13	ES	e	NN	_	14	NMOD
14	cells	cell	NNS	_	11	PMOD
15	to	to	TO	_	8	PRP
16	disrupt	disrupt	VB	_	15	IM
17	the	the	DT	_	19	NMOD
18	E2	e0	NN	_	19	NMOD
19	gene	gene	NN	_	16	OBJ
20	.	.	.	_	8	P

1	The	the	DT	_	3	NMOD
2	overall	overall	JJ	_	3	NMOD
3	strategy	strategy	NN	_	9	SBJ
4	for	for	IN	_	3	NMOD
5	disrupting	disrupt	VBG	_	4	PMOD
6	the	the	DT	_	8	NMOD
7	E2	e0	NN	_	8	NMOD
8	gene	gene	NN	_	5	OBJ
9	is	be	VBZ	_	0	ROOT
10	illustrated	illustrate	VBN	_	9	VC
11	in	in	IN	_	10	ADV
12	Fig.	fig.	NN	_	13	NMOD
13	1A	0a	NN	_	11	PMOD
14	.	.	.	_	9	P

1	The	the	DT	_	4	NMOD
2	gene	gene	NN	_	3	NMOD
3	targeting	targeting	NN	_	4	NMOD
4	construct	construct	NN	_	5	SBJ
5	was	be	VBD	_	0	ROOT
6	designed	design	VBN	_	5	VC
7	to	to	TO	_	6	PRP
8	replace	replace	VB	_	7	IM
9	a	a	DT	_	17	NMOD
10	1.67	0	CD	_	11	NMOD
11	kb	kb	NN	_	17	NMOD
12	EcoRV	ecorv	NN	_	14	NMOD
13	/	/	HYPH	_	12	P
14	Smal	smal	NN	_	17	NMOD
15	genomic	genomic	JJ	_	17	NMOD
16	DNA	dna	NN	_	17	NMOD
17	fragment	fragment	NN	_	8	OBJ
18	encompassing	encompass	VBG	_	17	NMOD
19	part	part	NN	_	18	OBJ
20	of	of	IN	_	19	NMOD
21	Exon	exon	NN	_	20	PMOD
22	4	0	CD	_	21	NMOD
23	and	and	CC	_	19	COORD
24	all	all	DT	_	23	CONJ
25	of	of	IN	_	24	NMOD
26	Exon	exon	NN	_	25	PMOD
27	5	0	CD	_	26	NMOD
28	with	with	IN	_	8	ADV
29	the	the	DT	_	33	NMOD
30	PGKneo	pgkneo	NN	_	33	NMOD
31	selectable	selectable	JJ	_	33	NMOD
32	marker	marker	NN	_	33	NMOD
33	cassette	cassette	NN	_	28	PMOD
34	.	.	.	_	5	P

1	Of	of	IN	_	14	NMOD
2	522	0	CD	_	5	NMOD
3	ES	e	NN	_	4	NMOD
4	cell	cell	NN	_	5	NMOD
5	clones	clone	NNS	_	1	PMOD
6	screened	screen	VBN	_	5	NMOD
7	for	for	IN	_	6	PRP
8	targeting	targeting	NN	_	7	PMOD
9	by	by	IN	_	6	MNR
10	Southern	southern	NNP	_	11	NMOD
11	blot	blot	NN	_	12	NMOD
12	analysis	analysis	NN	_	9	PMOD
13	,	,	,	_	14	P
14	29	0	CD	_	19	SBJ
15	(	(	-LRB-	_	17	P
16	5	0	CD	_	17	NMOD
17	%	%	NN	_	14	PRN
18	)	)	-RRB-	_	17	P
19	displayed	display	VBD	_	0	ROOT
20	the	the	DT	_	25	NMOD
21	predicted	predict	VBN	_	25	NMOD
22	restriction	restriction	NN	_	24	NMOD
23	fragment	fragment	NN	_	24	NMOD
24	length	length	NN	_	25	NMOD
25	polymorphisms	polymorphism	NNS	_	19	OBJ
26	indicative	indicative	JJ	_	25	NMOD
27	of	of	IN	_	26	AMOD
28	gene	gene	NN	_	27	PMOD
29	targeting	target	VBG	_	28	NMOD
30	at	at	IN	_	19	LOC
31	the	the	DT	_	33	NMOD
32	E2	e0	NN	_	33	NMOD
33	locus	locus	NN	_	30	PMOD
34	.	.	.	_	19	P

1	As	as	IN	_	24	ADV
2	illustrated	illustrate	VBN	_	1	SUB
3	in	in	IN	_	2	ADV
4	Fig.	fig.	NN	_	5	NMOD
5	1A	0a	NN	_	3	PMOD
6	and	and	CC	_	5	COORD
7	1B	0b	NN	_	6	CONJ
8	,	,	,	_	24	P
9	an	an	DT	_	14	NMOD
10	E2	e0	NN	_	14	NMOD
11	Exon	exon	NN	_	14	NMOD
12	6	0	CD	_	11	NMOD
13	specific	specific	JJ	_	14	NMOD
14	probe	probe	NN	_	24	SBJ
15	,	,	,	_	14	P
16	which	which	WDT	_	17	SBJ
17	is	be	VBZ	_	14	NMOD
18	external	external	JJ	_	17	PRD
19	to	to	IN	_	18	AMOD
20	the	the	DT	_	22	NMOD
21	targeting	targeting	NN	_	22	NMOD
22	construct	construct	NN	_	19	PMOD
23	,	,	,	_	24	P
24	hybridizes	hybridize	VBZ	_	0	ROOT
25	to	to	IN	_	24	ADV
26	only	only	RB	_	33	NMOD
27	a	a	DT	_	33	NMOD
28	~	~	SYM	_	29	P
29	16	0	CD	_	30	NMOD
30	kb	kb	NN	_	33	NMOD
31	BglI	bgli	NN	_	33	NMOD
32	restriction	restriction	NN	_	33	NMOD
33	fragment	fragment	NN	_	25	PMOD
34	from	from	IN	_	33	NMOD
35	the	the	DT	_	38	NMOD
36	wild	wild	JJ	_	37	NMOD
37	type	type	NN	_	38	NMOD
38	allele	allele	NN	_	34	PMOD
39	in	in	IN	_	38	LOC
40	the	the	DT	_	45	NMOD
41	parental	parental	JJ	_	45	NMOD
42	R1	r0	NN	_	45	NMOD
43	ES	e	NN	_	44	NMOD
44	cell	cell	NN	_	45	NMOD
45	line	line	NN	_	39	PMOD
46	.	.	.	_	24	P

1	In	in	IN	_	10	LOC
2	correctly	correctly	RB	_	3	AMOD
3	targeted	target	VBN	_	5	NMOD
4	ES	e	NN	_	5	NMOD
5	cells	cell	NNS	_	1	PMOD
6	,	,	,	_	10	P
7	this	this	DT	_	8	NMOD
8	probe	probe	NN	_	10	SBJ
9	also	also	RB	_	10	ADV
10	hybridizes	hybridize	VBZ	_	0	ROOT
11	to	to	IN	_	10	ADV
12	a	a	DT	_	18	NMOD
13	~	~	SYM	_	14	P
14	11	0	CD	_	15	NMOD
15	kb	kb	NN	_	18	NMOD
16	BglI	bgli	NN	_	18	NMOD
17	restriction	restriction	NN	_	18	NMOD
18	fragment	fragment	NN	_	11	PMOD
19	.	.	.	_	10	P

1	Targeting	targeting	NN	_	2	SBJ
2	was	be	VBD	_	0	ROOT
3	confirmed	confirm	VBN	_	2	VC
4	with	with	IN	_	3	MNR
5	several	several	JJ	_	8	NMOD
6	additional	additional	JJ	_	8	NMOD
7	restriction	restriction	NN	_	8	NMOD
8	enzymes	enzyme	NNS	_	4	PMOD
9	and	and	CC	_	8	COORD
10	probes	probe	NNS	_	9	CONJ
11	(	(	-LRB-	_	14	P
12	data	datum	NNS	_	14	SBJ
13	not	not	RB	_	14	ADV
14	shown	show	VBN	_	3	PRN
15	)	)	-RRB-	_	14	P
16	.	.	.	_	2	P

1	Correctly	correctly	RB	_	2	AMOD
2	targeted	target	VBN	_	4	NMOD
3	ES	e	NN	_	4	NMOD
4	cells	cell	NNS	_	5	SBJ
5	were	be	VBD	_	0	ROOT
6	microinjected	microinjected	VBN	_	5	VC
7	into	into	IN	_	6	ADV
8	blastocysts	blastocyst	NNS	_	7	PMOD
9	to	to	TO	_	6	PRP
10	produce	produce	VB	_	9	IM
11	chimeric	chimeric	JJ	_	12	NMOD
12	mice	mouse	NNS	_	10	OBJ
13	.	.	.	_	5	P

1	Chimerics	chimerics	NNS	_	2	SBJ
2	were	be	VBD	_	0	ROOT
3	bred	breed	VBN	_	2	VC
4	to	to	IN	_	3	ADV
5	C57BL	c0bl	NN	_	7	NMOD
6	/	/	HYPH	_	5	P
7	6J	0j	NN	_	8	NMOD
8	mice	mouse	NNS	_	4	PMOD
9	.	.	.	_	2	P

1	Following	follow	VBG	_	11	ADV
2	germline	germline	NN	_	3	NMOD
3	transmission	transmission	NN	_	1	PMOD
4	of	of	IN	_	3	NMOD
5	the	the	DT	_	7	NMOD
6	targeted	target	VBN	_	7	NMOD
7	allele	allele	NN	_	4	PMOD
8	,	,	,	_	11	P
9	heterozygous	heterozygous	JJ	_	10	NMOD
10	mice	mouse	NNS	_	11	SBJ
11	were	be	VBD	_	0	ROOT
12	interbred	interbreed	VBN	_	11	VC
13	to	to	TO	_	12	PRP
14	produce	produce	VB	_	13	IM
15	wild	wild	JJ	_	16	NMOD
16	type	type	NN	_	36	NMOD
17	(	(	-LRB-	_	20	P
18	+	+	SYM	_	20	P
19	/	/	HYPH	_	20	P
20	+	+	SYM	_	16	PRN
21	)	)	-RRB-	_	20	P
22	,	,	,	_	16	P
23	heterozygous	heterozygous	JJ	_	16	CONJ
24	(	(	-LRB-	_	27	P
25	+	+	SYM	_	27	P
26	/	/	HYPH	_	27	P
27	-	-	SYM	_	23	PRN
28	)	)	-RRB-	_	27	P
29	and	and	CC	_	23	COORD
30	homozygous	homozygous	JJ	_	29	CONJ
31	(	(	-LRB-	_	34	P
32	-	-	SYM	_	34	P
33	/	/	HYPH	_	34	P
34	-	-	SYM	_	30	PRN
35	)	)	-RRB-	_	34	P
36	animals	animal	NNS	_	14	OBJ
37	.	.	.	_	11	P

1	Mice	mouse	NNS	_	2	SBJ
2	were	be	VBD	_	0	ROOT
3	genotyped	genotyped	VBN	_	2	VC
4	by	by	IN	_	3	MNR
5	Southern	southern	NNP	_	6	NMOD
6	blot	blot	NN	_	7	NMOD
7	analysis	analysis	NN	_	4	PMOD
8	.	.	.	_	2	P

1	The	the	DT	_	5	NMOD
2	Exon	exon	NN	_	4	AMOD
3	6	0	CD	_	2	NMOD
4	specific	specific	JJ	_	5	NMOD
5	probe	probe	NN	_	6	SBJ
6	hybridized	hybridize	VBN	_	0	ROOT
7	to	to	IN	_	6	ADV
8	only	only	RB	_	15	NMOD
9	a	a	DT	_	15	NMOD
10	~	~	SYM	_	11	P
11	16	0	CD	_	12	NMOD
12	kb	kb	NN	_	15	NMOD
13	BglI	bgli	NN	_	15	NMOD
14	restriction	restriction	NN	_	15	NMOD
15	fragment	fragment	NN	_	7	PMOD
16	in	in	IN	_	15	LOC
17	+	+	SYM	_	19	P
18	/	/	HYPH	_	19	P
19	+	+	SYM	_	20	NMOD
20	mice	mouse	NNS	_	16	PMOD
21	,	,	,	_	15	P
22	a	a	DT	_	27	NMOD
23	~	~	SYM	_	24	P
24	11	0	CD	_	25	NMOD
25	kb	kb	NN	_	27	NMOD
26	BglI	bgli	NN	_	27	NMOD
27	fragment	fragment	NN	_	15	APPO
28	in	in	IN	_	27	LOC
29	-	-	SYM	_	31	P
30	/	/	HYPH	_	31	P
31	-	-	SYM	_	32	NMOD
32	mice	mouse	NNS	_	28	PMOD
33	,	,	,	_	7	P
34	and	and	CC	_	7	COORD
35	to	to	IN	_	34	CONJ
36	both	both	DT	_	35	PMOD
37	of	of	IN	_	36	NMOD
38	these	these	DT	_	39	NMOD
39	fragments	fragment	NNS	_	37	PMOD
40	in	in	IN	_	36	LOC
41	+	+	SYM	_	43	P
42	/	/	HYPH	_	43	P
43	-	-	SYM	_	44	NMOD
44	mice	mouse	NNS	_	40	PMOD
45	(	(	-LRB-	_	47	P
46	Fig.	fig.	NN	_	47	NMOD
47	1B	0b	NN	_	6	PRN
48	)	)	-RRB-	_	47	P
49	.	.	.	_	6	P

1	Mice	mouse	NNS	_	7	SBJ
2	homozygous	homozygous	JJ	_	1	NMOD
3	for	for	IN	_	2	AMOD
4	the	the	DT	_	6	NMOD
5	E2	e0	NN	_	6	NMOD
6	mutation	mutation	NN	_	3	PMOD
7	were	be	VBD	_	0	ROOT
8	born	bear	VBN	_	7	VC
9	at	at	IN	_	8	TMP
10	the	the	DT	_	12	NMOD
11	expected	expect	VBN	_	12	NMOD
12	frequency	frequency	NN	_	9	PMOD
13	.	.	.	_	7	P

1	Genotype	genotype	NN	_	2	NMOD
2	analysis	analysis	NN	_	15	SBJ
3	of	of	IN	_	2	NMOD
4	pups	pup	NNS	_	3	PMOD
5	derived	derive	VBN	_	4	NMOD
6	from	from	IN	_	5	ADV
7	+	+	SYM	_	9	P
8	/	/	HYPH	_	9	P
9	-	-	SYM	_	14	NMOD
10	by	by	IN	_	9	NMOD
11	+	+	SYM	_	13	P
12	/	/	HYPH	_	13	P
13	-	-	SYM	_	10	PMOD
14	matings	mating	NNS	_	6	PMOD
15	revealed	reveal	VBD	_	0	ROOT
16	that	that	IN	_	15	OBJ
17	+	+	SYM	_	19	P
18	/	/	HYPH	_	19	P
19	+	+	SYM	_	29	NMOD
20	,	,	,	_	19	P
21	+	+	SYM	_	23	P
22	/	/	HYPH	_	23	P
23	-	-	SYM	_	19	CONJ
24	,	,	,	_	23	P
25	and	and	CC	_	23	COORD
26	-	-	SYM	_	28	P
27	/	/	HYPH	_	28	P
28	-	-	SYM	_	25	CONJ
29	mice	mouse	NNS	_	30	SBJ
30	were	be	VBD	_	16	SUB
31	present	present	JJ	_	30	PRD
32	at	at	IN	_	30	TMP
33	nearly	nearly	RB	_	41	NMOD
34	the	the	DT	_	41	NMOD
35	expected	expect	VBN	_	41	NMOD
36	1	0	CD	_	40	NMOD
37	:	:	SYM	_	40	P
38	2	0	CD	_	40	NMOD
39	:	:	SYM	_	40	P
40	1	0	CD	_	41	NMOD
41	frequency	frequency	NN	_	32	PMOD
42	.	.	.	_	15	P

1	Of	of	IN	_	8	NMOD
2	the	the	DT	_	5	NMOD
3	initial	initial	JJ	_	5	NMOD
4	60	0	CD	_	5	NMOD
5	animals	animal	NNS	_	1	PMOD
6	genotyped	genotyped	VBN	_	5	NMOD
7	,	,	,	_	1	P
8	19	0	CD	_	13	SBJ
9	(	(	-LRB-	_	11	P
10	32	0	CD	_	11	NMOD
11	%	%	NN	_	8	PRN
12	)	)	-RRB-	_	11	P
13	were	be	VBD	_	0	ROOT
14	+	+	SYM	_	16	P
15	/	/	HYPH	_	16	P
16	+	+	SYM	_	13	PRD
17	,	,	,	_	13	P
18	27	0	CD	_	23	SBJ
19	(	(	-LRB-	_	21	P
20	45	0	CD	_	21	NMOD
21	%	%	NN	_	18	PRN
22	)	)	-RRB-	_	21	P
23	were	be	VBD	_	13	CONJ
24	+	+	SYM	_	26	P
25	/	/	HYPH	_	26	P
26	-	-	SYM	_	23	PRD
27	,	,	,	_	23	P
28	and	and	CC	_	23	COORD
29	14	0	CD	_	34	SBJ
30	(	(	-LRB-	_	32	P
31	23	0	CD	_	32	NMOD
32	%	%	NN	_	29	PRN
33	)	)	-RRB-	_	32	P
34	were	be	VBD	_	28	CONJ
35	-	-	SYM	_	37	P
36	/	/	HYPH	_	37	P
37	-	-	SYM	_	34	PRD
38	.	.	.	_	1	P

1	Thus	thus	RB	_	6	ADV
2	,	,	,	_	6	P
3	the	the	DT	_	5	NMOD
4	E2	e0	NN	_	5	NMOD
5	gene	gene	NN	_	6	SBJ
6	was	be	VBD	_	0	ROOT
7	dispensable	dispensable	JJ	_	6	PRD
8	for	for	IN	_	7	AMOD
9	normal	normal	JJ	_	11	NMOD
10	embryonic	embryonic	JJ	_	11	NMOD
11	development	development	NN	_	8	PMOD
12	.	.	.	_	6	P

1	However	however	RB	_	10	ADV
2	,	,	,	_	10	P
3	as	as	IN	_	10	ADV
4	expected	expect	VBN	_	3	SUB
5	,	,	,	_	10	P
6	nearly	nearly	RB	_	9	NMOD
7	all	all	DT	_	9	NMOD
8	homozygous	homozygous	JJ	_	9	NMOD
9	mice	mouse	NNS	_	10	SBJ
10	died	die	VBD	_	0	ROOT
11	in	in	IN	_	10	TMP
12	the	the	DT	_	14	NMOD
13	perinatal	perinatal	JJ	_	14	NMOD
14	period	period	NN	_	11	PMOD
15	.	.	.	_	10	P

1	Immediately	immediately	RB	_	2	PMOD
2	following	follow	VBG	_	7	TMP
3	birth	birth	NN	_	2	PMOD
4	,	,	,	_	7	P
5	homozygous	homozygous	JJ	_	6	NMOD
6	pups	pup	NNS	_	7	SBJ
7	were	be	VBD	_	21	DEP
8	indistinguishable	indistinguishable	JJ	_	7	PRD
9	from	from	IN	_	8	AMOD
10	their	their	PRP$	_	18	NMOD
11	+	+	SYM	_	13	P
12	/	/	HYPH	_	13	P
13	+	+	SYM	_	18	NMOD
14	and	and	CC	_	13	COORD
15	+	+	SYM	_	17	P
16	/	/	HYPH	_	17	P
17	-	-	SYM	_	14	CONJ
18	littermates	littermates	NNS	_	9	PMOD
19	;	;	:	_	21	P
20	they	they	PRP	_	21	SBJ
21	were	be	VBD	_	0	ROOT
22	vigorous	vigorous	JJ	_	21	PRD
23	,	,	,	_	22	P
24	active	active	JJ	_	22	CONJ
25	and	and	CC	_	24	COORD
26	able	able	JJ	_	25	CONJ
27	to	to	TO	_	26	AMOD
28	suckle	suckle	VB	_	27	IM
29	.	.	.	_	21	P

1	By	by	IN	_	16	TMP
2	mid	mid	JJ	_	5	NMOD
3	to	to	IN	_	2	AMOD
4	late	late	JJ	_	3	PMOD
5	day	day	NN	_	1	PMOD
6	on	on	IN	_	5	NMOD
7	postnatal	postnatal	JJ	_	8	NMOD
8	day	day	NN	_	6	PMOD
9	one	one	CD	_	8	NMOD
10	,	,	,	_	16	P
11	most	most	RBS	_	15	NMOD
12	-	-	SYM	_	14	P
13	/	/	HYPH	_	14	P
14	-	-	SYM	_	15	NMOD
15	pups	pup	NNS	_	16	SBJ
16	became	become	VBD	_	0	ROOT
17	moribund	moribund	JJ	_	16	PRD
18	and	and	CC	_	16	COORD
19	were	be	VBD	_	18	CONJ
20	readily	readily	RB	_	21	AMOD
21	identifiable	identifiable	JJ	_	19	PRD
22	as	as	IN	_	21	AMOD
23	they	they	PRP	_	24	SBJ
24	were	be	VBD	_	22	SUB
25	lethargic	lethargic	JJ	_	27	AMOD
26	,	,	,	_	27	P
27	pale	pale	JJ	_	24	PRD
28	,	,	,	_	24	P
29	and	and	CC	_	24	COORD
30	exhibited	exhibit	VBD	_	29	CONJ
31	gasping	gasp	VBG	_	33	NMOD
32	respiratory	respiratory	JJ	_	33	NMOD
33	movements	movement	NNS	_	30	OBJ
34	.	.	.	_	16	P

1	With	with	IN	_	9	ADV
2	few	few	JJ	_	3	NMOD
3	exceptions	exception	NNS	_	1	PMOD
4	,	,	,	_	9	P
5	-	-	SYM	_	7	P
6	/	/	HYPH	_	7	P
7	-	-	SYM	_	8	NMOD
8	pups	pup	NNS	_	9	SBJ
9	died	die	VBD	_	0	ROOT
10	within	within	IN	_	9	TMP
11	72	0	CD	_	12	NMOD
12	hours	hour	NNS	_	10	PMOD
13	of	of	IN	_	12	NMOD
14	birth	birth	NN	_	13	PMOD
15	.	.	.	_	9	P

1	We	we	PRP	_	2	SBJ
2	have	have	VBP	_	0	ROOT
3	observed	observe	VBN	_	2	VC
4	one	one	CD	_	9	NMOD
5	rare	rare	JJ	_	9	NMOD
6	-	-	SYM	_	8	P
7	/	/	HYPH	_	8	P
8	-	-	SYM	_	9	NMOD
9	pup	pup	NN	_	3	OBJ
10	that	that	WDT	_	11	SBJ
11	survived	survive	VBD	_	9	NMOD
12	to	to	IN	_	11	TMP
13	postnatal	postnatal	JJ	_	14	NMOD
14	day	day	NN	_	12	PMOD
15	13	0	CD	_	14	NMOD
16	.	.	.	_	2	P

1	The	the	DT	_	2	NMOD
2	reason	reason	NN	_	10	SBJ
3	for	for	IN	_	2	NMOD
4	the	the	DT	_	6	NMOD
5	prolonged	prolong	VBN	_	6	NMOD
6	survival	survival	NN	_	3	PMOD
7	of	of	IN	_	6	NMOD
8	this	this	DT	_	9	NMOD
9	pup	pup	NN	_	7	PMOD
10	is	be	VBZ	_	0	ROOT
11	unknown	unknown	JJ	_	10	PRD
12	.	.	.	_	10	P

1	E2	e0	NN	_	2	AMOD
2	deficient	deficient	JJ	_	3	NMOD
3	mice	mouse	NNS	_	5	SBJ
4	accurately	accurately	RB	_	5	ADV
5	model	model	VBP	_	0	ROOT
6	classic	classic	JJ	_	7	NMOD
7	MSUD	msud	NN	_	5	OBJ

1	To	to	TO	_	16	PRP
2	demonstrate	demonstrate	VB	_	1	IM
3	that	that	IN	_	2	OBJ
4	the	the	DT	_	7	NMOD
5	gene	gene	NN	_	6	NMOD
6	targeting	targeting	NN	_	7	NMOD
7	event	event	NN	_	8	SBJ
8	created	create	VBD	_	3	SUB
9	a	a	DT	_	13	NMOD
10	true	true	JJ	_	13	NMOD
11	E2	e0	NN	_	12	AMOD
12	null	null	JJ	_	13	NMOD
13	allele	allele	NN	_	8	OBJ
14	,	,	,	_	16	P
15	we	we	PRP	_	16	SBJ
16	determined	determine	VBD	_	0	ROOT
17	BCKDH	bckdh	NN	_	18	NMOD
18	activity	activity	NN	_	16	OBJ
19	in	in	IN	_	16	LOC
20	liver	liver	NN	_	21	NMOD
21	homogenates	homogenate	NNS	_	19	PMOD
22	of	of	IN	_	21	NMOD
23	postnatal	postnatal	JJ	_	24	NMOD
24	day	day	NN	_	27	NMOD
25	1	0	CD	_	24	NMOD
26	mouse	mouse	NN	_	27	NMOD
27	pups	pup	NNS	_	22	PMOD
28	derived	derive	VBN	_	27	NMOD
29	from	from	IN	_	28	ADV
30	+	+	SYM	_	32	P
31	/	/	HYPH	_	32	P
32	-	-	SYM	_	38	NMOD
33	by	by	IN	_	32	NMOD
34	+	+	SYM	_	36	P
35	/	/	HYPH	_	36	P
36	-	-	SYM	_	33	PMOD
37	mating	mating	NN	_	38	NMOD
38	pairs	pair	NNS	_	29	PMOD
39	.	.	.	_	16	P

1	As	as	IN	_	15	ADV
2	shown	show	VBN	_	1	SUB
3	in	in	IN	_	2	ADV
4	Figure	figure	NN	_	5	NMOD
5	2A	0a	NN	_	3	PMOD
6	,	,	,	_	15	P
7	the	the	DT	_	9	NMOD
8	BCKDH	bckdh	NN	_	9	NMOD
9	activity	activity	NN	_	15	SBJ
10	in	in	IN	_	9	LOC
11	+	+	SYM	_	13	P
12	/	/	HYPH	_	13	P
13	+	+	SYM	_	14	NMOD
14	mice	mouse	NNS	_	10	PMOD
15	was	be	VBD	_	0	ROOT
16	readily	readily	RB	_	17	AMOD
17	detectable	detectable	JJ	_	15	PRD
18	.	.	.	_	15	P

1	In	in	IN	_	7	ADV
2	marked	marked	JJ	_	3	NMOD
3	contrast	contrast	NN	_	1	PMOD
4	,	,	,	_	7	P
5	BCKDH	bckdh	NN	_	6	NMOD
6	activity	activity	NN	_	7	SBJ
7	was	be	VBD	_	0	ROOT
8	completely	completely	RB	_	9	AMOD
9	absent	absent	JJ	_	7	PRD
10	in	in	IN	_	7	LOC
11	-	-	SYM	_	13	P
12	/	/	HYPH	_	13	P
13	-	-	SYM	_	15	NMOD
14	mouse	mouse	NN	_	15	NMOD
15	livers	liver	NNS	_	10	PMOD
16	.	.	.	_	7	P

1	As	as	IN	_	10	ADV
2	expected	expect	VBN	_	1	SUB
3	,	,	,	_	10	P
4	homogenates	homogenate	NNS	_	10	SBJ
5	from	from	IN	_	4	NMOD
6	+	+	SYM	_	8	P
7	/	/	HYPH	_	8	P
8	-	-	SYM	_	9	NMOD
9	mice	mouse	NNS	_	5	PMOD
10	had	have	VBD	_	0	ROOT
11	approximately	approximately	RB	_	12	QMOD
12	half	half	PDT	_	14	NMOD
13	the	the	DT	_	14	NMOD
14	activity	activity	NN	_	10	OBJ
15	of	of	IN	_	14	NMOD
16	their	their	PRP$	_	20	NMOD
17	+	+	SYM	_	19	P
18	/	/	HYPH	_	19	P
19	+	+	SYM	_	20	NMOD
20	littermates	littermates	NNS	_	15	PMOD
21	(	(	-LRB-	_	23	P
22	Figure	figure	NN	_	23	NMOD
23	2A	0a	NN	_	10	PRN
24	)	)	-RRB-	_	23	P
25	.	.	.	_	10	P

1	The	the	DT	_	2	NMOD
2	results	result	NNS	_	8	SBJ
3	from	from	IN	_	2	NMOD
4	-	-	SYM	_	6	P
5	/	/	HYPH	_	6	P
6	-	-	SYM	_	7	NMOD
7	mice	mouse	NNS	_	3	PMOD
8	are	be	VBP	_	0	ROOT
9	similar	similar	JJ	_	8	PRD
10	to	to	IN	_	9	AMOD
11	that	that	DT	_	10	PMOD
12	observed	observe	VBN	_	11	NMOD
13	in	in	IN	_	12	LOC
14	humans	human	NNS	_	13	PMOD
15	with	with	IN	_	14	NMOD
16	classic	classic	JJ	_	17	NMOD
17	MSUD	msud	NN	_	15	PMOD
18	[	[	-LRB-	_	19	P
19	1	0	CD	_	8	PRN
20	]	]	-RRB-	_	19	P
21	.	.	.	_	8	P

1	Figure	figure	NN	_	0	ROOT
2	2	0	CD	_	1	NMOD

1	Biochemical	biochemical	JJ	_	2	NMOD
2	characterization	characterization	NN	_	0	ROOT
3	of	of	IN	_	2	NMOD
4	the	the	DT	_	8	NMOD
5	classic	classic	JJ	_	8	NMOD
6	MSUD	msud	NN	_	8	NMOD
7	murine	murine	JJ	_	8	NMOD
8	model	model	NN	_	3	PMOD
9	.	.	.	_	2	P

1	A	a	LS	_	5	NMOD
2	,	,	,	_	5	P
3	BCKDH	bckdh	NN	_	5	NMOD
4	enzyme	enzyme	NN	_	5	NMOD
5	activity	activity	NN	_	0	ROOT
6	in	in	IN	_	5	LOC
7	liver	liver	NN	_	6	PMOD
8	of	of	IN	_	7	NMOD
9	newborn	newborn	JJ	_	34	NMOD
10	wild	wild	JJ	_	11	NMOD
11	type	type	NN	_	12	NMOD
12	control	control	NN	_	33	NMOD
13	(	(	-LRB-	_	16	P
14	+	+	SYM	_	16	P
15	/	/	HYPH	_	16	P
16	+	+	SYM	_	12	PRN
17	)	)	-RRB-	_	16	P
18	,	,	,	_	12	P
19	heterozygous	heterozygous	JJ	_	12	CONJ
20	(	(	-LRB-	_	23	P
21	+	+	SYM	_	23	P
22	/	/	HYPH	_	23	P
23	-	-	SYM	_	19	PRN
24	)	)	-RRB-	_	23	P
25	,	,	,	_	19	P
26	and	and	CC	_	19	COORD
27	homozygous	homozygous	JJ	_	26	CONJ
28	(	(	-LRB-	_	31	P
29	-	-	SYM	_	31	P
30	/	/	HYPH	_	31	P
31	-	-	SYM	_	27	PRN
32	)	)	-RRB-	_	31	P
33	knockout	knockout	NN	_	34	NMOD
34	mice	mouse	NNS	_	8	PMOD
35	.	.	.	_	5	P

1	Enzyme	enzyme	NN	_	2	NMOD
2	activity	activity	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	significantly	significantly	RB	_	5	AMOD
5	reduced	reduced	JJ	_	3	PRD
6	in	in	IN	_	3	LOC
7	+	+	SYM	_	9	P
8	/	/	HYPH	_	9	P
9	-	-	SYM	_	10	NMOD
10	liver	liver	NN	_	6	PMOD
11	compared	compare	VBN	_	3	ADV
12	to	to	IN	_	11	PMOD
13	+	+	SYM	_	15	P
14	/	/	HYPH	_	15	P
15	+	+	SYM	_	12	PMOD
16	,	,	,	_	3	P
17	and	and	CC	_	3	COORD
18	was	be	VBD	_	17	CONJ
19	below	below	IN	_	18	PRD
20	the	the	DT	_	21	NMOD
21	level	level	NN	_	19	PMOD
22	of	of	IN	_	21	NMOD
23	detection	detection	NN	_	22	PMOD
24	in	in	IN	_	18	LOC
25	-	-	SYM	_	27	P
26	/	/	HYPH	_	27	P
27	-	-	SYM	_	28	NMOD
28	liver	liver	NN	_	24	PMOD
29	.	.	.	_	3	P

1	B	b	LS	_	5	NMOD
2	,	,	,	_	5	P
3	Total	total	JJ	_	5	NMOD
4	BCAA	bcaa	NN	_	5	NMOD
5	concentrations	concentration	NNS	_	0	ROOT
6	in	in	IN	_	5	LOC
7	blood	blood	NN	_	6	PMOD
8	of	of	IN	_	7	NMOD
9	mice	mouse	NNS	_	8	PMOD
10	.	.	.	_	5	P

1	Total	total	JJ	_	2	NMOD
2	BCAA	bcaa	NN	_	3	SBJ
3	represent	represent	VBP	_	0	ROOT
4	the	the	DT	_	5	NMOD
5	sum	sum	NN	_	3	OBJ
6	of	of	IN	_	5	NMOD
7	leucine	leucine	NN	_	6	PMOD
8	,	,	,	_	7	P
9	isoleucine	isoleucine	NN	_	7	CONJ
10	,	,	,	_	9	P
11	and	and	CC	_	9	COORD
12	valine	valine	NN	_	11	CONJ
13	.	.	.	_	3	P

1	Total	total	JJ	_	3	NMOD
2	BCAA	bcaa	NN	_	3	NMOD
3	concentrations	concentration	NNS	_	11	SBJ
4	in	in	IN	_	3	NMOD
5	blood	blood	NN	_	4	PMOD
6	from	from	IN	_	5	NMOD
7	-	-	SYM	_	9	P
8	/	/	HYPH	_	9	P
9	-	-	SYM	_	10	NMOD
10	mice	mouse	NNS	_	6	PMOD
11	were	be	VBD	_	0	ROOT
12	significantly	significantly	RB	_	13	AMOD
13	elevated	elevated	JJ	_	11	PRD
14	compared	compare	VBN	_	11	ADV
15	to	to	IN	_	14	PMOD
16	+	+	SYM	_	18	P
17	/	/	HYPH	_	18	P
18	+	+	SYM	_	15	PMOD
19	and	and	CC	_	18	COORD
20	+	+	SYM	_	22	P
21	/	/	HYPH	_	22	P
22	-	-	SYM	_	19	CONJ
23	.	.	.	_	11	P

1	C	c	LS	_	3	NMOD
2	,	,	,	_	3	P
3	Ratio	ratio	NN	_	0	ROOT
4	of	of	IN	_	3	NMOD
5	total	total	JJ	_	6	NMOD
6	BCAA	bcaa	NN	_	4	PMOD
7	to	to	IN	_	3	NMOD
8	alanine	alanine	NN	_	7	PMOD
9	in	in	IN	_	3	LOC
10	blood	blood	NN	_	9	PMOD
11	of	of	IN	_	10	NMOD
12	mice	mouse	NNS	_	11	PMOD
13	.	.	.	_	3	P

1	This	this	DT	_	2	NMOD
2	ratio	ratio	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	significantly	significantly	RB	_	5	AMOD
5	elevated	elevated	JJ	_	3	PRD
6	in	in	IN	_	3	LOC
7	-	-	SYM	_	9	P
8	/	/	HYPH	_	9	P
9	-	-	SYM	_	10	NMOD
10	mice	mouse	NNS	_	6	PMOD
11	compared	compare	VBN	_	3	ADV
12	to	to	IN	_	11	PMOD
13	+	+	SYM	_	15	P
14	/	/	HYPH	_	15	P
15	+	+	SYM	_	20	NMOD
16	and	and	CC	_	15	COORD
17	+	+	SYM	_	19	P
18	/	/	HYPH	_	19	P
19	-	-	SYM	_	16	CONJ
20	mice	mouse	NNS	_	12	PMOD
21	.	.	.	_	3	P

1	The	the	DT	_	2	NMOD
2	numbers	number	NNS	_	6	SBJ
3	on	on	IN	_	2	NMOD
4	the	the	DT	_	5	NMOD
5	bars	bar	NNS	_	3	PMOD
6	indicates	indicate	VBZ	_	0	ROOT
7	the	the	DT	_	8	NMOD
8	number	number	NN	_	6	OBJ
9	of	of	IN	_	8	NMOD
10	mice	mouse	NNS	_	9	PMOD
11	analyzed	analyze	VBN	_	10	NMOD
12	.	.	.	_	6	P

1	*	*	SYM	_	0	ROOT
2	,	,	,	_	1	P
3	Significantly	significantly	RB	_	4	AMOD
4	different	different	JJ	_	1	DEP
5	from	from	IN	_	4	AMOD
6	+	+	SYM	_	8	P
7	/	/	HYPH	_	8	P
8	+	+	SYM	_	5	PMOD
9	(	(	-LRB-	_	12	P
10	P	p	NN	_	12	SBJ
11	<	<	SYM	_	12	P
12	0.001	0	CD	_	4	PRN
13	)	)	-RRB-	_	12	P
14	;	;	:	_	1	P
15	**	**	SYM	_	1	DEP
16	,	,	,	_	15	P
17	significantly	significantly	RB	_	18	AMOD
18	different	different	JJ	_	15	DEP
19	from	from	IN	_	18	AMOD
20	+	+	SYM	_	22	P
21	/	/	HYPH	_	22	P
22	+	+	SYM	_	19	PMOD
23	and	and	CC	_	22	COORD
24	+	+	SYM	_	26	P
25	/	/	HYPH	_	26	P
26	-	-	SYM	_	23	CONJ
27	(	(	-LRB-	_	30	P
28	P	p	NN	_	30	SBJ
29	<	<	SYM	_	30	P
30	0.001	0	CD	_	18	PRN
31	)	)	-RRB-	_	30	P
32	.	.	.	_	1	P

1	Immunohistochemistry	immunohistochemistry	NN	_	7	SBJ
2	with	with	IN	_	1	NMOD
3	an	an	DT	_	6	NMOD
4	E2	e0	NN	_	5	AMOD
5	specific	specific	JJ	_	6	NMOD
6	antibody	antibody	NN	_	2	PMOD
7	was	be	VBD	_	0	ROOT
8	used	use	VBN	_	7	VC
9	to	to	TO	_	8	PRP
10	examine	examine	VB	_	9	IM
11	E2	e0	NN	_	12	NMOD
12	protein	protein	NN	_	10	OBJ
13	in	in	IN	_	10	LOC
14	the	the	DT	_	15	NMOD
15	mice	mouse	NNS	_	13	PMOD
16	.	.	.	_	7	P

1	As	as	IN	_	12	ADV
2	shown	show	VBN	_	1	SUB
3	in	in	IN	_	2	ADV
4	Figure	figure	NN	_	5	NMOD
5	1C	0c	NN	_	3	PMOD
6	and	and	CC	_	5	COORD
7	1D	0d	NN	_	6	CONJ
8	,	,	,	_	12	P
9	immunoreactive	immunoreactive	JJ	_	11	NMOD
10	E2	e0	NN	_	11	NMOD
11	protein	protein	NN	_	12	SBJ
12	was	be	VBD	_	0	ROOT
13	abundant	abundant	JJ	_	12	PRD
14	in	in	IN	_	12	LOC
15	liver	liver	NN	_	14	PMOD
16	and	and	CC	_	15	COORD
17	embryonic	embryonic	JJ	_	18	NMOD
18	fibroblasts	fibroblast	NNS	_	16	CONJ
19	of	of	IN	_	15	NMOD
20	+	+	SYM	_	22	P
21	/	/	HYPH	_	22	P
22	+	+	SYM	_	23	NMOD
23	mice	mouse	NNS	_	19	PMOD
24	.	.	.	_	12	P

1	In	in	IN	_	8	ADV
2	marked	marked	JJ	_	3	NMOD
3	contrast	contrast	NN	_	1	PMOD
4	,	,	,	_	8	P
5	immunoreactive	immunoreactive	JJ	_	7	NMOD
6	E2	e0	NN	_	7	NMOD
7	protein	protein	NN	_	8	SBJ
8	was	be	VBD	_	0	ROOT
9	absent	absent	JJ	_	8	PRD
10	in	in	IN	_	8	LOC
11	these	these	DT	_	13	NMOD
12	same	same	JJ	_	13	NMOD
13	tissues	tissue	NNS	_	10	PMOD
14	of	of	IN	_	13	NMOD
15	-	-	SYM	_	17	P
16	/	/	HYPH	_	17	P
17	-	-	SYM	_	18	NMOD
18	mice	mouse	NNS	_	14	PMOD
19	.	.	.	_	8	P

1	Homozygous	homozygous	JJ	_	3	NMOD
2	E2	e0	NN	_	3	NMOD
3	knockout	knockout	NN	_	4	NMOD
4	mice	mouse	NNS	_	5	SBJ
5	had	have	VBD	_	0	ROOT
6	a	a	DT	_	11	NMOD
7	nearly	nearly	RB	_	8	QMOD
8	3	0	CD	_	10	QMOD
9	-	-	HYPH	_	8	P
10	fold	fold	JJ	_	11	NMOD
11	increase	increase	NN	_	5	OBJ
12	in	in	IN	_	11	NMOD
13	blood	blood	NN	_	25	NMOD
14	(	(	-LRB-	_	16	P
15	Figure	figure	NN	_	16	NMOD
16	2B	0b	NN	_	13	PRN
17	)	)	-RRB-	_	16	P
18	and	and	CC	_	13	COORD
19	urine	urine	NN	_	18	CONJ
20	(	(	-LRB-	_	23	P
21	data	datum	NNS	_	23	SBJ
22	not	not	RB	_	23	ADV
23	shown	show	VBN	_	19	PRN
24	)	)	-RRB-	_	23	P
25	levels	level	NNS	_	12	PMOD
26	of	of	IN	_	25	NMOD
27	BCAA	bcaa	NN	_	26	PMOD
28	(	(	-LRB-	_	29	P
29	sum	sum	NN	_	27	PRN
30	of	of	IN	_	29	NMOD
31	leucine	leucine	NN	_	30	PMOD
32	,	,	,	_	31	P
33	isoleucine	isoleucine	NN	_	31	CONJ
34	,	,	,	_	33	P
35	and	and	CC	_	33	COORD
36	valine	valine	NN	_	35	CONJ
37	)	)	-RRB-	_	29	P
38	as	as	IN	_	11	NMOD
39	compared	compare	VBN	_	38	PMOD
40	to	to	IN	_	39	PMOD
41	their	their	PRP$	_	45	NMOD
42	+	+	SYM	_	44	P
43	/	/	HYPH	_	44	P
44	+	+	SYM	_	45	NMOD
45	littermates	littermates	NNS	_	40	PMOD
46	.	.	.	_	5	P

1	Because	because	IN	_	20	PRP
2	amino	amino	NN	_	3	NMOD
3	acids	acid	NNS	_	4	SBJ
4	were	be	VBD	_	1	SUB
5	analyzed	analyze	VBN	_	4	VC
6	by	by	IN	_	5	MNR
7	tandem	tandem	NN	_	9	NMOD
8	mass	mass	NN	_	9	NMOD
9	spectrometry	spectrometry	NN	_	6	PMOD
10	,	,	,	_	20	P
11	the	the	DT	_	12	NMOD
12	sum	sum	NN	_	20	SBJ
13	of	of	IN	_	12	NMOD
14	BCAA	bcaa	NN	_	13	PMOD
15	shown	show	VBN	_	12	NMOD
16	in	in	IN	_	15	ADV
17	Figure	figure	NN	_	18	NMOD
18	2B	0b	NN	_	16	PMOD
19	also	also	RB	_	20	ADV
20	may	may	MD	_	0	ROOT
21	include	include	VB	_	20	VC
22	alloisoleucine	alloisoleucine	NN	_	21	OBJ
23	that	that	WDT	_	24	SBJ
24	may	may	MD	_	22	NMOD
25	have	have	VB	_	24	VC
26	been	be	VBN	_	25	VC
27	produced	produce	VBN	_	26	VC
28	in	in	IN	_	27	LOC
29	-	-	SYM	_	31	P
30	/	/	HYPH	_	31	P
31	-	-	SYM	_	33	NMOD
32	MSUD	msud	NN	_	33	NMOD
33	mice	mouse	NNS	_	28	PMOD
34	.	.	.	_	20	P

1	The	the	DT	_	2	NMOD
2	metabolism	metabolism	NN	_	5	SBJ
3	of	of	IN	_	2	NMOD
4	BCAA	bcaa	NN	_	3	PMOD
5	is	be	VBZ	_	0	ROOT
6	linked	link	VBN	_	5	VC
7	with	with	IN	_	6	ADV
8	the	the	DT	_	9	NMOD
9	synthesis	synthesis	NN	_	7	PMOD
10	of	of	IN	_	9	NMOD
11	alanine	alanine	NN	_	10	PMOD
12	,	,	,	_	11	P
13	glutamate	glutamate	NN	_	11	CONJ
14	,	,	,	_	13	P
15	and	and	CC	_	13	COORD
16	glutamine	glutamine	NN	_	15	CONJ
17	[	[	-LRB-	_	18	P
18	33	0	CD	_	6	PRN
19	]	]	-RRB-	_	18	P
20	.	.	.	_	5	P

1	Because	because	IN	_	23	PRP
2	of	of	IN	_	1	PMOD
3	impaired	impaired	JJ	_	4	NMOD
4	metabolism	metabolism	NN	_	1	PMOD
5	of	of	IN	_	4	NMOD
6	BCAA	bcaa	NN	_	5	PMOD
7	in	in	IN	_	4	LOC
8	MSUD	msud	NN	_	9	NMOD
9	mice	mouse	NNS	_	7	PMOD
10	,	,	,	_	1	P
11	and	and	CC	_	1	COORD
12	to	to	TO	_	11	CONJ
13	further	far	RB	_	12	ADV
14	characterize	characterize	VB	_	12	IM
15	the	the	DT	_	17	NMOD
16	abnormal	abnormal	JJ	_	17	NMOD
17	biochemistry	biochemistry	NN	_	14	OBJ
18	in	in	IN	_	14	LOC
19	this	this	DT	_	20	NMOD
20	model	model	NN	_	18	PMOD
21	,	,	,	_	23	P
22	we	we	PRP	_	23	SBJ
23	analyzed	analyze	VBD	_	0	ROOT
24	the	the	DT	_	26	NMOD
25	blood	blood	NN	_	26	NMOD
26	levels	level	NNS	_	23	OBJ
27	of	of	IN	_	26	NMOD
28	the	the	DT	_	29	NMOD
29	alanine	alanine	NN	_	27	PMOD
30	,	,	,	_	29	P
31	glutamate	glutamate	NN	_	29	CONJ
32	,	,	,	_	31	P
33	and	and	CC	_	31	COORD
34	glutamine	glutamine	NN	_	33	CONJ
35	.	.	.	_	23	P

1	As	as	IN	_	17	ADV
2	shown	show	VBN	_	1	SUB
3	in	in	IN	_	2	ADV
4	Table	table	NN	_	3	PMOD
5	1	0	CD	_	4	NMOD
6	,	,	,	_	17	P
7	the	the	DT	_	8	NMOD
8	levels	level	NNS	_	17	SBJ
9	of	of	IN	_	8	NMOD
10	all	all	DT	_	13	NMOD
11	three	three	CD	_	13	NMOD
12	amino	amino	NN	_	13	NMOD
13	acids	acid	NNS	_	9	PMOD
14	in	in	IN	_	8	LOC
15	homozygous	homozygous	JJ	_	16	NMOD
16	mice	mouse	NNS	_	14	PMOD
17	were	be	VBD	_	0	ROOT
18	markedly	markedly	RB	_	19	AMOD
19	lower	low	JJR	_	17	PRD
20	than	than	IN	_	19	AMOD
21	the	the	DT	_	22	NMOD
22	levels	level	NNS	_	20	PMOD
23	in	in	IN	_	22	NMOD
24	+	+	SYM	_	26	P
25	/	/	HYPH	_	26	P
26	+	+	SYM	_	31	NMOD
27	or	or	CC	_	26	COORD
28	+	+	SYM	_	30	P
29	/	/	HYPH	_	30	P
30	-	-	SYM	_	27	CONJ
31	mice	mouse	NNS	_	23	PMOD
32	.	.	.	_	17	P

1	The	the	DT	_	2	NMOD
2	levels	level	NNS	_	13	SBJ
3	of	of	IN	_	2	NMOD
4	these	these	DT	_	6	NMOD
5	amino	amino	NN	_	6	NMOD
6	acids	acid	NNS	_	3	PMOD
7	in	in	IN	_	2	LOC
8	the	the	DT	_	12	NMOD
9	+	+	SYM	_	11	P
10	/	/	HYPH	_	11	P
11	-	-	SYM	_	12	NMOD
12	mice	mouse	NNS	_	7	PMOD
13	were	be	VBD	_	0	ROOT
14	comparable	comparable	JJ	_	13	PRD
15	to	to	IN	_	14	AMOD
16	those	those	DT	_	15	PMOD
17	in	in	IN	_	16	LOC
18	+	+	SYM	_	20	P
19	/	/	HYPH	_	20	P
20	+	+	SYM	_	21	NMOD
21	mice	mouse	NNS	_	17	PMOD
22	(	(	-LRB-	_	23	P
23	Table	table	NN	_	13	PRN
24	1	0	CD	_	23	NMOD
25	)	)	-RRB-	_	23	P
26	.	.	.	_	13	P

1	Because	because	IN	_	30	PRP
2	of	of	IN	_	1	PMOD
3	the	the	DT	_	5	NMOD
4	abnormal	abnormal	JJ	_	5	NMOD
5	decrease	decrease	NN	_	1	PMOD
6	in	in	IN	_	5	NMOD
7	the	the	DT	_	10	NMOD
8	blood	blood	NN	_	10	NMOD
9	alanine	alanine	NN	_	10	NMOD
10	level	level	NN	_	6	PMOD
11	and	and	CC	_	5	COORD
12	marked	marked	JJ	_	13	NMOD
13	rise	rise	NN	_	11	CONJ
14	in	in	IN	_	13	NMOD
15	blood	blood	NN	_	17	NMOD
16	BCAA	bcaa	NN	_	17	NMOD
17	levels	level	NNS	_	14	PMOD
18	that	that	WDT	_	19	SBJ
19	are	be	VBP	_	5	NMOD
20	characteristic	characteristic	JJ	_	19	PRD
21	of	of	IN	_	20	AMOD
22	MSUD	msud	NN	_	21	PMOD
23	,	,	,	_	30	P
24	a	a	DT	_	26	NMOD
25	recent	recent	JJ	_	26	NMOD
26	report	report	NN	_	30	SBJ
27	on	on	IN	_	26	NMOD
28	MSUD	msud	NN	_	29	NMOD
29	patients	patient	NNS	_	27	PMOD
30	has	have	VBZ	_	0	ROOT
31	suggested	suggest	VBN	_	30	VC
32	that	that	IN	_	31	OBJ
33	the	the	DT	_	34	NMOD
34	ratio	ratio	NN	_	39	SBJ
35	of	of	IN	_	34	NMOD
36	BCAA	bcaa	NN	_	38	NMOD
37	/	/	HYPH	_	36	P
38	alanine	alanine	NN	_	35	PMOD
39	provides	provide	VBZ	_	32	SUB
40	a	a	DT	_	43	NMOD
41	more	more	RBR	_	42	AMOD
42	sensitive	sensitive	JJ	_	43	NMOD
43	measure	measure	NN	_	39	OBJ
44	of	of	IN	_	43	NMOD
45	the	the	DT	_	47	NMOD
46	abnormal	abnormal	JJ	_	47	NMOD
47	biochemistry	biochemistry	NN	_	44	PMOD
48	of	of	IN	_	47	NMOD
49	MSUD	msud	NN	_	48	PMOD
50	than	than	IN	_	43	NMOD
51	BCAA	bcaa	NN	_	52	NMOD
52	level	level	NN	_	50	PMOD
53	alone	alone	RB	_	52	NMOD
54	[	[	-LRB-	_	55	P
55	8	0	CD	_	31	PRN
56	]	]	-RRB-	_	55	P
57	.	.	.	_	30	P

1	Therefore	therefore	RB	_	5	ADV
2	,	,	,	_	5	P
3	we	we	PRP	_	5	SBJ
4	also	also	RB	_	5	ADV
5	expressed	express	VBD	_	0	ROOT
6	the	the	DT	_	9	NMOD
7	amino	amino	NN	_	8	NMOD
8	acid	acid	NN	_	9	NMOD
9	results	result	NNS	_	5	OBJ
10	as	as	IN	_	5	MNR
11	BCAA	bcaa	NN	_	13	NMOD
12	/	/	HYPH	_	11	P
13	alanine	alanine	NN	_	14	NMOD
14	ratio	ratio	NN	_	10	PMOD
15	.	.	.	_	5	P

1	As	as	IN	_	14	ADV
2	shown	show	VBN	_	1	SUB
3	in	in	IN	_	2	ADV
4	Figure	figure	NN	_	5	NMOD
5	2C	0c	NN	_	3	PMOD
6	,	,	,	_	14	P
7	this	this	DT	_	8	NMOD
8	ratio	ratio	NN	_	14	SBJ
9	in	in	IN	_	8	LOC
10	-	-	SYM	_	12	P
11	/	/	HYPH	_	12	P
12	-	-	SYM	_	13	NMOD
13	pups	pup	NNS	_	9	PMOD
14	was	be	VBD	_	0	ROOT
15	more	more	RBR	_	20	AMOD
16	than	than	IN	_	15	QMOD
17	6	0	CD	_	15	QMOD
18	-	-	HYPH	_	15	P
19	fold	fold	RB	_	15	QMOD
20	higher	high	JJR	_	14	PRD
21	than	than	IN	_	20	AMOD
22	+	+	SYM	_	24	P
23	/	/	HYPH	_	24	P
24	+	+	SYM	_	29	NMOD
25	or	or	CC	_	24	COORD
26	+	+	SYM	_	28	P
27	/	/	HYPH	_	28	P
28	-	-	SYM	_	25	CONJ
29	littermates	littermates	NNS	_	21	PMOD
30	.	.	.	_	14	P

1	These	these	DT	_	5	NMOD
2	blood	blood	NN	_	5	NMOD
3	amino	amino	NN	_	4	NMOD
4	acid	acid	NN	_	5	NMOD
5	results	result	NNS	_	6	SBJ
6	are	be	VBP	_	0	ROOT
7	consistent	consistent	JJ	_	6	PRD
8	with	with	IN	_	7	AMOD
9	the	the	DT	_	10	NMOD
10	concentrations	concentration	NNS	_	8	PMOD
11	seen	see	VBN	_	10	NMOD
12	in	in	IN	_	11	LOC
13	patients	patient	NNS	_	12	PMOD
14	with	with	IN	_	13	NMOD
15	MSUD	msud	NN	_	14	PMOD
16	[	[	-LRB-	_	21	P
17	1	0	CD	_	21	NMOD
18	,	,	,	_	21	P
19	8	0	CD	_	21	NMOD
20	,	,	,	_	21	P
21	15	0	CD	_	6	PRN
22	]	]	-RRB-	_	21	P
23	.	.	.	_	6	P

1	Table	table	NN	_	0	ROOT
2	1	0	CD	_	1	NMOD

1	Summary	summary	NN	_	0	ROOT
2	of	of	IN	_	1	NMOD
3	additional	additional	JJ	_	7	NMOD
4	blood	blood	NN	_	7	NMOD
5	amino	amino	NN	_	6	NMOD
6	acid	acid	NN	_	7	NMOD
7	levels	level	NNS	_	2	PMOD
8	in	in	IN	_	7	LOC
9	the	the	DT	_	12	NMOD
10	classic	classic	JJ	_	12	NMOD
11	MSUD	msud	NN	_	12	NMOD
12	model	model	NN	_	8	PMOD
13	and	and	CC	_	12	COORD
14	control	control	NN	_	15	NMOD
15	littermates	littermates	NNS	_	13	CONJ
16	as	as	IN	_	7	ADV
17	determined	determine	VBN	_	16	SUB
18	by	by	IN	_	17	MNR
19	tandem	tandem	JJ	_	21	NMOD
20	mass	mass	NN	_	21	NMOD
21	spectrometry	spectrometry	NN	_	18	PMOD
22	.	.	.	_	1	P

1	All	all	DT	_	2	NMOD
2	samples	sample	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	collected	collect	VBN	_	3	VC
5	on	on	IN	_	4	TMP
6	the	the	DT	_	7	NMOD
7	day	day	NN	_	5	PMOD
8	of	of	IN	_	7	NMOD
9	birth	birth	NN	_	8	PMOD
10	.	.	.	_	3	P

1	All	all	DT	_	2	NMOD
2	values	value	NNS	_	3	SBJ
3	are	be	VBP	_	0	ROOT
4	mean	mean	NN	_	3	PRD
5	+	+	SYM	_	4	COORD
6	/	/	HYPH	_	5	P
7	-	-	SYM	_	5	P
8	SEM	sem	NN	_	5	CONJ
9	.	.	.	_	3	P

1	*	*	SYM	_	0	ROOT
2	:	:	:	_	1	P
3	Significantly	significantly	RB	_	4	AMOD
4	different	different	JJ	_	1	DEP
5	from	from	IN	_	4	AMOD
6	+	+	SYM	_	8	P
7	/	/	HYPH	_	8	P
8	+	+	SYM	_	5	PMOD
9	and	and	CC	_	8	COORD
10	+	+	SYM	_	12	P
11	/	/	HYPH	_	12	P
12	-	-	SYM	_	9	CONJ
13	(	(	-LRB-	_	16	P
14	P	p	NN	_	16	SBJ
15	<	<	SYM	_	16	P
16	0.001	0	CD	_	5	PRN
17	)	)	-RRB-	_	16	P
18	.	.	.	_	1	P

1	In	in	IN	_	7	ADV
2	summary	summary	NN	_	1	PMOD
3	,	,	,	_	7	P
4	E2	e0	NN	_	6	NMOD
5	knockout	knockout	NN	_	6	NMOD
6	mice	mouse	NNS	_	7	SBJ
7	lack	lack	VBP	_	0	ROOT
8	BCKDH	bckdh	NN	_	10	NMOD
9	enzymatic	enzymatic	JJ	_	10	NMOD
10	activity	activity	NN	_	7	OBJ
11	,	,	,	_	10	P
12	E2	e0	NN	_	13	NMOD
13	immunoreactivity	immunoreactivity	NN	_	10	APPO
14	,	,	,	_	7	P
15	and	and	CC	_	7	COORD
16	have	have	VBP	_	15	CONJ
17	markedly	markedly	RB	_	18	AMOD
18	elevated	elevate	VBN	_	19	NMOD
19	levels	level	NNS	_	16	OBJ
20	of	of	IN	_	19	NMOD
21	BCAA	bcaa	NN	_	20	PMOD
22	in	in	IN	_	16	LOC
23	the	the	DT	_	24	NMOD
24	blood	blood	NN	_	22	PMOD
25	and	and	CC	_	24	COORD
26	urine	urine	NN	_	25	CONJ
27	.	.	.	_	7	P

1	These	these	DT	_	3	NMOD
2	metabolic	metabolic	JJ	_	3	NMOD
3	derangements	derangement	NNS	_	5	SBJ
4	ultimately	ultimately	RB	_	5	ADV
5	result	result	VBP	_	0	ROOT
6	in	in	IN	_	5	ADV
7	neonatal	neonatal	JJ	_	8	NMOD
8	lethality	lethality	NN	_	6	PMOD
9	.	.	.	_	5	P

1	These	these	DT	_	2	NMOD
2	phenotypes	phenotype	NNS	_	3	SBJ
3	are	be	VBP	_	0	ROOT
4	remarkably	remarkably	RB	_	5	AMOD
5	similar	similar	JJ	_	3	PRD
6	to	to	IN	_	5	AMOD
7	that	that	DT	_	6	PMOD
8	observed	observe	VBN	_	7	NMOD
9	in	in	IN	_	8	LOC
10	humans	human	NNS	_	9	PMOD
11	with	with	IN	_	10	NMOD
12	the	the	DT	_	14	NMOD
13	classic	classic	JJ	_	14	NMOD
14	form	form	NN	_	11	PMOD
15	of	of	IN	_	14	NMOD
16	MSUD	msud	NN	_	15	PMOD
17	.	.	.	_	3	P

1	Thus	thus	RB	_	7	ADV
2	,	,	,	_	7	P
3	E2	e0	NN	_	5	NMOD
4	knockout	knockout	NN	_	5	NMOD
5	mice	mouse	NNS	_	7	SBJ
6	closely	closely	RB	_	7	ADV
7	model	model	VBP	_	0	ROOT
8	classic	classic	JJ	_	9	NMOD
9	MSUD	msud	NN	_	7	OBJ
10	.	.	.	_	7	P

1	Knockout	knockout	NN	_	2	NMOD
2	mice	mouse	NNS	_	8	SBJ
3	expressing	express	VBG	_	2	NMOD
4	a	a	DT	_	7	NMOD
5	human	human	JJ	_	7	NMOD
6	E2	e0	NN	_	7	NMOD
7	transgene	transgene	NN	_	3	OBJ
8	model	model	VBP	_	0	ROOT
9	a	a	DT	_	11	NMOD
10	variant	variant	JJ	_	11	NMOD
11	form	form	NN	_	8	OBJ
12	of	of	IN	_	11	NMOD
13	MSUD	msud	NN	_	12	PMOD
14	that	that	WDT	_	15	SBJ
15	mimics	mimic	VBZ	_	11	NMOD
16	intermediate	intermediate	JJ	_	17	NMOD
17	MSUD	msud	NN	_	15	OBJ

1	To	to	TO	_	15	PRP
2	create	create	VB	_	1	IM
3	a	a	DT	_	5	NMOD
4	murine	murine	JJ	_	5	NMOD
5	model	model	NN	_	2	OBJ
6	of	of	IN	_	5	NMOD
7	the	the	DT	_	10	NMOD
8	intermediate	intermediate	JJ	_	10	NMOD
9	variant	variant	NN	_	10	NMOD
10	form	form	NN	_	6	PMOD
11	of	of	IN	_	10	NMOD
12	MSUD	msud	NN	_	11	PMOD
13	,	,	,	_	15	P
14	we	we	PRP	_	15	SBJ
15	used	use	VBD	_	0	ROOT
16	a	a	DT	_	18	NMOD
17	transgenic	transgenic	JJ	_	18	NMOD
18	strategy	strategy	NN	_	15	OBJ
19	to	to	TO	_	15	PRP
20	rescue	rescue	VB	_	19	IM
21	the	the	DT	_	23	NMOD
22	severe	severe	JJ	_	23	NMOD
23	elevation	elevation	NN	_	20	OBJ
24	of	of	IN	_	23	NMOD
25	BCAA	bcaa	NN	_	24	PMOD
26	and	and	CC	_	23	COORD
27	neonatal	neonatal	JJ	_	28	NMOD
28	lethality	lethality	NN	_	26	CONJ
29	that	that	WDT	_	30	SBJ
30	occurs	occur	VBZ	_	28	NMOD
31	in	in	IN	_	30	ADV
32	the	the	DT	_	36	NMOD
33	classic	classic	JJ	_	36	NMOD
34	MSUD	msud	NN	_	36	NMOD
35	mouse	mouse	NN	_	36	NMOD
36	model	model	NN	_	31	PMOD
37	.	.	.	_	15	P

1	Our	our	PRP$	_	2	NMOD
2	strategy	strategy	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	composed	compose	VBN	_	3	VC
5	of	of	IN	_	4	ADV
6	a	a	DT	_	10	NMOD
7	two	two	CD	_	8	NMOD
8	part	part	NN	_	10	NMOD
9	transgenic	transgenic	JJ	_	10	NMOD
10	system	system	NN	_	5	PMOD
11	to	to	TO	_	10	NMOD
12	express	express	VB	_	11	IM
13	human	human	JJ	_	14	NMOD
14	E2	e0	NN	_	12	OBJ
15	in	in	IN	_	12	LOC
16	liver	liver	NN	_	15	PMOD
17	on	on	IN	_	12	ADV
18	the	the	DT	_	21	NMOD
19	E2	e0	NN	_	20	NMOD
20	knockout	knockout	NN	_	21	NMOD
21	background	background	NN	_	17	PMOD
22	.	.	.	_	3	P

1	This	this	DT	_	3	NMOD
2	bi-transgenic	bi-transgenic	JJ	_	3	NMOD
3	system	system	NN	_	4	SBJ
4	consisted	consist	VBD	_	0	ROOT
5	of	of	IN	_	4	ADV
6	a	a	DT	_	10	NMOD
7	LAP	lap	NN	_	9	NMOD
8	-	-	HYPH	_	7	P
9	tTA	tta	NN	_	10	NMOD
10	transgene	transgene	NN	_	5	PMOD
11	and	and	CC	_	10	COORD
12	a	a	DT	_	16	NMOD
13	TRE	tre	NN	_	15	NMOD
14	-	-	HYPH	_	13	P
15	E2	e0	NN	_	16	NMOD
16	transgene	transgene	NN	_	11	CONJ
17	(	(	-LRB-	_	19	P
18	Fig.	fig.	NN	_	19	NMOD
19	3A	0a	NN	_	4	PRN
20	)	)	-RRB-	_	19	P
21	.	.	.	_	4	P

1	The	the	DT	_	5	NMOD
2	LAP	lap	NN	_	4	NMOD
3	-	-	HYPH	_	2	P
4	tTA	tta	NN	_	5	NMOD
5	transgene	transgene	NN	_	9	SBJ
6	[	[	-LRB-	_	7	P
7	34	0	CD	_	5	PRN
8	]	]	-RRB-	_	7	P
9	directs	direct	VBZ	_	0	ROOT
10	high	high	JJ	_	11	NMOD
11	levels	level	NNS	_	9	OBJ
12	of	of	IN	_	11	NMOD
13	liver	liver	NN	_	14	AMOD
14	specific	specific	JJ	_	15	NMOD
15	expression	expression	NN	_	12	PMOD
16	of	of	IN	_	15	NMOD
17	the	the	DT	_	23	NMOD
18	tetracycline	tetracycline	NN	_	20	AMOD
19	-	-	HYPH	_	18	P
20	controlled	control	VBN	_	21	NMOD
21	transactivator	transactivator	NN	_	23	NMOD
22	(	(	-LRB-	_	23	P
23	tTA	tta	NN	_	28	NMOD
24	)	)	-RRB-	_	28	P
25	,	,	,	_	28	P
26	a	a	DT	_	28	NMOD
27	transcription	transcription	NN	_	28	NMOD
28	factor	factor	NN	_	16	PMOD
29	that	that	WDT	_	30	SBJ
30	stimulates	stimulate	VBZ	_	28	NMOD
31	expression	expression	NN	_	30	OBJ
32	of	of	IN	_	31	NMOD
33	promoters	promoter	NNS	_	32	PMOD
34	that	that	WDT	_	35	SBJ
35	harbor	harbor	VBP	_	33	NMOD
36	a	a	DT	_	41	NMOD
37	transactivator	transactivator	NN	_	39	NMOD
38	response	response	NN	_	39	NMOD
39	element	element	NN	_	41	NMOD
40	(	(	-LRB-	_	41	P
41	TRE	tre	NN	_	35	OBJ
42	)	)	-RRB-	_	9	P
43	.	.	.	_	9	P

1	The	the	DT	_	5	NMOD
2	TRE	tre	NN	_	4	NMOD
3	-	-	HYPH	_	2	P
4	E2	e0	NN	_	5	NMOD
5	transgene	transgene	NN	_	6	SBJ
6	was	be	VBD	_	0	ROOT
7	designed	design	VBN	_	6	VC
8	to	to	TO	_	7	PRP
9	express	express	VB	_	8	IM
10	a	a	DT	_	13	NMOD
11	human	human	JJ	_	13	NMOD
12	E2	e0	NN	_	13	NMOD
13	cDNA	cdna	NN	_	9	OBJ
14	from	from	IN	_	9	ADV
15	a	a	DT	_	16	NMOD
16	TRE	tre	NN	_	14	PMOD
17	containing	contain	VBG	_	16	NMOD
18	minimal	minimal	JJ	_	19	NMOD
19	promoter	promoter	NN	_	17	OBJ
20	upon	upon	IN	_	9	TMP
21	stimulation	stimulation	NN	_	20	PMOD
22	by	by	IN	_	21	NMOD
23	tTA	tta	NN	_	22	PMOD
24	.	.	.	_	6	P

1	Figure	figure	NN	_	0	ROOT
2	3	0	CD	_	1	NMOD

1	Transgenic	transgenic	JJ	_	3	NMOD
2	mouse	mouse	NN	_	3	NMOD
3	production	production	NN	_	0	ROOT
4	and	and	CC	_	3	COORD
5	characterization	characterization	NN	_	4	CONJ
6	.	.	.	_	3	P

1	A	a	LS	_	4	NMOD
2	,	,	,	_	4	P
3	Transgenic	transgenic	JJ	_	4	NMOD
4	strategy	strategy	NN	_	0	ROOT
5	used	use	VBN	_	4	NMOD
6	to	to	TO	_	5	PRP
7	produce	produce	VB	_	6	IM
8	mice	mouse	NNS	_	7	OBJ
9	that	that	WDT	_	10	SBJ
10	express	express	VBP	_	8	NMOD
11	human	human	JJ	_	12	NMOD
12	E2	e0	NN	_	10	OBJ
13	.	.	.	_	4	P

1	LAP	lap	NN	_	3	NMOD
2	-	-	HYPH	_	1	P
3	tTA	tta	NN	_	5	NMOD
4	transgenic	transgenic	JJ	_	5	NMOD
5	mice	mouse	NNS	_	6	SBJ
6	have	have	VBP	_	0	ROOT
7	been	be	VBN	_	6	VC
8	previously	previously	RB	_	7	TMP
9	described	describe	VBN	_	7	VC
10	[	[	-LRB-	_	11	P
11	34	0	CD	_	7	PRN
12	]	]	-RRB-	_	11	P
13	.	.	.	_	6	P

1	These	these	DT	_	2	NMOD
2	mice	mouse	NNS	_	3	SBJ
3	express	express	VBP	_	0	ROOT
4	the	the	DT	_	10	NMOD
5	tetracycline	tetracycline	NN	_	7	AMOD
6	-	-	HYPH	_	5	P
7	controlled	control	VBN	_	8	NMOD
8	transactivator	transactivator	NN	_	10	NMOD
9	(	(	-LRB-	_	10	P
10	tTA	tta	NN	_	3	OBJ
11	)	)	-RRB-	_	10	P
12	from	from	IN	_	10	NMOD
13	the	the	DT	_	17	NMOD
14	liver	liver	NN	_	15	AMOD
15	specific	specific	JJ	_	17	NMOD
16	LAP	lap	NN	_	17	NMOD
17	promoter	promoter	NN	_	12	PMOD
18	.	.	.	_	3	P

1	The	the	DT	_	5	NMOD
2	TRE	tre	NN	_	4	NMOD
3	-	-	HYPH	_	2	P
4	E2	e0	NN	_	5	NMOD
5	transgene	transgene	NN	_	6	SBJ
6	contains	contain	VBZ	_	0	ROOT
7	the	the	DT	_	12	NMOD
8	tetracycline	tetracycline	NN	_	10	NMOD
9	response	response	NN	_	10	NMOD
10	element	element	NN	_	12	NMOD
11	(	(	-LRB-	_	12	P
12	TRE	tre	NN	_	6	OBJ
13	)	)	-RRB-	_	12	P
14	as	as	IN	_	12	NMOD
15	part	part	NN	_	14	PMOD
16	of	of	IN	_	15	NMOD
17	the	the	DT	_	18	NMOD
18	promoter	promoter	NN	_	16	PMOD
19	,	,	,	_	12	P
20	a	a	DT	_	22	NMOD
21	synthetic	synthetic	JJ	_	22	NMOD
22	intron	intron	NN	_	12	CONJ
23	(	(	-LRB-	_	25	P
24	thin	thin	JJ	_	25	NMOD
25	line	line	NN	_	22	PRN
26	)	)	-RRB-	_	25	P
27	,	,	,	_	22	P
28	the	the	DT	_	31	NMOD
29	human	human	JJ	_	31	NMOD
30	E2	e0	NN	_	31	NMOD
31	cDNA	cdna	NN	_	22	CONJ
32	,	,	,	_	31	P
33	an	an	DT	_	35	NMOD
34	alanine	alanine	NN	_	35	NMOD
35	spacer	spacer	NN	_	31	CONJ
36	,	,	,	_	35	P
37	a	a	DT	_	42	NMOD
38	c	c	NN	_	40	NMOD
39	-	-	HYPH	_	38	P
40	myc	myc	NN	_	42	NMOD
41	epitope	epitope	NN	_	42	NMOD
42	tag	tag	NN	_	35	CONJ
43	,	,	,	_	42	P
44	and	and	CC	_	42	COORD
45	SV40	sv0	NN	_	46	AMOD
46	derived	derive	VBN	_	48	NMOD
47	polyadenylation	polyadenylation	NN	_	48	NMOD
48	sequence	sequence	NN	_	44	CONJ
49	.	.	.	_	6	P

1	This	this	DT	_	2	NMOD
2	construct	construct	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	used	use	VBN	_	3	VC
5	to	to	TO	_	4	PRP
6	create	create	VB	_	5	IM
7	several	several	JJ	_	8	NMOD
8	lines	line	NNS	_	6	OBJ
9	of	of	IN	_	8	NMOD
10	transgenic	transgenic	JJ	_	11	NMOD
11	mice	mouse	NNS	_	9	PMOD
12	.	.	.	_	3	P

1	B	b	LS	_	5	NMOD
2	,	,	,	_	5	P
3	Western	western	NNP	_	4	NMOD
4	blot	blot	NN	_	5	NMOD
5	analysis	analysis	NN	_	0	ROOT
6	of	of	IN	_	5	NMOD
7	E2	e0	NN	_	8	NMOD
8	protein	protein	NN	_	6	PMOD
9	in	in	IN	_	8	LOC
10	liver	liver	NN	_	9	PMOD
11	of	of	IN	_	10	NMOD
12	control	control	NN	_	16	NMOD
13	and	and	CC	_	12	COORD
14	intermediate	intermediate	JJ	_	13	CONJ
15	MSUD	msud	NN	_	16	NMOD
16	mice	mouse	NNS	_	11	PMOD
17	.	.	.	_	5	P

1	Note	note	VB	_	0	ROOT
2	that	that	IN	_	1	OBJ
3	the	the	DT	_	4	NMOD
4	amount	amount	NN	_	24	SBJ
5	of	of	IN	_	4	NMOD
6	human	human	JJ	_	8	NMOD
7	E2	e0	NN	_	8	NMOD
8	protein	protein	NN	_	5	PMOD
9	(	(	-LRB-	_	14	P
10	predicted	predict	VBN	_	11	NMOD
11	MW	mw	NN	_	14	NMOD
12	~	~	SYM	_	13	P
13	54	0	CD	_	14	NMOD
14	Kd	kd	NN	_	8	PRN
15	)	)	-RRB-	_	14	P
16	in	in	IN	_	4	LOC
17	mice	mouse	NNS	_	16	PMOD
18	from	from	IN	_	17	NMOD
19	Lines	line	NNS	_	20	NMOD
20	A	a	NN	_	18	PMOD
21	and	and	CC	_	20	COORD
22	525	0	CD	_	23	NMOD
23	A	a	NN	_	21	CONJ
24	was	be	VBD	_	2	SUB
25	variable	variable	JJ	_	24	PRD
26	but	but	CC	_	24	COORD
27	in	in	IN	_	34	LOC
28	many	many	JJ	_	27	PMOD
29	of	of	IN	_	28	NMOD
30	the	the	DT	_	31	NMOD
31	animals	animal	NNS	_	29	PMOD
32	the	the	DT	_	33	NMOD
33	amount	amount	NN	_	34	SBJ
34	was	be	VBD	_	26	CONJ
35	similar	similar	JJ	_	34	PRD
36	to	to	IN	_	35	AMOD
37	the	the	DT	_	38	NMOD
38	amount	amount	NN	_	36	PMOD
39	of	of	IN	_	38	NMOD
40	mouse	mouse	NN	_	41	NMOD
41	E2	e0	NN	_	39	PMOD
42	(	(	-LRB-	_	47	P
43	MW	mw	NN	_	47	SBJ
44	=	=	SYM	_	47	P
45	~	~	SYM	_	46	P
46	47	0	CD	_	47	NMOD
47	Kd	kd	NN	_	41	PRN
48	)	)	-RRB-	_	47	P
49	in	in	IN	_	38	LOC
50	control	control	NN	_	51	NMOD
51	animals	animal	NNS	_	49	PMOD
52	.	.	.	_	1	P

1	Re	re	NN	_	3	NMOD
2	-	-	HYPH	_	1	P
3	probing	probing	NN	_	11	SBJ
4	with	with	IN	_	3	NMOD
5	a	a	DT	_	10	NMOD
6	c	c	NN	_	8	NMOD
7	-	-	HYPH	_	6	P
8	myc	myc	NN	_	10	NMOD
9	tag	tag	NN	_	10	NMOD
10	antibody	antibody	NN	_	4	PMOD
11	confirmed	confirm	VBD	_	0	ROOT
12	the	the	DT	_	13	NMOD
13	presence	presence	NN	_	11	OBJ
14	of	of	IN	_	13	NMOD
15	the	the	DT	_	25	NMOD
16	transgene	transgene	NN	_	17	AMOD
17	derived	derive	VBN	_	25	NMOD
18	,	,	,	_	25	P
19	c	c	NN	_	21	NMOD
20	-	-	HYPH	_	19	P
21	myc	myc	NN	_	22	AMOD
22	tagged	tag	VBN	_	25	NMOD
23	,	,	,	_	25	P
24	human	human	JJ	_	25	NMOD
25	E2	e0	NN	_	14	PMOD
26	in	in	IN	_	11	LOC
27	transgenic	transgenic	JJ	_	28	NMOD
28	mice	mouse	NNS	_	26	PMOD
29	but	but	CC	_	26	COORD
30	not	not	RB	_	29	ADV
31	in	in	IN	_	29	CONJ
32	controls	control	NNS	_	31	PMOD
33	.	.	.	_	11	P

1	Western	western	NNP	_	2	NMOD
2	blot	blot	NN	_	3	NMOD
3	analysis	analysis	NN	_	20	SBJ
4	of	of	IN	_	3	NMOD
5	brain	brain	NN	_	4	PMOD
6	(	(	-LRB-	_	7	P
7	C	c	NN	_	5	PRN
8	)	)	-RRB-	_	7	P
9	,	,	,	_	5	P
10	kidney	kidney	NN	_	5	CONJ
11	(	(	-LRB-	_	12	P
12	D	d	NN	_	10	PRN
13	)	)	-RRB-	_	12	P
14	,	,	,	_	10	P
15	and	and	CC	_	10	COORD
16	muscle	muscle	NN	_	15	CONJ
17	(	(	-LRB-	_	18	P
18	E	e	NN	_	16	PRN
19	)	)	-RRB-	_	18	P
20	revealed	reveal	VBD	_	0	ROOT
21	negligible	negligible	JJ	_	22	NMOD
22	amounts	amount	NNS	_	20	OBJ
23	of	of	IN	_	22	NMOD
24	transgene	transgene	NN	_	25	AMOD
25	derived	derive	VBN	_	26	NMOD
26	E2	e0	NN	_	23	PMOD
27	in	in	IN	_	20	LOC
28	those	those	DT	_	29	NMOD
29	tissues	tissue	NNS	_	27	PMOD
30	.	.	.	_	20	P

1	All	all	DT	_	2	NMOD
2	blots	blot	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	re-probed	re-probed	VBN	_	3	VC
5	with	with	IN	_	4	MNR
6	an	an	DT	_	8	NMOD
7	actin	actin	NN	_	8	NMOD
8	antibody	antibody	NN	_	5	PMOD
9	to	to	TO	_	4	PRP
10	allow	allow	VB	_	9	IM
11	amount	amount	NN	_	18	SBJ
12	of	of	IN	_	11	NMOD
13	protein	protein	NN	_	12	PMOD
14	loaded	load	VBN	_	13	NMOD
15	in	in	IN	_	14	ADV
16	each	each	DT	_	17	NMOD
17	lane	lane	NN	_	15	PMOD
18	to	to	TO	_	10	OPRD
19	be	be	VB	_	18	IM
20	compared	compare	VBN	_	19	VC
21	.	.	.	_	3	P

1	LAP	lap	NN	_	3	NMOD
2	-	-	HYPH	_	1	P
3	tTA	tta	NN	_	4	NMOD
4	mice	mouse	NNS	_	5	SBJ
5	were	be	VBD	_	0	ROOT
6	previously	previously	RB	_	5	TMP
7	produced	produce	VBN	_	5	VC
8	and	and	CC	_	7	COORD
9	characterized	characterize	VBN	_	8	CONJ
10	by	by	IN	_	7	LGS
11	the	the	DT	_	13	NMOD
12	Bujard	bujard	NNP	_	13	NMOD
13	laboratory	laboratory	NN	_	10	PMOD
14	[	[	-LRB-	_	15	P
15	34	0	CD	_	7	PRN
16	]	]	-RRB-	_	15	P
17	.	.	.	_	5	P

1	Pronuclear	pronuclear	JJ	_	2	NMOD
2	microinjection	microinjection	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	used	use	VBN	_	3	VC
5	to	to	TO	_	4	PRP
6	produce	produce	VB	_	5	IM
7	transgenic	transgenic	JJ	_	8	NMOD
8	mice	mouse	NNS	_	6	OBJ
9	that	that	WDT	_	10	SBJ
10	harbored	harbor	VBD	_	8	NMOD
11	the	the	DT	_	15	NMOD
12	TRE	tre	NN	_	14	NMOD
13	-	-	HYPH	_	12	P
14	E2	e0	NN	_	15	NMOD
15	transgene	transgene	NN	_	10	OBJ
16	.	.	.	_	3	P

1	From	from	IN	_	13	ADV
2	injections	injection	NNS	_	1	PMOD
3	at	at	IN	_	2	NMOD
4	the	the	DT	_	5	NMOD
5	University	university	NNP	_	3	PMOD
6	of	of	IN	_	5	NMOD
7	Pittsburgh	pittsburgh	NNP	_	6	PMOD
8	,	,	,	_	13	P
9	2	0	CD	_	12	NMOD
10	transgene	transgene	NN	_	11	AMOD
11	positive	positive	JJ	_	12	NMOD
12	founders	founder	NNS	_	13	SBJ
13	were	be	VBD	_	0	ROOT
14	identified	identify	VBN	_	13	VC
15	that	that	WDT	_	16	SBJ
16	led	lead	VBD	_	12	NMOD
17	to	to	IN	_	16	ADV
18	the	the	DT	_	19	NMOD
19	generation	generation	NN	_	17	PMOD
20	of	of	IN	_	19	NMOD
21	3	0	CD	_	24	NMOD
22	different	different	JJ	_	24	NMOD
23	transgenic	transgenic	JJ	_	24	NMOD
24	lines	line	NNS	_	20	PMOD
25	(	(	-LRB-	_	27	P
26	Lines	line	NNS	_	27	NMOD
27	A	a	NN	_	24	PRN
28	,	,	,	_	27	P
29	B	b	NN	_	27	CONJ
30	,	,	,	_	29	P
31	&	and	CC	_	29	COORD
32	D	d	NN	_	31	CONJ
33	)	)	-RRB-	_	27	P
34	.	.	.	_	13	P

1	From	from	IN	_	11	ADV
2	the	the	DT	_	3	NMOD
3	injections	injection	NNS	_	1	PMOD
4	at	at	IN	_	3	NMOD
5	the	the	DT	_	6	NMOD
6	University	university	NNP	_	4	PMOD
7	of	of	IN	_	6	NMOD
8	Cincinnati	cincinnati	NNP	_	7	PMOD
9	,	,	,	_	11	P
10	we	we	PRP	_	11	SBJ
11	obtained	obtain	VBD	_	0	ROOT
12	8	0	CD	_	15	NMOD
13	transgene	transgene	NN	_	14	AMOD
14	positive	positive	JJ	_	15	NMOD
15	founders	founder	NNS	_	11	OBJ
16	.	.	.	_	11	P

1	Subsequent	subsequent	JJ	_	2	NMOD
2	breeding	breeding	NN	_	6	SBJ
3	of	of	IN	_	2	NMOD
4	these	these	DT	_	5	NMOD
5	founders	founder	NNS	_	3	PMOD
6	revealed	reveal	VBD	_	0	ROOT
7	that	that	IN	_	6	OBJ
8	many	many	JJ	_	12	SBJ
9	of	of	IN	_	8	NMOD
10	the	the	DT	_	11	NMOD
11	animals	animal	NNS	_	9	PMOD
12	had	have	VBD	_	7	SUB
13	multiple	multiple	JJ	_	16	NMOD
14	transgene	transgene	NN	_	16	NMOD
15	insertion	insertion	NN	_	16	NMOD
16	sites	site	NNS	_	12	OBJ
17	that	that	WDT	_	18	SBJ
18	segregated	segregate	VBD	_	16	NMOD
19	.	.	.	_	6	P

1	We	we	PRP	_	2	SBJ
2	established	establish	VBD	_	0	ROOT
3	a	a	DT	_	4	NMOD
4	total	total	NN	_	2	OBJ
5	of	of	IN	_	4	NMOD
6	15	0	CD	_	9	NMOD
7	different	different	JJ	_	9	NMOD
8	transgenic	transgenic	JJ	_	9	NMOD
9	lines	line	NNS	_	5	PMOD
10	from	from	IN	_	2	ADV
11	these	these	DT	_	12	NMOD
12	founders	founder	NNS	_	10	PMOD
13	.	.	.	_	2	P

1	Limited	limit	VBN	_	2	NMOD
2	resources	resource	NNS	_	3	SBJ
3	allowed	allow	VBD	_	0	ROOT
4	us	us	PRP	_	5	SBJ
5	to	to	TO	_	3	OPRD
6	only	only	RB	_	5	ADV
7	focus	focus	VB	_	5	IM
8	on	on	IN	_	7	ADV
9	a	a	DT	_	10	NMOD
10	total	total	NN	_	8	PMOD
11	of	of	IN	_	10	NMOD
12	9	0	CD	_	11	PMOD
13	of	of	IN	_	12	NMOD
14	these	these	DT	_	15	NMOD
15	lines	line	NNS	_	13	PMOD
16	.	.	.	_	3	P

1	These	these	DT	_	2	NMOD
2	lines	line	NNS	_	3	SBJ
3	differed	differ	VBD	_	0	ROOT
4	substantially	substantially	RB	_	3	ADV
5	in	in	IN	_	3	MNR
6	transgene	transgene	NN	_	8	NMOD
7	copy	copy	NN	_	8	NMOD
8	number	number	NN	_	5	PMOD
9	as	as	IN	_	3	ADV
10	compared	compare	VBN	_	9	SUB
11	by	by	IN	_	10	MNR
12	Southern	southern	NNP	_	13	NMOD
13	blot	blot	NN	_	14	NMOD
14	analysis	analysis	NN	_	11	PMOD
15	of	of	IN	_	14	NMOD
16	tail	tail	NN	_	17	NMOD
17	DNA	dna	NN	_	15	PMOD
18	(	(	-LRB-	_	21	P
19	data	datum	NNS	_	21	SBJ
20	not	not	RB	_	21	ADV
21	shown	show	VBN	_	3	PRN
22	)	)	-RRB-	_	21	P
23	.	.	.	_	3	P

1	Transgenic	transgenic	JJ	_	5	NMOD
2	TRE	tre	NN	_	4	NMOD
3	-	-	HYPH	_	2	P
4	E2	e0	NN	_	5	NMOD
5	mice	mouse	NNS	_	16	SBJ
6	from	from	IN	_	5	NMOD
7	each	each	DT	_	8	NMOD
8	line	line	NN	_	6	PMOD
9	(	(	-LRB-	_	14	P
10	either	either	CC	_	14	COORD
11	founders	founder	NNS	_	14	NMOD
12	or	or	CC	_	11	COORD
13	F1	f0	NN	_	12	CONJ
14	offspring	offspring	NN	_	8	PRN
15	)	)	-RRB-	_	14	P
16	were	be	VBD	_	0	ROOT
17	crossed	cross	VBN	_	16	VC
18	to	to	IN	_	17	ADV
19	mice	mouse	NNS	_	18	PMOD
20	that	that	WDT	_	21	SBJ
21	were	be	VBD	_	19	NMOD
22	positive	positive	JJ	_	21	PRD
23	for	for	IN	_	22	AMOD
24	the	the	DT	_	28	NMOD
25	LAP	lap	NN	_	27	NMOD
26	-	-	HYPH	_	25	P
27	tTA	tta	NN	_	28	NMOD
28	transgene	transgene	NN	_	23	PMOD
29	and	and	CC	_	21	COORD
30	were	be	VBD	_	29	CONJ
31	heterozygous	heterozygous	JJ	_	30	PRD
32	for	for	IN	_	31	AMOD
33	the	the	DT	_	35	NMOD
34	E2	e0	NN	_	35	NMOD
35	knockout	knockout	NN	_	32	PMOD
36	.	.	.	_	16	P

1	Ultimately	ultimately	RB	_	5	ADV
2	,	,	,	_	5	P
3	breeding	breed	VBG	_	4	NMOD
4	pairs	pair	NNS	_	5	SBJ
5	were	be	VBD	_	0	ROOT
6	used	use	VBN	_	5	VC
7	in	in	IN	_	11	ADV
8	which	which	WDT	_	7	PMOD
9	the	the	DT	_	10	NMOD
10	mice	mouse	NNS	_	11	SBJ
11	were	be	VBD	_	4	NMOD
12	heterozygous	heterozygous	JJ	_	11	PRD
13	for	for	IN	_	12	AMOD
14	the	the	DT	_	18	NMOD
15	LAP	lap	NN	_	17	NMOD
16	-	-	HYPH	_	15	P
17	tTA	tta	NN	_	18	NMOD
18	transgene	transgene	NN	_	13	PMOD
19	,	,	,	_	18	P
20	the	the	DT	_	24	NMOD
21	TRE	tre	NN	_	23	NMOD
22	-	-	HYPH	_	21	P
23	E2	e0	NN	_	24	NMOD
24	transgene	transgene	NN	_	18	CONJ
25	,	,	,	_	24	P
26	and	and	CC	_	24	COORD
27	the	the	DT	_	29	NMOD
28	E2	e0	NN	_	29	NMOD
29	knockout	knockout	NN	_	26	CONJ
30	.	.	.	_	5	P

1	To	to	TO	_	19	PRP
2	efficiently	efficiently	RB	_	1	ADV
3	screen	screen	VB	_	1	IM
4	for	for	IN	_	3	ADV
5	the	the	DT	_	6	NMOD
6	ability	ability	NN	_	4	PMOD
7	of	of	IN	_	6	NMOD
8	the	the	DT	_	9	NMOD
9	transgenes	transgene	NNS	_	7	PMOD
10	to	to	TO	_	6	NMOD
11	rescue	rescue	VB	_	10	IM
12	the	the	DT	_	13	NMOD
13	knockout	knockout	NN	_	11	OBJ
14	from	from	IN	_	11	ADV
15	neonatal	neonatal	JJ	_	16	NMOD
16	lethality	lethality	NN	_	14	PMOD
17	,	,	,	_	19	P
18	we	we	PRP	_	19	SBJ
19	genotyped	genotyped	VBD	_	0	ROOT
20	litters	litter	NNS	_	19	OBJ
21	at	at	IN	_	19	TMP
22	weaning	weaning	NN	_	21	PMOD
23	.	.	.	_	19	P

1	This	this	DT	_	3	NMOD
2	breeding	breed	VBG	_	3	NMOD
3	strategy	strategy	NN	_	4	SBJ
4	is	be	VBZ	_	0	ROOT
5	expected	expect	VBN	_	4	VC
6	to	to	TO	_	5	OPRD
7	result	result	VB	_	6	IM
8	in	in	IN	_	7	ADV
9	a	a	DT	_	11	NMOD
10	theoretical	theoretical	JJ	_	11	NMOD
11	maximum	maximum	NN	_	8	PMOD
12	of	of	IN	_	11	NMOD
13	animals	animal	NNS	_	12	PMOD
14	with	with	IN	_	13	NMOD
15	the	the	DT	_	17	NMOD
16	rescue	rescue	NN	_	17	NMOD
17	genotype	genotype	NN	_	14	PMOD
18	(	(	-LRB-	_	19	P
19	i.e.	i.e.	FW	_	17	PRN
20	,	,	,	_	19	P
21	homozygous	homozygous	JJ	_	23	NMOD
22	E2	e0	NN	_	23	NMOD
23	knockout	knockout	NN	_	19	CONJ
24	and	and	CC	_	23	COORD
25	positive	positive	JJ	_	24	CONJ
26	for	for	IN	_	25	AMOD
27	both	both	DT	_	28	NMOD
28	transgenes	transgene	NNS	_	26	PMOD
29	)	)	-RRB-	_	19	P
30	of	of	IN	_	11	NMOD
31	14	0	CD	_	32	NMOD
32	%	%	NN	_	30	PMOD
33	.	.	.	_	4	P

1	Fig.	fig.	NN	_	2	NMOD
2	4A	0a	NN	_	3	SBJ
3	shows	show	VBZ	_	0	ROOT
4	the	the	DT	_	5	NMOD
5	percentage	percentage	NN	_	3	OBJ
6	of	of	IN	_	5	NMOD
7	mice	mouse	NNS	_	6	PMOD
8	alive	alive	JJ	_	7	NMOD
9	at	at	IN	_	8	TMP
10	weaning	weaning	NN	_	9	PMOD
11	with	with	IN	_	5	NMOD
12	the	the	DT	_	14	NMOD
13	rescue	rescue	NN	_	14	NMOD
14	genotype	genotype	NN	_	11	PMOD
15	from	from	IN	_	14	NMOD
16	each	each	DT	_	18	NMOD
17	transgenic	transgenic	JJ	_	18	NMOD
18	line	line	NN	_	15	PMOD
19	tested	test	VBN	_	18	NMOD
20	.	.	.	_	3	P

1	Considerable	considerable	JJ	_	2	NMOD
2	variability	variability	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	observed	observe	VBN	_	3	VC
5	between	between	IN	_	4	ADV
6	lines	line	NNS	_	5	PMOD
7	.	.	.	_	3	P

1	The	the	DT	_	2	NMOD
2	line	line	NN	_	12	SBJ
3	with	with	IN	_	2	NMOD
4	the	the	DT	_	6	NMOD
5	highest	high	JJS	_	6	NMOD
6	percentage	percentage	NN	_	3	PMOD
7	of	of	IN	_	6	NMOD
8	rescue	rescue	NN	_	9	NMOD
9	mice	mouse	NNS	_	7	PMOD
10	at	at	IN	_	6	TMP
11	weaning	weaning	NN	_	10	PMOD
12	was	be	VBD	_	0	ROOT
13	line	line	NN	_	15	NMOD
14	525	0	CD	_	15	NMOD
15	A	a	NN	_	12	PRD
16	.	.	.	_	12	P

1	Approximately	approximately	RB	_	2	QMOD
2	10	0	CD	_	3	NMOD
3	%	%	NN	_	12	SBJ
4	of	of	IN	_	3	NMOD
5	weaned	wean	VBN	_	8	NMOD
6	,	,	,	_	8	P
7	surviving	survive	VBG	_	8	NMOD
8	pups	pup	NNS	_	4	PMOD
9	from	from	IN	_	3	NMOD
10	this	this	DT	_	11	NMOD
11	line	line	NN	_	9	PMOD
12	had	have	VBD	_	0	ROOT
13	the	the	DT	_	15	NMOD
14	rescue	rescue	NN	_	15	NMOD
15	genotype	genotype	NN	_	12	OBJ
16	.	.	.	_	12	P

1	Thus	thus	RB	_	6	ADV
2	,	,	,	_	6	P
3	the	the	DT	_	5	NMOD
4	525A	0a	NN	_	5	NMOD
5	transgene	transgene	NN	_	6	SBJ
6	appears	appear	VBZ	_	0	ROOT
7	to	to	TO	_	6	OPRD
8	be	be	VB	_	7	IM
9	highly	highly	RB	_	10	AMOD
10	effective	effective	JJ	_	8	PRD
11	at	at	IN	_	10	AMOD
12	rescuing	rescue	VBG	_	11	PMOD
13	the	the	DT	_	16	NMOD
14	neonatal	neonatal	JJ	_	16	NMOD
15	lethal	lethal	JJ	_	16	NMOD
16	phenotype	phenotype	NN	_	12	OBJ
17	of	of	IN	_	16	NMOD
18	the	the	DT	_	20	NMOD
19	E2	e0	NN	_	20	NMOD
20	knockout	knockout	NN	_	17	PMOD
21	.	.	.	_	6	P

1	In	in	IN	_	7	ADV
2	contrast	contrast	NN	_	1	PMOD
3	,	,	,	_	7	P
4	line	line	NN	_	5	NMOD
5	520B	0b	NN	_	7	SBJ
6	completely	completely	RB	_	7	ADV
7	failed	fail	VBD	_	0	ROOT
8	to	to	TO	_	7	OPRD
9	rescue	rescue	VB	_	8	IM
10	the	the	DT	_	13	NMOD
11	neonatal	neonatal	JJ	_	13	NMOD
12	lethal	lethal	JJ	_	13	NMOD
13	phenotype	phenotype	NN	_	9	OBJ
14	.	.	.	_	7	P

1	All	all	DT	_	3	NMOD
2	other	other	JJ	_	3	NMOD
3	lines	line	NNS	_	5	SBJ
4	tested	test	VBN	_	3	NMOD
5	produced	produce	VBD	_	0	ROOT
6	surviving	survive	VBG	_	8	NMOD
7	rescue	rescue	NN	_	8	NMOD
8	animals	animal	NNS	_	5	OBJ
9	at	at	IN	_	5	TMP
10	a	a	DT	_	11	NMOD
11	frequency	frequency	NN	_	9	PMOD
12	between	between	IN	_	11	NMOD
13	1	0	CD	_	16	NMOD
14	and	and	CC	_	13	COORD
15	5	0	CD	_	14	CONJ
16	%	%	NN	_	12	PMOD
17	of	of	IN	_	16	NMOD
18	weaned	wean	VBN	_	19	NMOD
19	pups	pup	NNS	_	17	PMOD
20	.	.	.	_	5	P

1	Figure	figure	NN	_	0	ROOT
2	4	0	CD	_	1	NMOD

1	Characterization	characterization	NN	_	0	ROOT
2	of	of	IN	_	1	NMOD
3	the	the	DT	_	7	NMOD
4	intermediate	intermediate	JJ	_	7	NMOD
5	MSUD	msud	NN	_	7	NMOD
6	murine	murine	JJ	_	7	NMOD
7	model	model	NN	_	2	PMOD
8	.	.	.	_	1	P

1	A	a	LS	_	4	NMOD
2	,	,	,	_	4	P
3	Survival	survival	NN	_	4	NMOD
4	analysis	analysis	NN	_	0	ROOT
5	of	of	IN	_	4	NMOD
6	transgenic	transgenic	JJ	_	8	NMOD
7	rescue	rescue	NN	_	8	NMOD
8	lines	line	NNS	_	5	PMOD
9	.	.	.	_	4	P

1	Presented	present	VBN	_	2	DEP
2	are	be	VBP	_	0	ROOT
3	percentages	percentage	NNS	_	2	SBJ
4	of	of	IN	_	3	NMOD
5	mice	mouse	NNS	_	4	PMOD
6	alive	alive	JJ	_	5	NMOD
7	at	at	IN	_	6	TMP
8	weaning	wean	VBG	_	7	PMOD
9	from	from	IN	_	5	NMOD
10	each	each	DT	_	12	NMOD
11	transgenic	transgenic	JJ	_	12	NMOD
12	line	line	NN	_	9	PMOD
13	tested	test	VBN	_	12	NMOD
14	that	that	WDT	_	15	SBJ
15	had	have	VBD	_	12	NMOD
16	the	the	DT	_	18	NMOD
17	rescue	rescue	NN	_	18	NMOD
18	genotype	genotype	NN	_	15	OBJ
19	(	(	-LRB-	_	22	P
20	i.e.	i.e.	FW	_	22	AMOD
21	,	,	,	_	22	P
22	homozygous	homozygous	JJ	_	15	PRN
23	for	for	IN	_	22	AMOD
24	knockout	knockout	NN	_	23	PMOD
25	of	of	IN	_	24	NMOD
26	endogenous	endogenous	JJ	_	27	NMOD
27	E2	e0	NN	_	25	PMOD
28	and	and	CC	_	22	COORD
29	positive	positive	JJ	_	28	CONJ
30	for	for	IN	_	29	AMOD
31	both	both	CC	_	40	COORD
32	the	the	DT	_	40	NMOD
33	LAP	lap	NN	_	35	NMOD
34	-	-	HYPH	_	33	P
35	tTA	tta	NN	_	40	NMOD
36	and	and	CC	_	35	COORD
37	TRE	tre	NN	_	39	NMOD
38	-	-	HYPH	_	37	P
39	E2	e0	NN	_	36	CONJ
40	transgenes	transgene	NNS	_	30	PMOD
41	)	)	-RRB-	_	22	P
42	.	.	.	_	2	P

1	Also	also	RB	_	3	ADV
2	plotted	plot	VBN	_	3	DEP
3	is	be	VBZ	_	0	ROOT
4	the	the	DT	_	7	NMOD
5	theoretical	theoretical	JJ	_	7	NMOD
6	maximum	maximum	JJ	_	7	NMOD
7	frequency	frequency	NN	_	2	OBJ
8	at	at	IN	_	13	TMP
9	which	which	WDT	_	8	PMOD
10	this	this	DT	_	11	NMOD
11	genotype	genotype	NN	_	12	SBJ
12	is	be	VBZ	_	7	NMOD
13	expected	expect	VBN	_	12	VC
14	in	in	IN	_	13	ADV
15	this	this	DT	_	16	NMOD
16	population	population	NN	_	14	PMOD
17	of	of	IN	_	16	NMOD
18	animals	animal	NNS	_	17	PMOD
19	.	.	.	_	3	P

1	The	the	DT	_	2	NMOD
2	numbers	number	NNS	_	6	SBJ
3	on	on	IN	_	2	NMOD
4	the	the	DT	_	5	NMOD
5	bars	bar	NNS	_	3	PMOD
6	indicates	indicate	VBZ	_	0	ROOT
7	the	the	DT	_	8	NMOD
8	numbers	number	NNS	_	6	OBJ
9	of	of	IN	_	8	NMOD
10	observations	observation	NNS	_	9	PMOD
11	for	for	IN	_	8	NMOD
12	each	each	DT	_	13	NMOD
13	line	line	NN	_	11	PMOD
14	.	.	.	_	6	P

1	B	b	LS	_	3	NMOD
2	,	,	,	_	3	P
3	Ratio	ratio	NN	_	0	ROOT
4	of	of	IN	_	3	NMOD
5	total	total	JJ	_	6	NMOD
6	BCAA	bcaa	NN	_	4	PMOD
7	to	to	IN	_	3	NMOD
8	alanine	alanine	NN	_	7	PMOD
9	in	in	IN	_	3	LOC
10	blood	blood	NN	_	9	PMOD
11	of	of	IN	_	10	NMOD
12	mice	mouse	NNS	_	11	PMOD
13	from	from	IN	_	3	NMOD
14	controls	control	NNS	_	13	PMOD
15	and	and	CC	_	14	COORD
16	Lines	line	NNS	_	17	NMOD
17	A	a	NN	_	15	CONJ
18	and	and	CC	_	17	COORD
19	525A	0a	NN	_	18	CONJ
20	.	.	.	_	3	P

1	Total	total	JJ	_	2	NMOD
2	BCAA	bcaa	NN	_	3	SBJ
3	represent	represent	VBP	_	0	ROOT
4	the	the	DT	_	5	NMOD
5	sum	sum	NN	_	3	OBJ
6	of	of	IN	_	5	NMOD
7	leucine	leucine	NN	_	6	PMOD
8	,	,	,	_	7	P
9	isoleucine	isoleucine	NN	_	7	CONJ
10	,	,	,	_	9	P
11	and	and	CC	_	9	COORD
12	valine	valine	NN	_	11	CONJ
13	.	.	.	_	3	P

1	BCAA	bcaa	NN	_	3	NMOD
2	/	/	HYPH	_	1	P
3	alanine	alanine	NN	_	4	NMOD
4	values	value	NNS	_	5	SBJ
5	were	be	VBD	_	0	ROOT
6	significantly	significantly	RB	_	7	AMOD
7	greater	great	JJR	_	5	PRD
8	for	for	IN	_	7	AMOD
9	Lines	line	NNS	_	10	NMOD
10	A	a	NN	_	8	PMOD
11	and	and	CC	_	10	COORD
12	525A	0a	NN	_	11	CONJ
13	compared	compare	VBN	_	7	AMOD
14	to	to	IN	_	13	PMOD
15	controls	control	NNS	_	14	PMOD
16	at	at	IN	_	5	TMP
17	all	all	DT	_	18	NMOD
18	ages	age	NNS	_	16	PMOD
19	tested	test	VBN	_	18	NMOD
20	.	.	.	_	5	P

1	The	the	DT	_	2	NMOD
2	numbers	number	NNS	_	6	SBJ
3	on	on	IN	_	2	NMOD
4	the	the	DT	_	5	NMOD
5	bars	bar	NNS	_	3	PMOD
6	indicates	indicate	VBZ	_	0	ROOT
7	the	the	DT	_	8	NMOD
8	numbers	number	NNS	_	6	OBJ
9	of	of	IN	_	8	NMOD
10	samples	sample	NNS	_	9	PMOD
11	analyzed	analyze	VBN	_	10	NMOD
12	.	.	.	_	6	P

1	*	*	SYM	_	5	P
2	,	,	,	_	5	P
3	P	p	NN	_	5	SBJ
4	≤	≤	SYM	_	5	P
5	0.01	0	CD	_	11	DEP
6	;	;	:	_	11	P
7	**	**	SYM	_	11	P
8	,	,	,	_	11	P
9	P	p	NN	_	11	SBJ
10	<	<	SYM	_	11	P
11	0.005	0	CD	_	0	ROOT
12	.	.	.	_	11	P

1	C	c	LS	_	5	NMOD
2	,	,	,	_	5	P
3	BCKDH	bckdh	NN	_	5	NMOD
4	enzyme	enzyme	NN	_	5	NMOD
5	activity	activity	NN	_	0	ROOT
6	in	in	IN	_	5	LOC
7	liver	liver	NN	_	6	PMOD
8	of	of	IN	_	7	NMOD
9	control	control	NN	_	15	NMOD
10	and	and	CC	_	9	COORD
11	Lines	line	NNS	_	12	NMOD
12	A	a	NN	_	10	CONJ
13	and	and	CC	_	12	COORD
14	525A	0a	NN	_	13	CONJ
15	mice	mouse	NNS	_	8	PMOD
16	.	.	.	_	5	P

1	*	*	SYM	_	5	P
2	,	,	,	_	5	P
3	P	p	NN	_	5	SBJ
4	≤	≤	SYM	_	5	P
5	0.001	0	CD	_	11	DEP
6	;	;	:	_	11	P
7	**	**	SYM	_	11	P
8	,	,	,	_	11	P
9	P	p	NN	_	11	SBJ
10	≤	≤	SYM	_	11	P
11	0.0001	0	CD	_	0	ROOT
12	.	.	.	_	11	P

1	D	d	LS	_	4	NMOD
2	,	,	,	_	4	P
3	Survival	survival	NN	_	4	NMOD
4	curves	curve	NNS	_	0	ROOT
5	for	for	IN	_	4	NMOD
6	mice	mouse	NNS	_	5	PMOD
7	from	from	IN	_	6	NMOD
8	Lines	line	NNS	_	9	NMOD
9	A	a	NN	_	7	PMOD
10	and	and	CC	_	9	COORD
11	525A	0a	NN	_	10	CONJ
12	.	.	.	_	4	P

1	Rescue	rescue	NN	_	2	NMOD
2	mice	mouse	NNS	_	6	SBJ
3	alive	alive	JJ	_	2	NMOD
4	at	at	IN	_	3	TMP
5	weaning	weaning	NN	_	4	PMOD
6	were	be	VBD	_	0	ROOT
7	monitored	monitor	VBN	_	6	VC
8	until	until	IN	_	7	TMP
9	they	they	PRP	_	10	SBJ
10	were	be	VBD	_	8	SUB
11	moribund	moribund	JJ	_	10	PRD
12	and	and	CC	_	11	COORD
13	subsequently	subsequently	RB	_	14	ADV
14	sacrificed	sacrifice	VBN	_	12	CONJ
15	or	or	CC	_	10	COORD
16	were	be	VBD	_	15	CONJ
17	found	find	VBN	_	16	VC
18	dead	dead	JJ	_	17	ADV
19	in	in	IN	_	17	LOC
20	their	their	PRP$	_	21	NMOD
21	cages	cage	NNS	_	19	PMOD
22	.	.	.	_	6	P

1	Lines	line	NNS	_	2	NMOD
2	A	a	NN	_	5	SBJ
3	and	and	CC	_	2	COORD
4	525A	0a	NN	_	3	CONJ
5	were	be	VBD	_	0	ROOT
6	selected	select	VBN	_	5	VC
7	for	for	IN	_	6	ADV
8	detailed	detail	VBN	_	9	NMOD
9	characterization	characterization	NN	_	7	PMOD
10	.	.	.	_	5	P

1	Fig.	fig.	NN	_	2	NMOD
2	4B	0b	NN	_	3	SBJ
3	shows	show	VBZ	_	0	ROOT
4	the	the	DT	_	5	NMOD
5	results	result	NNS	_	3	OBJ
6	of	of	IN	_	5	NMOD
7	blood	blood	NN	_	10	NMOD
8	amino	amino	NN	_	9	NMOD
9	acid	acid	NN	_	10	NMOD
10	analysis	analysis	NN	_	6	PMOD
11	presented	present	VBN	_	5	NMOD
12	as	as	IN	_	11	MNR
13	a	a	DT	_	14	NMOD
14	ratio	ratio	NN	_	12	PMOD
15	of	of	IN	_	14	NMOD
16	total	total	JJ	_	17	NMOD
17	BCAA	bcaa	NN	_	15	PMOD
18	to	to	IN	_	14	NMOD
19	alanine	alanine	NN	_	18	PMOD
20	.	.	.	_	3	P

1	The	the	DT	_	5	NMOD
2	BCAA	bcaa	NN	_	4	NMOD
3	/	/	HYPH	_	2	P
4	alanine	alanine	NN	_	5	NMOD
5	values	value	NNS	_	11	SBJ
6	for	for	IN	_	5	NMOD
7	mice	mouse	NNS	_	6	PMOD
8	from	from	IN	_	7	NMOD
9	both	both	DT	_	10	NMOD
10	lines	line	NNS	_	8	PMOD
11	were	be	VBD	_	0	ROOT
12	significantly	significantly	RB	_	13	AMOD
13	elevated	elevated	JJ	_	11	PRD
14	compared	compare	VBN	_	11	ADV
15	to	to	IN	_	14	PMOD
16	controls	control	NNS	_	15	PMOD
17	for	for	IN	_	16	NMOD
18	all	all	DT	_	17	PMOD
19	of	of	IN	_	18	NMOD
20	the	the	DT	_	22	NMOD
21	time	time	NN	_	22	NMOD
22	points	point	NNS	_	19	PMOD
23	analyzed	analyze	VBN	_	22	NMOD
24	.	.	.	_	11	P

1	Note	note	VB	_	0	ROOT
2	that	that	IN	_	1	OBJ
3	the	the	DT	_	7	NMOD
4	BCAA	bcaa	NN	_	6	NMOD
5	/	/	HYPH	_	4	P
6	alanine	alanine	NN	_	7	NMOD
7	values	value	NNS	_	12	SBJ
8	for	for	IN	_	7	NMOD
9	the	the	DT	_	11	NMOD
10	transgenic	transgenic	JJ	_	11	NMOD
11	mice	mouse	NNS	_	8	PMOD
12	are	be	VBP	_	2	SUB
13	intermediate	intermediate	JJ	_	12	PRD
14	between	between	IN	_	12	ADV
15	controls	control	NNS	_	14	PMOD
16	and	and	CC	_	15	COORD
17	knockouts	knockout	NNS	_	16	CONJ
18	(	(	-LRB-	_	19	P
19	see	see	VB	_	12	PRN
20	Figure	figure	NN	_	21	NMOD
21	2C	0c	NN	_	19	OBJ
22	)	)	-RRB-	_	19	P
23	.	.	.	_	1	P

1	Blood	blood	NN	_	2	NMOD
2	levels	level	NNS	_	10	SBJ
3	of	of	IN	_	2	NMOD
4	alanine	alanine	NN	_	3	PMOD
5	,	,	,	_	4	P
6	glutamate	glutamate	NN	_	4	CONJ
7	,	,	,	_	6	P
8	and	and	CC	_	6	COORD
9	glutamine	glutamine	NN	_	8	CONJ
10	were	be	VBD	_	0	ROOT
11	reduced	reduce	VBN	_	10	VC
12	in	in	IN	_	11	LOC
13	Line	line	NN	_	14	NMOD
14	A	a	NN	_	15	NMOD
15	mice	mouse	NNS	_	12	PMOD
16	,	,	,	_	11	P
17	as	as	IN	_	11	ADV
18	was	be	VBD	_	17	SUB
19	glutamate	glutamate	NN	_	18	SBJ
20	in	in	IN	_	19	LOC
21	Line	line	NN	_	22	NMOD
22	525A	0a	NN	_	23	NMOD
23	mice	mouse	NNS	_	20	PMOD
24	,	,	,	_	19	P
25	compared	compare	VBN	_	19	NMOD
26	to	to	IN	_	25	PMOD
27	controls	control	NNS	_	26	PMOD
28	(	(	-LRB-	_	29	P
29	Table	table	NN	_	18	PRN
30	2	0	CD	_	29	NMOD
31	)	)	-RRB-	_	29	P
32	.	.	.	_	10	P

1	Table	table	NN	_	0	ROOT
2	2	0	CD	_	1	NMOD

1	Summary	summary	NN	_	0	ROOT
2	of	of	IN	_	1	NMOD
3	additional	additional	JJ	_	7	NMOD
4	blood	blood	NN	_	7	NMOD
5	amino	amino	NN	_	6	NMOD
6	acid	acid	NN	_	7	NMOD
7	levels	level	NNS	_	2	PMOD
8	in	in	IN	_	7	LOC
9	the	the	DT	_	12	NMOD
10	intermediate	intermediate	JJ	_	12	NMOD
11	MSUD	msud	NN	_	12	NMOD
12	model	model	NN	_	8	PMOD
13	and	and	CC	_	12	COORD
14	littermate	littermate	NN	_	15	NMOD
15	controls	control	NNS	_	13	CONJ
16	as	as	IN	_	7	NMOD
17	determined	determine	VBN	_	16	SUB
18	by	by	IN	_	17	MNR
19	tandem	tandem	JJ	_	21	NMOD
20	mass	mass	NN	_	21	NMOD
21	spectrometry	spectrometry	NN	_	18	PMOD
22	.	.	.	_	1	P

1	Samples	sample	NNS	_	2	SBJ
2	were	be	VBD	_	0	ROOT
3	collected	collect	VBN	_	2	VC
4	from	from	IN	_	3	ADV
5	mice	mouse	NNS	_	4	PMOD
6	that	that	WDT	_	7	SBJ
7	were	be	VBD	_	5	NMOD
8	4	0	CD	_	11	NMOD
9	–	–	SYM	_	8	P
10	6	0	CD	_	8	QMOD
11	weeks	week	NNS	_	7	PRD
12	of	of	IN	_	11	NMOD
13	age	age	NN	_	12	PMOD
14	.	.	.	_	2	P

1	All	all	DT	_	2	NMOD
2	values	value	NNS	_	3	SBJ
3	are	be	VBP	_	0	ROOT
4	mean	mean	NN	_	3	PRD
5	+	+	SYM	_	4	COORD
6	/	/	HYPH	_	5	P
7	-	-	SYM	_	5	P
8	SEM	sem	NN	_	5	CONJ
9	.	.	.	_	3	P

1	*	*	SYM	_	0	ROOT
2	:	:	:	_	1	P
3	Significantly	significantly	RB	_	4	AMOD
4	different	different	JJ	_	1	DEP
5	from	from	IN	_	4	AMOD
6	control	control	NN	_	5	PMOD
7	(	(	-LRB-	_	10	P
8	P	p	NN	_	10	SBJ
9	<	<	SYM	_	10	P
10	0.05	0	CD	_	4	PRN
11	)	)	-RRB-	_	10	P
12	.	.	.	_	1	P

1	**	**	SYM	_	0	ROOT
2	:	:	:	_	1	P
3	Significantly	significantly	RB	_	4	AMOD
4	different	different	JJ	_	1	DEP
5	from	from	IN	_	4	AMOD
6	control	control	NN	_	5	PMOD
7	(	(	-LRB-	_	10	P
8	P	p	NN	_	10	SBJ
9	<	<	SYM	_	10	P
10	0.01	0	CD	_	4	PRN
11	)	)	-RRB-	_	10	P
12	.	.	.	_	1	P

1	***	***	SYM	_	0	ROOT
2	:	:	:	_	1	P
3	Significantly	significantly	RB	_	4	AMOD
4	different	different	JJ	_	1	DEP
5	from	from	IN	_	4	AMOD
6	Line	line	NN	_	7	NMOD
7	525A	0a	NN	_	5	PMOD
8	(	(	-LRB-	_	11	P
9	P	p	NN	_	11	SBJ
10	<	<	SYM	_	11	P
11	0.05	0	CD	_	4	PRN
12	)	)	-RRB-	_	11	P
13	.	.	.	_	1	P

1	Because	because	IN	_	45	PRP
2	the	the	DT	_	6	NMOD
3	LAP	lap	NN	_	5	NMOD
4	-	-	HYPH	_	3	P
5	tTA	tta	NN	_	6	NMOD
6	mice	mouse	NNS	_	17	SBJ
7	that	that	WDT	_	8	SBJ
8	were	be	VBD	_	6	NMOD
9	used	use	VBN	_	8	VC
10	to	to	TO	_	9	PRP
11	drive	drive	VB	_	10	IM
12	expression	expression	NN	_	11	OBJ
13	of	of	IN	_	12	NMOD
14	transgenic	transgenic	JJ	_	16	NMOD
15	human	human	JJ	_	16	NMOD
16	E2	e0	NN	_	13	PMOD
17	have	have	VBP	_	1	SUB
18	been	be	VBN	_	17	VC
19	demonstrated	demonstrate	VBN	_	18	VC
20	to	to	TO	_	19	OPRD
21	produce	produce	VB	_	20	IM
22	liver	liver	NN	_	23	AMOD
23	specific	specific	JJ	_	24	NMOD
24	expression	expression	NN	_	21	OBJ
25	[	[	-LRB-	_	26	P
26	34	0	CD	_	19	PRN
27	]	]	-RRB-	_	26	P
28	,	,	,	_	45	P
29	BCKDH	bckdh	NN	_	31	NMOD
30	enzyme	enzyme	NN	_	31	NMOD
31	activity	activity	NN	_	45	SBJ
32	and	and	CC	_	31	COORD
33	production	production	NN	_	32	CONJ
34	of	of	IN	_	33	NMOD
35	human	human	JJ	_	37	NMOD
36	E2	e0	NN	_	37	NMOD
37	protein	protein	NN	_	34	PMOD
38	in	in	IN	_	31	LOC
39	liver	liver	NN	_	38	PMOD
40	of	of	IN	_	39	NMOD
41	Lines	line	NNS	_	42	NMOD
42	A	a	NN	_	40	PMOD
43	and	and	CC	_	42	COORD
44	525A	0a	NN	_	43	CONJ
45	was	be	VBD	_	0	ROOT
46	examined	examine	VBN	_	45	VC
47	.	.	.	_	45	P

1	BCKDH	bckdh	NN	_	3	NMOD
2	enzymatic	enzymatic	JJ	_	3	NMOD
3	activity	activity	NN	_	11	SBJ
4	in	in	IN	_	3	LOC
5	liver	liver	NN	_	4	PMOD
6	from	from	IN	_	5	NMOD
7	Lines	line	NNS	_	8	NMOD
8	A	a	NN	_	6	PMOD
9	and	and	CC	_	8	COORD
10	525A	0a	NN	_	9	CONJ
11	was	be	VBD	_	0	ROOT
12	~	~	SYM	_	13	P
13	6	0	CD	_	16	NMOD
14	and	and	CC	_	13	COORD
15	5	0	CD	_	14	CONJ
16	%	%	NN	_	11	PRD
17	,	,	,	_	16	P
18	respectively	respectively	RB	_	11	ADV
19	,	,	,	_	16	P
20	of	of	IN	_	16	NMOD
21	the	the	DT	_	23	NMOD
22	enzymatic	enzymatic	JJ	_	23	NMOD
23	activity	activity	NN	_	20	PMOD
24	present	present	JJ	_	23	NMOD
25	in	in	IN	_	24	AMOD
26	control	control	NN	_	27	NMOD
27	liver	liver	NN	_	25	PMOD
28	(	(	-LRB-	_	30	P
29	Fig.	fig.	NN	_	30	NMOD
30	4C	0c	NN	_	11	PRN
31	)	)	-RRB-	_	30	P
32	.	.	.	_	11	P

1	As	as	IN	_	23	ADV
2	shown	show	VBN	_	1	SUB
3	in	in	IN	_	2	ADV
4	Fig.	fig.	NNP	_	5	NMOD
5	3B	0b	NN	_	3	PMOD
6	,	,	,	_	23	P
7	the	the	DT	_	8	NMOD
8	amount	amount	NN	_	23	SBJ
9	of	of	IN	_	8	NMOD
10	human	human	JJ	_	11	NMOD
11	E2	e0	NN	_	9	PMOD
12	(	(	-LRB-	_	14	P
13	predicted	predict	VBN	_	14	NMOD
14	MW	mw	NN	_	11	PRN
15	~	~	SYM	_	16	P
16	54	0	NN	_	17	NMOD
17	Kd	kd	NN	_	14	OPRD
18	)	)	-RRB-	_	14	P
19	in	in	IN	_	8	LOC
20	these	these	DT	_	22	NMOD
21	transgenic	transgenic	JJ	_	22	NMOD
22	mice	mouse	NNS	_	19	PMOD
23	was	be	VBD	_	0	ROOT
24	quite	quite	RB	_	25	AMOD
25	variable	variable	JJ	_	23	PRD
26	between	between	IN	_	25	AMOD
27	mice	mouse	NNS	_	26	PMOD
28	.	.	.	_	23	P

1	In	in	IN	_	13	LOC
2	some	some	DT	_	1	PMOD
3	of	of	IN	_	2	NMOD
4	these	these	DT	_	6	NMOD
5	transgenic	transgenic	JJ	_	6	NMOD
6	mice	mouse	NNS	_	3	PMOD
7	,	,	,	_	13	P
8	the	the	DT	_	9	NMOD
9	level	level	NN	_	13	SBJ
10	of	of	IN	_	9	NMOD
11	human	human	JJ	_	12	NMOD
12	E2	e0	NN	_	10	PMOD
13	was	be	VBD	_	0	ROOT
14	approximately	approximately	RB	_	15	AMOD
15	equal	equal	JJ	_	13	PRD
16	to	to	IN	_	15	AMOD
17	the	the	DT	_	18	NMOD
18	amount	amount	NN	_	16	PMOD
19	of	of	IN	_	18	NMOD
20	mouse	mouse	NN	_	21	NMOD
21	E2	e0	NN	_	19	PMOD
22	(	(	-LRB-	_	25	P
23	~	~	SYM	_	24	P
24	47	0	CD	_	25	NMOD
25	Kd	kd	NN	_	21	PRN
26	)	)	-RRB-	_	25	P
27	produced	produce	VBN	_	18	NMOD
28	in	in	IN	_	27	LOC
29	liver	liver	NN	_	28	PMOD
30	of	of	IN	_	29	NMOD
31	nontransgenic	nontransgenic	JJ	_	33	NMOD
32	control	control	NN	_	33	NMOD
33	mice	mouse	NNS	_	30	PMOD
34	.	.	.	_	13	P

1	The	the	DT	_	2	NMOD
2	observations	observation	NNS	_	24	SBJ
3	that	that	IN	_	2	NMOD
4	these	these	DT	_	7	NMOD
5	near	near	RB	_	6	AMOD
6	normal	normal	JJ	_	7	NMOD
7	amounts	amount	NNS	_	11	SBJ
8	of	of	IN	_	7	NMOD
9	E2	e0	NN	_	10	NMOD
10	protein	protein	NN	_	8	PMOD
11	result	result	VBP	_	3	SUB
12	in	in	IN	_	11	ADV
13	only	only	RB	_	15	QMOD
14	~	~	SYM	_	15	P
15	5	0	CD	_	18	NMOD
16	–	–	SYM	_	15	P
17	6	0	CD	_	15	QMOD
18	%	%	NN	_	12	PMOD
19	of	of	IN	_	18	NMOD
20	normal	normal	JJ	_	23	NMOD
21	BCKDH	bckdh	NN	_	23	NMOD
22	enzyme	enzyme	NN	_	23	NMOD
23	activity	activity	NN	_	19	PMOD
24	suggest	suggest	VBP	_	0	ROOT
25	that	that	IN	_	24	OBJ
26	transgene	transgene	NN	_	28	NMOD
27	derived	derive	VBN	_	28	NMOD
28	E2	e0	NN	_	29	SBJ
29	is	be	VBZ	_	25	SUB
30	functioning	function	VBG	_	29	VC
31	at	at	IN	_	30	MNR
32	a	a	DT	_	34	NMOD
33	suboptimal	suboptimal	JJ	_	34	NMOD
34	level	level	NN	_	31	PMOD
35	.	.	.	_	24	P

1	It	it	PRP	_	2	SBJ
2	is	be	VBZ	_	0	ROOT
3	probable	probable	JJ	_	2	PRD
4	that	that	IN	_	2	OBJ
5	the	the	DT	_	9	NMOD
6	c	c	NN	_	8	NMOD
7	-	-	HYPH	_	6	P
8	myc	myc	NN	_	9	NMOD
9	tag	tag	NN	_	20	SBJ
10	at	at	IN	_	9	LOC
11	the	the	DT	_	13	NMOD
12	carboxy	carboxy	NN	_	13	NMOD
13	terminus	terminus	NN	_	10	PMOD
14	of	of	IN	_	13	NMOD
15	the	the	DT	_	19	NMOD
16	transgene	transgene	NN	_	17	AMOD
17	derived	derive	VBN	_	19	NMOD
18	human	human	JJ	_	19	NMOD
19	E2	e0	NN	_	14	PMOD
20	interfered	interfere	VBD	_	4	SUB
21	with	with	IN	_	20	ADV
22	enzymatic	enzymatic	JJ	_	23	NMOD
23	activity	activity	NN	_	21	PMOD
24	.	.	.	_	2	P

1	This	this	DT	_	2	NMOD
2	interpretation	interpretation	NN	_	3	SBJ
3	is	be	VBZ	_	0	ROOT
4	consistent	consistent	JJ	_	3	PRD
5	with	with	IN	_	4	AMOD
6	previous	previous	JJ	_	7	NMOD
7	studies	study	NNS	_	5	PMOD
8	which	which	WDT	_	9	SBJ
9	have	have	VBP	_	7	NMOD
10	revealed	reveal	VBN	_	9	VC
11	that	that	IN	_	10	OBJ
12	the	the	DT	_	14	NMOD
13	carboxy	carboxy	NN	_	14	NMOD
14	terminus	terminus	NN	_	24	SBJ
15	of	of	IN	_	14	NMOD
16	an	an	DT	_	18	NMOD
17	analogous	analogous	JJ	_	18	NMOD
18	subunit	subunit	NN	_	15	PMOD
19	of	of	IN	_	18	NMOD
20	the	the	DT	_	23	NMOD
21	pyruvate	pyruvate	NN	_	23	NMOD
22	dehydrogenase	dehydrogenase	NN	_	23	NMOD
23	complex	complex	NN	_	19	PMOD
24	is	be	VBZ	_	11	SUB
25	essential	essential	JJ	_	24	PRD
26	for	for	IN	_	25	AMOD
27	subunit	subunit	NN	_	28	NMOD
28	interactions	interaction	NNS	_	26	PMOD
29	[	[	-LRB-	_	30	P
30	35	0	CD	_	24	PRN
31	]	]	-RRB-	_	30	P
32	and	and	CC	_	24	COORD
33	insertion	insertion	NN	_	48	SBJ
34	of	of	IN	_	33	NMOD
35	a	a	DT	_	37	NMOD
36	Hisx6	hisx0	NN	_	37	NMOD
37	tag	tag	NN	_	34	PMOD
38	on	on	IN	_	33	LOC
39	the	the	DT	_	41	NMOD
40	carboxy	carboxy	NN	_	41	NMOD
41	terminus	terminus	NN	_	38	PMOD
42	of	of	IN	_	41	NMOD
43	an	an	DT	_	47	NMOD
44	analogous	analogous	JJ	_	47	NMOD
45	E.	e.	FW	_	46	NMOD
46	coli	coli	FW	_	47	NMOD
47	subunit	subunit	NN	_	42	PMOD
48	interfered	interfere	VBD	_	32	CONJ
49	with	with	IN	_	48	ADV
50	normal	normal	JJ	_	52	NMOD
51	subunit	subunit	NN	_	52	NMOD
52	assembly	assembly	NN	_	49	PMOD
53	[	[	-LRB-	_	54	P
54	36	0	CD	_	48	PRN
55	]	]	-RRB-	_	54	P
56	.	.	.	_	3	P

1	It	it	PRP	_	2	SBJ
2	is	be	VBZ	_	0	ROOT
3	also	also	RB	_	2	ADV
4	possible	possible	JJ	_	2	PRD
5	that	that	IN	_	2	OBJ
6	human	human	JJ	_	7	NMOD
7	E2	e0	NN	_	8	SBJ
8	was	be	VBD	_	5	SUB
9	not	not	RB	_	8	ADV
10	fully	fully	RB	_	11	AMOD
11	functional	functional	JJ	_	8	PRD
12	when	when	WRB	_	13	TMP
13	complexed	complexed	VBN	_	8	TMP
14	with	with	IN	_	13	ADV
15	mouse	mouse	NN	_	16	NMOD
16	E1	e0	NN	_	14	PMOD
17	and	and	CC	_	16	COORD
18	E3	e0	NN	_	19	NMOD
19	subunits	subunit	NNS	_	17	CONJ
20	.	.	.	_	2	P

1	Human	human	JJ	_	2	NMOD
2	E2	e0	NN	_	3	SBJ
3	shares	share	VBZ	_	0	ROOT
4	~	~	SYM	_	5	P
5	88	0	CD	_	6	NMOD
6	%	%	NN	_	7	NMOD
7	identity	identity	NN	_	3	OBJ
8	to	to	IN	_	7	NMOD
9	mouse	mouse	NN	_	10	NMOD
10	E2	e0	NN	_	8	PMOD
11	at	at	IN	_	3	LOC
12	the	the	DT	_	15	NMOD
13	amino	amino	NN	_	14	NMOD
14	acid	acid	NN	_	15	NMOD
15	level	level	NN	_	11	PMOD
16	.	.	.	_	3	P

1	We	we	PRP	_	3	SBJ
2	also	also	RB	_	3	ADV
3	used	use	VBD	_	0	ROOT
4	western	western	NNP	_	5	NMOD
5	blot	blot	NN	_	6	NMOD
6	analysis	analysis	NN	_	3	OBJ
7	to	to	TO	_	3	PRP
8	analyze	analyze	VB	_	7	IM
9	expression	expression	NN	_	8	OBJ
10	of	of	IN	_	9	NMOD
11	the	the	DT	_	13	NMOD
12	E2	e0	NN	_	13	NMOD
13	transgene	transgene	NN	_	10	PMOD
14	in	in	IN	_	8	LOC
15	brain	brain	NN	_	14	PMOD
16	,	,	,	_	15	P
17	kidney	kidney	NN	_	15	CONJ
18	and	and	CC	_	17	COORD
19	muscle	muscle	NN	_	18	CONJ
20	.	.	.	_	3	P

1	As	as	IN	_	15	ADV
2	shown	show	VBN	_	1	SUB
3	in	in	IN	_	2	ADV
4	Figure	figure	NN	_	5	NMOD
5	3C	0c	NN	_	3	PMOD
6	,	,	,	_	5	P
7	D	d	NN	_	5	CONJ
8	and	and	CC	_	7	COORD
9	3E	0e	NN	_	8	CONJ
10	respectively	respectively	RB	_	2	ADV
11	,	,	,	_	15	P
12	expression	expression	NN	_	15	SBJ
13	of	of	IN	_	12	NMOD
14	E2	e0	NN	_	13	PMOD
15	is	be	VBZ	_	0	ROOT
16	negligible	negligible	JJ	_	15	PRD
17	in	in	IN	_	15	LOC
18	those	those	DT	_	19	NMOD
19	tissues	tissue	NNS	_	17	PMOD
20	.	.	.	_	15	P

1	Long	long	JJ	_	3	NMOD
2	-	-	HYPH	_	1	P
3	term	term	NN	_	4	NMOD
4	survival	survival	NN	_	17	SBJ
5	of	of	IN	_	4	NMOD
6	the	the	DT	_	7	NMOD
7	mice	mouse	NNS	_	5	PMOD
8	from	from	IN	_	7	NMOD
9	these	these	DT	_	12	NMOD
10	two	two	CD	_	12	NMOD
11	transgenic	transgenic	JJ	_	12	NMOD
12	lines	line	NNS	_	8	PMOD
13	that	that	WDT	_	14	SBJ
14	survived	survive	VBD	_	12	NMOD
15	beyond	beyond	IN	_	14	TMP
16	weaning	weaning	NN	_	15	PMOD
17	is	be	VBZ	_	0	ROOT
18	plotted	plot	VBN	_	17	VC
19	in	in	IN	_	18	ADV
20	Fig.	fig.	NN	_	21	NMOD
21	4D	0d	NN	_	19	PMOD
22	.	.	.	_	17	P

1	Although	although	IN	_	12	ADV
2	survival	survival	NN	_	3	NMOD
3	data	datum	NNS	_	7	SBJ
4	for	for	IN	_	3	NMOD
5	control	control	NN	_	6	NMOD
6	animals	animal	NNS	_	4	PMOD
7	was	be	VBD	_	1	SUB
8	not	not	RB	_	7	ADV
9	collected	collect	VBN	_	7	VC
10	,	,	,	_	12	P
11	it	it	PRP	_	12	SBJ
12	is	be	VBZ	_	0	ROOT
13	readily	readily	RB	_	14	AMOD
14	apparent	apparent	JJ	_	12	PRD
15	that	that	IN	_	12	OBJ
16	survival	survival	NN	_	21	SBJ
17	of	of	IN	_	16	NMOD
18	the	the	DT	_	20	NMOD
19	rescue	rescue	NN	_	20	NMOD
20	mice	mouse	NNS	_	17	PMOD
21	was	be	VBD	_	15	SUB
22	compromised	compromise	VBN	_	21	VC
23	.	.	.	_	12	P

1	By	by	IN	_	10	TMP
2	16	0	CD	_	3	NMOD
3	weeks	week	NNS	_	1	PMOD
4	,	,	,	_	10	P
5	all	all	DT	_	6	NMOD
6	mice	mouse	NNS	_	10	SBJ
7	of	of	IN	_	6	NMOD
8	Line	line	NN	_	9	NMOD
9	A	a	NN	_	7	PMOD
10	were	be	VBD	_	0	ROOT
11	moribund	moribund	JJ	_	10	PRD
12	and	and	CC	_	11	COORD
13	humanely	humanely	RB	_	14	ADV
14	sacrificed	sacrifice	VBN	_	12	CONJ
15	,	,	,	_	10	P
16	or	or	CC	_	10	COORD
17	were	be	VBD	_	16	CONJ
18	found	find	VBN	_	17	VC
19	dead	dead	JJ	_	18	ADV
20	in	in	IN	_	18	LOC
21	their	their	PRP$	_	22	NMOD
22	cage	cage	NN	_	20	PMOD
23	.	.	.	_	10	P

1	Survival	survival	NN	_	5	SBJ
2	of	of	IN	_	1	NMOD
3	Line	line	NN	_	4	NMOD
4	525A	0a	NN	_	2	PMOD
5	appeared	appear	VBD	_	0	ROOT
6	to	to	TO	_	5	OPRD
7	be	be	VB	_	6	IM
8	somewhat	somewhat	RB	_	9	AMOD
9	better	good	JJR	_	7	PRD
10	.	.	.	_	5	P

1	At	at	IN	_	17	TMP
2	20	0	CD	_	3	NMOD
3	weeks	week	NNS	_	1	PMOD
4	of	of	IN	_	3	NMOD
5	age	age	NN	_	4	PMOD
6	,	,	,	_	17	P
7	~	~	SYM	_	8	P
8	12	0	CD	_	9	NMOD
9	%	%	NN	_	17	SBJ
10	of	of	IN	_	9	NMOD
11	mice	mouse	NNS	_	10	PMOD
12	(	(	-LRB-	_	13	P
13	2	0	CD	_	11	PRN
14	of	of	IN	_	13	NMOD
15	16	0	CD	_	14	PMOD
16	)	)	-RRB-	_	13	P
17	were	be	VBD	_	0	ROOT
18	still	still	RB	_	17	TMP
19	alive	alive	JJ	_	17	PRD
20	.	.	.	_	17	P

1	These	these	DT	_	4	NMOD
2	two	two	CD	_	4	NMOD
3	rare	rare	JJ	_	4	NMOD
4	survivors	survivor	NNS	_	5	SBJ
5	died	die	VBD	_	0	ROOT
6	at	at	IN	_	5	TMP
7	40	0	CD	_	10	NMOD
8	and	and	CC	_	7	COORD
9	60	0	CD	_	8	CONJ
10	weeks	week	NNS	_	6	PMOD
11	of	of	IN	_	10	NMOD
12	age	age	NN	_	11	PMOD
13	.	.	.	_	5	P

1	In	in	IN	_	7	ADV
2	summary	summary	NN	_	1	PMOD
3	,	,	,	_	7	P
4	these	these	DT	_	6	NMOD
5	surviving	survive	VBG	_	6	NMOD
6	mice	mouse	NNS	_	7	SBJ
7	had	have	VBD	_	0	ROOT
8	BCAA	bcaa	NN	_	10	NMOD
9	/	/	HYPH	_	8	P
10	alanine	alanine	NN	_	11	NMOD
11	ratios	ratio	NNS	_	7	OBJ
12	that	that	WDT	_	13	SBJ
13	were	be	VBD	_	11	NMOD
14	intermediate	intermediate	JJ	_	13	PRD
15	between	between	IN	_	14	AMOD
16	controls	control	NNS	_	15	PMOD
17	and	and	CC	_	16	COORD
18	knockouts	knockout	NNS	_	17	CONJ
19	and	and	CC	_	7	COORD
20	they	they	PRP	_	21	SBJ
21	expressed	express	VBD	_	19	CONJ
22	~	~	SYM	_	23	P
23	5	0	CD	_	26	NMOD
24	–	–	SYM	_	23	P
25	6	0	CD	_	23	QMOD
26	%	%	NN	_	21	OBJ
27	of	of	IN	_	26	NMOD
28	normal	normal	JJ	_	31	NMOD
29	BCKDH	bckdh	NN	_	31	NMOD
30	enzyme	enzyme	NN	_	31	NMOD
31	activity	activity	NN	_	27	PMOD
32	in	in	IN	_	31	LOC
33	the	the	DT	_	34	NMOD
34	liver	liver	NN	_	32	PMOD
35	.	.	.	_	7	P

1	These	these	DT	_	3	NMOD
2	phenotypic	phenotypic	JJ	_	3	NMOD
3	observations	observation	NNS	_	4	SBJ
4	are	be	VBP	_	0	ROOT
5	remarkably	remarkably	RB	_	6	AMOD
6	similar	similar	JJ	_	4	PRD
7	to	to	IN	_	6	AMOD
8	the	the	DT	_	10	NMOD
9	clinical	clinical	JJ	_	10	NMOD
10	phenotype	phenotype	NN	_	7	PMOD
11	observed	observe	VBN	_	10	NMOD
12	in	in	IN	_	11	LOC
13	MSUD	msud	NN	_	14	NMOD
14	patients	patient	NNS	_	12	PMOD
15	with	with	IN	_	14	NMOD
16	the	the	DT	_	18	NMOD
17	intermediate	intermediate	JJ	_	18	NMOD
18	form	form	NN	_	15	PMOD
19	of	of	IN	_	18	NMOD
20	the	the	DT	_	21	NMOD
21	disease	disease	NN	_	19	PMOD
22	[	[	-LRB-	_	23	P
23	1	0	CD	_	4	PRN
24	]	]	-RRB-	_	23	P
25	.	.	.	_	4	P

1	Thus	thus	RB	_	6	ADV
2	,	,	,	_	6	P
3	these	these	DT	_	5	NMOD
4	rescue	rescue	NN	_	5	NMOD
5	mice	mouse	NNS	_	6	SBJ
6	represent	represent	VBP	_	0	ROOT
7	a	a	DT	_	10	NMOD
8	very	very	RB	_	9	AMOD
9	useful	useful	JJ	_	10	NMOD
10	model	model	NN	_	6	OBJ
11	of	of	IN	_	10	NMOD
12	the	the	DT	_	15	NMOD
13	intermediate	intermediate	JJ	_	15	NMOD
14	MSUD	msud	NN	_	15	NMOD
15	phenotype	phenotype	NN	_	11	PMOD
16	.	.	.	_	6	P

1	Discussion	discussion	NN	_	0	ROOT

1	A	a	DT	_	3	NMOD
2	major	major	JJ	_	3	NMOD
3	hurdle	hurdle	NN	_	10	SBJ
4	in	in	IN	_	3	NMOD
5	developing	develop	VBG	_	4	PMOD
6	new	new	JJ	_	7	NMOD
7	treatments	treatment	NNS	_	5	OBJ
8	for	for	IN	_	7	NMOD
9	MSUD	msud	NN	_	8	PMOD
10	has	have	VBZ	_	0	ROOT
11	been	be	VBN	_	10	VC
12	the	the	DT	_	13	NMOD
13	lack	lack	NN	_	11	PRD
14	of	of	IN	_	13	NMOD
15	a	a	DT	_	20	NMOD
16	practical	practical	JJ	_	20	NMOD
17	,	,	,	_	20	P
18	accurate	accurate	JJ	_	20	NMOD
19	animal	animal	NN	_	20	NMOD
20	model	model	NN	_	14	PMOD
21	of	of	IN	_	20	NMOD
22	the	the	DT	_	23	NMOD
23	disease	disease	NN	_	21	PMOD
24	.	.	.	_	10	P

1	This	this	DT	_	2	NMOD
2	hurdle	hurdle	NN	_	3	SBJ
3	has	have	VBZ	_	0	ROOT
4	now	now	RB	_	3	TMP
5	been	be	VBN	_	3	VC
6	overcome	overcome	VBN	_	5	VC
7	.	.	.	_	3	P

1	In	in	IN	_	6	ADV
2	this	this	DT	_	3	NMOD
3	report	report	NN	_	1	PMOD
4	,	,	,	_	6	P
5	we	we	PRP	_	6	SBJ
6	describe	describe	VBP	_	0	ROOT
7	the	the	DT	_	8	NMOD
8	development	development	NN	_	6	OBJ
9	and	and	CC	_	8	COORD
10	characterization	characterization	NN	_	9	CONJ
11	of	of	IN	_	8	NMOD
12	two	two	CD	_	16	NMOD
13	genetically	genetically	RB	_	14	AMOD
14	engineered	engineer	VBN	_	16	NMOD
15	mouse	mouse	NN	_	16	NMOD
16	models	model	NNS	_	11	PMOD
17	that	that	WDT	_	18	SBJ
18	are	be	VBP	_	16	NMOD
19	phenotypically	phenotypically	RB	_	18	ADV
20	very	very	RB	_	21	AMOD
21	similar	similar	JJ	_	18	PRD
22	to	to	IN	_	21	AMOD
23	MSUD	msud	NN	_	24	NMOD
24	patients	patient	NNS	_	22	PMOD
25	with	with	IN	_	24	NMOD
26	the	the	DT	_	30	NMOD
27	classic	classic	JJ	_	30	NMOD
28	and	and	CC	_	27	COORD
29	intermediate	intermediate	JJ	_	28	CONJ
30	forms	form	NNS	_	25	PMOD
31	of	of	IN	_	30	NMOD
32	the	the	DT	_	33	NMOD
33	disease	disease	NN	_	31	PMOD
34	.	.	.	_	6	P

1	Our	our	PRP$	_	2	NMOD
2	model	model	NN	_	6	SBJ
3	of	of	IN	_	2	NMOD
4	classic	classic	JJ	_	5	NMOD
5	MSUD	msud	NN	_	3	PMOD
6	was	be	VBD	_	0	ROOT
7	created	create	VBN	_	6	VC
8	by	by	IN	_	7	MNR
9	gene	gene	NN	_	10	NMOD
10	knockout	knockout	NN	_	8	PMOD
11	of	of	IN	_	10	NMOD
12	the	the	DT	_	14	NMOD
13	E2	e0	NN	_	14	NMOD
14	subunit	subunit	NN	_	11	PMOD
15	of	of	IN	_	14	NMOD
16	BCKDH	bckdh	NN	_	15	PMOD
17	.	.	.	_	6	P

1	The	the	DT	_	2	NMOD
2	phenotype	phenotype	NN	_	7	SBJ
3	of	of	IN	_	2	NMOD
4	these	these	DT	_	6	NMOD
5	knockout	knockout	NN	_	6	NMOD
6	animals	animal	NNS	_	3	PMOD
7	is	be	VBZ	_	0	ROOT
8	strikingly	strikingly	RB	_	9	AMOD
9	similar	similar	JJ	_	7	PRD
10	to	to	IN	_	9	AMOD
11	humans	human	NNS	_	10	PMOD
12	with	with	IN	_	11	NMOD
13	classic	classic	JJ	_	14	NMOD
14	MSUD	msud	NN	_	12	PMOD
15	.	.	.	_	7	P

1	Knockout	knockout	NN	_	2	NMOD
2	mice	mouse	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	born	bear	VBN	_	3	VC
5	at	at	IN	_	4	TMP
6	the	the	DT	_	8	NMOD
7	expected	expect	VBN	_	8	NMOD
8	frequency	frequency	NN	_	5	PMOD
9	and	and	CC	_	3	COORD
10	appeared	appear	VBD	_	9	CONJ
11	normal	normal	JJ	_	10	OPRD
12	at	at	IN	_	10	TMP
13	birth	birth	NN	_	12	PMOD
14	.	.	.	_	3	P

1	Within	within	IN	_	14	TMP
2	a	a	DT	_	3	NMOD
3	day	day	NN	_	1	PMOD
4	of	of	IN	_	3	NMOD
5	birth	birth	NN	_	4	PMOD
6	and	and	CC	_	1	COORD
7	following	follow	VBG	_	6	CONJ
8	suckling	suckling	NN	_	7	PMOD
9	,	,	,	_	14	P
10	blood	blood	NN	_	11	NMOD
11	levels	level	NNS	_	14	SBJ
12	of	of	IN	_	11	NMOD
13	BCAA	bcaa	NN	_	12	PMOD
14	were	be	VBD	_	0	ROOT
15	markedly	markedly	RB	_	16	AMOD
16	elevated	elevated	JJ	_	14	PRD
17	.	.	.	_	14	P

1	Concomitantly	concomitantly	RB	_	25	ADV
2	,	,	,	_	25	P
3	levels	level	NNS	_	25	SBJ
4	of	of	IN	_	3	NMOD
5	the	the	DT	_	7	NMOD
6	amino	amino	NN	_	7	NMOD
7	acids	acid	NNS	_	8	NMOD
8	alanine	alanine	NN	_	4	PMOD
9	,	,	,	_	8	P
10	glutamate	glutamate	NN	_	8	CONJ
11	,	,	,	_	10	P
12	and	and	CC	_	10	COORD
13	glutamine	glutamine	NN	_	12	CONJ
14	,	,	,	_	8	P
15	whose	whose	WP$	_	16	NMOD
16	synthesis	synthesis	NN	_	17	SBJ
17	is	be	VBZ	_	8	NMOD
18	linked	link	VBN	_	17	VC
19	with	with	IN	_	18	ADV
20	normal	normal	JJ	_	21	NMOD
21	metabolism	metabolism	NN	_	19	PMOD
22	of	of	IN	_	21	NMOD
23	BCAA	bcaa	NN	_	22	PMOD
24	,	,	,	_	25	P
25	were	be	VBD	_	0	ROOT
26	decreased	decrease	VBN	_	25	VC
27	(	(	-LRB-	_	28	P
28	Table	table	NN	_	26	PRN
29	1	0	CD	_	28	NMOD
30	)	)	-RRB-	_	28	P
31	.	.	.	_	25	P

1	The	the	DT	_	2	NMOD
2	activity	activity	NN	_	12	SBJ
3	of	of	IN	_	2	NMOD
4	BCKDH	bckdh	NN	_	3	PMOD
5	in	in	IN	_	2	LOC
6	livers	liver	NNS	_	5	PMOD
7	of	of	IN	_	6	NMOD
8	homozygous	homozygous	JJ	_	9	NMOD
9	knockout	knockout	NN	_	11	NMOD
10	mouse	mouse	NN	_	11	NMOD
11	pups	pup	NNS	_	7	PMOD
12	was	be	VBD	_	0	ROOT
13	undetectable	undetectable	JJ	_	12	PRD
14	,	,	,	_	12	P
15	accounting	account	VBG	_	12	ADV
16	for	for	IN	_	15	ADV
17	the	the	DT	_	18	NMOD
18	accumulation	accumulation	NN	_	16	PMOD
19	of	of	IN	_	18	NMOD
20	unmetabolized	unmetabolized	JJ	_	21	NMOD
21	BCAA	bcaa	NN	_	19	PMOD
22	.	.	.	_	12	P

1	Immunoreactive	immunoreactive	JJ	_	3	NMOD
2	E2	e0	NN	_	3	NMOD
3	protein	protein	NN	_	4	SBJ
4	was	be	VBD	_	0	ROOT
5	absent	absent	JJ	_	4	PRD
6	in	in	IN	_	4	LOC
7	liver	liver	NN	_	6	PMOD
8	and	and	CC	_	7	COORD
9	fibroblasts	fibroblast	NNS	_	8	CONJ
10	of	of	IN	_	7	NMOD
11	homozygous	homozygous	JJ	_	12	NMOD
12	pups	pup	NNS	_	10	PMOD
13	.	.	.	_	4	P

1	The	the	DT	_	3	NMOD
2	phenotypic	phenotypic	JJ	_	3	NMOD
3	behavior	behavior	NN	_	8	SBJ
4	of	of	IN	_	3	NMOD
5	homozygous	homozygous	JJ	_	7	NMOD
6	mouse	mouse	NN	_	7	NMOD
7	pups	pup	NNS	_	4	PMOD
8	resembles	resemble	VBZ	_	0	ROOT
9	symptoms	symptom	NNS	_	8	OBJ
10	seen	see	VBN	_	9	NMOD
11	in	in	IN	_	10	LOC
12	newborn	newborn	JJ	_	15	NMOD
13	classic	classic	JJ	_	15	NMOD
14	MSUD	msud	NN	_	15	NMOD
15	patients	patient	NNS	_	11	PMOD
16	.	.	.	_	8	P

1	These	these	DT	_	2	SBJ
2	include	include	VBP	_	0	ROOT
3	signs	sign	NNS	_	2	OBJ
4	of	of	IN	_	3	NMOD
5	neurologic	neurologic	JJ	_	6	NMOD
6	dysfunction	dysfunction	NN	_	4	PMOD
7	such	such	JJ	_	8	PMOD
8	as	as	IN	_	3	NMOD
9	seizures	seizure	NNS	_	8	PMOD
10	,	,	,	_	9	P
11	stupor	stupor	NN	_	9	CONJ
12	,	,	,	_	11	P
13	lethargy	lethargy	NN	_	11	CONJ
14	,	,	,	_	13	P
15	loss	loss	NN	_	13	CONJ
16	of	of	IN	_	15	NMOD
17	motor	motor	NN	_	18	NMOD
18	activity	activity	NN	_	16	PMOD
19	,	,	,	_	15	P
20	and	and	CC	_	15	COORD
21	respiratory	respiratory	JJ	_	22	NMOD
22	difficulties	difficulty	NNS	_	20	CONJ
23	[	[	-LRB-	_	24	P
24	1	0	CD	_	2	PRN
25	]	]	-RRB-	_	24	P
26	.	.	.	_	2	P

1	These	these	DT	_	3	NMOD
2	neurologic	neurologic	JJ	_	3	NMOD
3	symptoms	symptom	NNS	_	4	SBJ
4	may	may	MD	_	0	ROOT
5	result	result	VB	_	4	VC
6	from	from	IN	_	5	ADV
7	reduced	reduce	VBN	_	8	NMOD
8	levels	level	NNS	_	6	PMOD
9	of	of	IN	_	8	NMOD
10	glutamate	glutamate	NN	_	9	PMOD
11	,	,	,	_	10	P
12	glutamine	glutamine	NN	_	10	CONJ
13	,	,	,	_	12	P
14	alanine	alanine	NN	_	12	CONJ
15	,	,	,	_	14	P
16	and	and	CC	_	14	COORD
17	other	other	JJ	_	21	NMOD
18	similar	similar	JJ	_	21	NMOD
19	neuroactive	neuroactive	JJ	_	21	NMOD
20	amino	amino	NN	_	21	NMOD
21	acids	acid	NNS	_	16	CONJ
22	,	,	,	_	10	P
23	which	which	WDT	_	24	SBJ
24	are	be	VBP	_	10	NMOD
25	considered	consider	VBN	_	24	VC
26	the	the	DT	_	27	NMOD
27	culprit	culprit	NN	_	25	OPRD
28	for	for	IN	_	27	NMOD
29	MSUD	msud	NN	_	30	NMOD
30	encephalopathies	encephalopathy	NNS	_	28	PMOD
31	in	in	IN	_	27	LOC
32	patients	patient	NNS	_	31	PMOD
33	[	[	-LRB-	_	36	P
34	1	0	CD	_	36	NMOD
35	,	,	,	_	36	P
36	37	0	CD	_	5	PRN
37	]	]	-RRB-	_	36	P
38	.	.	.	_	4	P

1	Finally	finally	RB	_	9	ADV
2	,	,	,	_	9	P
3	nearly	nearly	RB	_	4	NMOD
4	all	all	DT	_	9	SBJ
5	of	of	IN	_	4	NMOD
6	the	the	DT	_	8	NMOD
7	homozygous	homozygous	JJ	_	8	NMOD
8	pups	pup	NNS	_	5	PMOD
9	died	die	VBD	_	0	ROOT
10	within	within	IN	_	9	TMP
11	72	0	CD	_	12	NMOD
12	hours	hour	NNS	_	10	PMOD
13	of	of	IN	_	12	NMOD
14	birth	birth	NN	_	13	PMOD
15	.	.	.	_	9	P

1	This	this	DT	_	3	NMOD
2	neonatal	neonatal	JJ	_	3	NMOD
3	lethality	lethality	NN	_	4	SBJ
4	is	be	VBZ	_	0	ROOT
5	likely	likely	RB	_	6	PMOD
6	due	due	IN	_	4	PRD
7	to	to	IN	_	6	PMOD
8	the	the	DT	_	9	NMOD
9	accumulation	accumulation	NN	_	6	PMOD
10	of	of	IN	_	9	NMOD
11	BCAA	bcaa	NN	_	10	PMOD
12	to	to	IN	_	9	NMOD
13	neurotoxic	neurotoxic	JJ	_	14	NMOD
14	levels	level	NNS	_	12	PMOD
15	,	,	,	_	14	P
16	ketoacidosis	ketoacidosis	NN	_	14	CONJ
17	,	,	,	_	16	P
18	brain	brain	NN	_	19	NMOD
19	edema	edema	NN	_	16	CONJ
20	,	,	,	_	19	P
21	dehydration	dehydration	NN	_	19	CONJ
22	,	,	,	_	21	P
23	and	and	CC	_	21	COORD
24	malnutrition	malnutrition	NN	_	23	CONJ
25	as	as	IN	_	4	ADV
26	observed	observe	VBN	_	25	SUB
27	in	in	IN	_	26	LOC
28	the	the	DT	_	30	NMOD
29	MSUD	msud	NN	_	30	NMOD
30	calf	calf	NN	_	27	PMOD
31	[	[	-LRB-	_	32	P
32	17	0	CD	_	30	PRN
33	]	]	-RRB-	_	32	P
34	and	and	CC	_	27	COORD
35	in	in	IN	_	34	CONJ
36	classic	classic	JJ	_	38	NMOD
37	MSUD	msud	NN	_	38	NMOD
38	patients	patient	NNS	_	35	PMOD
39	[	[	-LRB-	_	40	P
40	1	0	CD	_	38	PRN
41	]	]	-RRB-	_	40	P
42	.	.	.	_	4	P

1	Heterozygous	heterozygous	JJ	_	2	NMOD
2	knockouts	knockout	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	normal	normal	JJ	_	3	PRD
5	and	and	CC	_	3	COORD
6	had	have	VBD	_	5	CONJ
7	normal	normal	JJ	_	8	NMOD
8	levels	level	NNS	_	6	OBJ
9	of	of	IN	_	8	NMOD
10	BCAA	bcaa	NN	_	9	PMOD
11	despite	despite	IN	_	6	ADV
12	having	have	VBG	_	11	PMOD
13	approximately	approximately	RB	_	14	NMOD
14	half	half	NN	_	12	OBJ
15	of	of	IN	_	14	NMOD
16	BCKDH	bckdh	NN	_	18	NMOD
17	enzymatic	enzymatic	JJ	_	18	NMOD
18	activity	activity	NN	_	15	PMOD
19	.	.	.	_	3	P

1	From	from	IN	_	14	ADV
2	the	the	DT	_	4	NMOD
3	characterization	characterization	NN	_	4	NMOD
4	studies	study	NNS	_	1	PMOD
5	completed	complete	VBN	_	4	NMOD
6	thus	thus	RB	_	7	AMOD
7	far	far	RB	_	5	TMP
8	,	,	,	_	14	P
9	the	the	DT	_	12	NMOD
10	null	null	JJ	_	11	NMOD
11	mutation	mutation	NN	_	12	NMOD
12	mouse	mouse	NN	_	14	SBJ
13	accurately	accurately	RB	_	14	ADV
14	represents	represent	VBZ	_	0	ROOT
15	a	a	DT	_	16	NMOD
16	model	model	NN	_	14	OBJ
17	of	of	IN	_	16	NMOD
18	classic	classic	JJ	_	19	NMOD
19	MSUD	msud	NN	_	17	PMOD
20	and	and	CC	_	14	COORD
21	appears	appear	VBZ	_	20	CONJ
22	to	to	TO	_	21	OPRD
23	be	be	VB	_	22	IM
24	a	a	DT	_	26	NMOD
25	faithful	faithful	JJ	_	26	NMOD
26	model	model	NN	_	23	PRD
27	of	of	IN	_	26	NMOD
28	the	the	DT	_	30	NMOD
29	human	human	JJ	_	30	NMOD
30	disease	disease	NN	_	27	PMOD
31	with	with	IN	_	23	MNR
32	respect	respect	NN	_	31	PMOD
33	to	to	IN	_	32	NMOD
34	several	several	JJ	_	36	NMOD
35	biochemical	biochemical	JJ	_	36	NMOD
36	phenotypes	phenotype	NNS	_	33	PMOD
37	[	[	-LRB-	_	38	P
38	1	0	CD	_	21	PRN
39	]	]	-RRB-	_	38	P
40	.	.	.	_	14	P

1	To	to	TO	_	10	PRP
2	create	create	VB	_	1	IM
3	a	a	DT	_	4	NMOD
4	model	model	NN	_	2	OBJ
5	of	of	IN	_	4	NMOD
6	intermediate	intermediate	JJ	_	7	NMOD
7	MSUD	msud	NN	_	5	PMOD
8	,	,	,	_	10	P
9	we	we	PRP	_	10	SBJ
10	used	use	VBD	_	0	ROOT
11	a	a	DT	_	13	NMOD
12	transgenic	transgenic	JJ	_	13	NMOD
13	strategy	strategy	NN	_	10	OBJ
14	to	to	TO	_	10	PRP
15	express	express	VB	_	14	IM
16	human	human	JJ	_	17	NMOD
17	E2	e0	NN	_	15	OBJ
18	in	in	IN	_	15	LOC
19	the	the	DT	_	20	NMOD
20	liver	liver	NN	_	18	PMOD
21	of	of	IN	_	20	NMOD
22	E2	e0	NN	_	24	NMOD
23	knockout	knockout	NN	_	24	NMOD
24	mice	mouse	NNS	_	21	PMOD
25	.	.	.	_	10	P

1	As	as	IN	_	11	ADV
2	mentioned	mention	VBN	_	1	SUB
3	above	above	RB	_	2	ADV
4	,	,	,	_	11	P
5	E2	e0	NN	_	6	NMOD
6	knockouts	knockout	NNS	_	11	SBJ
7	without	without	IN	_	6	NMOD
8	transgene	transgene	NN	_	9	AMOD
9	derived	derive	VBN	_	10	NMOD
10	E2	e0	NN	_	7	PMOD
11	die	die	VBP	_	0	ROOT
12	during	during	IN	_	11	TMP
13	the	the	DT	_	16	NMOD
14	early	early	JJ	_	15	AMOD
15	neonatal	neonatal	JJ	_	16	NMOD
16	period	period	NN	_	12	PMOD
17	.	.	.	_	11	P

1	We	we	PRP	_	2	SBJ
2	show	show	VBP	_	0	ROOT
3	that	that	IN	_	2	OBJ
4	expression	expression	NN	_	17	SBJ
5	of	of	IN	_	4	NMOD
6	a	a	DT	_	9	NMOD
7	human	human	JJ	_	9	NMOD
8	E2	e0	NN	_	9	NMOD
9	transgene	transgene	NN	_	5	PMOD
10	in	in	IN	_	4	LOC
11	the	the	DT	_	12	NMOD
12	liver	liver	NN	_	10	PMOD
13	of	of	IN	_	12	NMOD
14	these	these	DT	_	16	NMOD
15	knockout	knockout	NN	_	16	NMOD
16	mice	mouse	NNS	_	13	PMOD
17	is	be	VBZ	_	3	SUB
18	able	able	JJ	_	17	PRD
19	to	to	TO	_	18	AMOD
20	rescue	rescue	VB	_	19	IM
21	the	the	DT	_	23	NMOD
22	neonatal	neonatal	JJ	_	23	NMOD
23	lethality	lethality	NN	_	20	OBJ
24	.	.	.	_	2	P

1	Many	many	JJ	_	6	SBJ
2	of	of	IN	_	1	NMOD
3	the	the	DT	_	5	NMOD
4	rescue	rescue	NN	_	5	NMOD
5	mice	mouse	NNS	_	2	PMOD
6	survived	survive	VBD	_	0	ROOT
7	to	to	IN	_	6	TMP
8	adulthood	adulthood	NN	_	7	PMOD
9	.	.	.	_	6	P

1	It	it	PRP	_	2	SBJ
2	is	be	VBZ	_	0	ROOT
3	interesting	interesting	JJ	_	2	PRD
4	to	to	TO	_	2	OPRD
5	note	note	VB	_	4	IM
6	that	that	IN	_	5	OBJ
7	in	in	IN	_	24	LOC
8	these	these	DT	_	10	NMOD
9	mouse	mouse	NN	_	10	NMOD
10	lines	line	NNS	_	7	PMOD
11	only	only	RB	_	13	QMOD
12	~	~	SYM	_	13	P
13	5	0	CD	_	16	NMOD
14	–	–	SYM	_	13	P
15	6	0	CD	_	13	QMOD
16	%	%	NN	_	24	SBJ
17	of	of	IN	_	16	NMOD
18	normal	normal	JJ	_	20	NMOD
19	BCKDH	bckdh	NN	_	20	NMOD
20	activity	activity	NN	_	17	PMOD
21	in	in	IN	_	20	LOC
22	the	the	DT	_	23	NMOD
23	liver	liver	NN	_	21	PMOD
24	was	be	VBD	_	6	SUB
25	sufficient	sufficient	JJ	_	24	PRD
26	to	to	TO	_	25	AMOD
27	allow	allow	VB	_	26	IM
28	survival	survival	NN	_	27	OBJ
29	.	.	.	_	2	P

1	We	we	PRP	_	3	SBJ
2	also	also	RB	_	3	ADV
3	demonstrated	demonstrate	VBD	_	0	ROOT
4	that	that	IN	_	3	OBJ
5	BCAA	bcaa	NN	_	6	NMOD
6	levels	level	NNS	_	13	SBJ
7	in	in	IN	_	6	LOC
8	blood	blood	NN	_	7	PMOD
9	of	of	IN	_	8	NMOD
10	these	these	DT	_	12	NMOD
11	rescue	rescue	NN	_	12	NMOD
12	mice	mouse	NNS	_	9	PMOD
13	were	be	VBD	_	4	SUB
14	intermediate	intermediate	JJ	_	13	PRD
15	between	between	IN	_	13	ADV
16	controls	control	NNS	_	15	PMOD
17	and	and	CC	_	16	COORD
18	knockouts	knockout	NNS	_	17	CONJ
19	.	.	.	_	3	P

1	The	the	DT	_	2	NMOD
2	hallmarks	hallmark	NNS	_	8	SBJ
3	of	of	IN	_	2	NMOD
4	intermediate	intermediate	JJ	_	7	NMOD
5	MSUD	msud	NN	_	7	NMOD
6	human	human	JJ	_	7	NMOD
7	patients	patient	NNS	_	3	PMOD
8	are	be	VBP	_	0	ROOT
9	persistently	persistently	RB	_	10	AMOD
10	increased	increase	VBN	_	11	NMOD
11	levels	level	NNS	_	8	PRD
12	of	of	IN	_	11	NMOD
13	BCAA	bcaa	NN	_	16	NMOD
14	and	and	CC	_	13	COORD
15	BCKDH	bckdh	NN	_	14	CONJ
16	activity	activity	NN	_	12	PMOD
17	in	in	IN	_	11	NMOD
18	the	the	DT	_	19	NMOD
19	range	range	NN	_	17	PMOD
20	of	of	IN	_	19	NMOD
21	3	0	CD	_	24	NMOD
22	–	–	SYM	_	21	P
23	30	0	CD	_	21	QMOD
24	%	%	NN	_	20	PMOD
25	of	of	IN	_	24	NMOD
26	normal	normal	JJ	_	25	PMOD
27	[	[	-LRB-	_	28	P
28	1	0	CD	_	8	PRN
29	]	]	-RRB-	_	28	P
30	.	.	.	_	8	P

1	Because	because	IN	_	19	PRP
2	of	of	IN	_	1	PMOD
3	the	the	DT	_	5	NMOD
4	phenotypic	phenotypic	JJ	_	5	NMOD
5	similarities	similarity	NNS	_	1	PMOD
6	of	of	IN	_	5	NMOD
7	the	the	DT	_	9	NMOD
8	rescue	rescue	NN	_	9	NMOD
9	mice	mouse	NNS	_	6	PMOD
10	to	to	IN	_	5	NMOD
11	the	the	DT	_	13	NMOD
12	human	human	JJ	_	13	NMOD
13	patients	patient	NNS	_	10	PMOD
14	,	,	,	_	19	P
15	these	these	DT	_	18	NMOD
16	genetically	genetically	RB	_	17	AMOD
17	engineered	engineer	VBN	_	18	NMOD
18	mice	mouse	NNS	_	19	SBJ
19	represent	represent	VBP	_	0	ROOT
20	a	a	DT	_	24	NMOD
21	useful	useful	JJ	_	24	NMOD
22	small	small	JJ	_	23	NMOD
23	animal	animal	NN	_	24	NMOD
24	model	model	NN	_	19	OBJ
25	of	of	IN	_	24	NMOD
26	the	the	DT	_	28	NMOD
27	intermediate	intermediate	JJ	_	28	NMOD
28	form	form	NN	_	25	PMOD
29	of	of	IN	_	28	NMOD
30	MSUD	msud	NN	_	29	PMOD
31	.	.	.	_	19	P

1	The	the	DT	_	3	NMOD
2	transgenic	transgenic	JJ	_	3	NMOD
3	approach	approach	NN	_	13	SBJ
4	that	that	WDT	_	5	SBJ
5	was	be	VBD	_	3	NMOD
6	used	use	VBN	_	5	VC
7	to	to	TO	_	6	PRP
8	create	create	VB	_	7	IM
9	the	the	DT	_	12	NMOD
10	intermediate	intermediate	JJ	_	12	NMOD
11	MSUD	msud	NN	_	12	NMOD
12	model	model	NN	_	8	OBJ
13	was	be	VBD	_	0	ROOT
14	based	base	VBN	_	13	VC
15	on	on	IN	_	14	ADV
16	the	the	DT	_	21	NMOD
17	tetracycline	tetracycline	NN	_	18	AMOD
18	regulated	regulate	VBN	_	21	NMOD
19	gene	gene	NN	_	20	NMOD
20	switch	switch	NN	_	21	NMOD
21	system	system	NN	_	15	PMOD
22	that	that	WDT	_	23	SBJ
23	has	have	VBZ	_	21	NMOD
24	been	be	VBN	_	23	VC
25	used	use	VBN	_	24	VC
26	with	with	IN	_	25	ADV
27	great	great	JJ	_	28	NMOD
28	success	success	NN	_	26	PMOD
29	in	in	IN	_	25	ADV
30	other	other	JJ	_	31	NMOD
31	studies	study	NNS	_	29	PMOD
32	,	,	,	_	25	P
33	for	for	IN	_	25	ADV
34	example	example	NN	_	33	PMOD
35	[	[	-LRB-	_	36	P
36	34	0	CD	_	14	PRN
37	]	]	-RRB-	_	36	P
38	.	.	.	_	13	P

1	The	the	DT	_	2	NMOD
2	strategy	strategy	NN	_	6	SBJ
3	behind	behind	IN	_	2	NMOD
4	our	our	PRP$	_	5	NMOD
5	approach	approach	NN	_	3	PMOD
6	was	be	VBD	_	0	ROOT
7	to	to	TO	_	6	PRD
8	create	create	VB	_	7	IM
9	mice	mouse	NNS	_	8	OBJ
10	with	with	IN	_	9	NMOD
11	an	an	DT	_	14	NMOD
12	intermediate	intermediate	JJ	_	14	NMOD
13	MSUD	msud	NN	_	14	NMOD
14	phenotype	phenotype	NN	_	10	PMOD
15	that	that	WDT	_	16	SBJ
16	could	could	MD	_	14	NMOD
17	be	be	VB	_	16	VC
18	converted	convert	VBN	_	17	VC
19	to	to	IN	_	18	ADV
20	the	the	DT	_	22	NMOD
21	classic	classic	JJ	_	22	NMOD
22	phenotype	phenotype	NN	_	19	PMOD
23	at	at	IN	_	18	ADV
24	the	the	DT	_	25	NMOD
25	investigator	investigator	NN	_	27	NMOD
26	's	's	POS	_	25	NMOD
27	discretion	discretion	NN	_	23	PMOD
28	by	by	IN	_	18	MNR
29	turning	turn	VBG	_	28	PMOD
30	off	off	RP	_	29	PRT
31	the	the	DT	_	33	NMOD
32	rescuing	rescue	VBG	_	33	NMOD
33	transgene	transgene	NN	_	29	OBJ
34	.	.	.	_	6	P

1	However	however	RB	_	4	ADV
2	,	,	,	_	4	P
3	we	we	PRP	_	4	SBJ
4	were	be	VBD	_	0	ROOT
5	unable	unable	JJ	_	4	PRD
6	to	to	TO	_	5	AMOD
7	consistently	consistently	RB	_	6	ADV
8	turn	turn	VB	_	6	IM
9	off	off	RP	_	8	PRT
10	the	the	DT	_	14	NMOD
11	human	human	JJ	_	14	NMOD
12	E2	e0	NN	_	14	NMOD
13	expression	expression	NN	_	14	NMOD
14	cassette	cassette	NN	_	8	OBJ
15	by	by	IN	_	8	MNR
16	the	the	DT	_	19	NMOD
17	potent	potent	JJ	_	19	NMOD
18	tetracycline	tetracycline	NN	_	19	NMOD
19	analogue	analogue	NN	_	15	PMOD
20	,	,	,	_	19	P
21	doxycycline	doxycycline	NN	_	19	APPO
22	in	in	IN	_	8	LOC
23	either	either	DT	_	22	PMOD
24	of	of	IN	_	23	NMOD
25	the	the	DT	_	28	NMOD
26	two	two	CD	_	28	NMOD
27	transgenic	transgenic	JJ	_	28	NMOD
28	lines	line	NNS	_	24	PMOD
29	tested	test	VBN	_	28	NMOD
30	(	(	-LRB-	_	33	P
31	data	datum	NNS	_	33	SBJ
32	not	not	RB	_	33	ADV
33	shown	show	VBN	_	4	PRN
34	)	)	-RRB-	_	33	P
35	.	.	.	_	4	P

1	The	the	DT	_	2	NMOD
2	reason	reason	NN	_	10	SBJ
3	these	these	DT	_	5	NMOD
4	two	two	CD	_	5	NMOD
5	lines	line	NNS	_	6	SBJ
6	were	be	VBD	_	2	NMOD
7	unresponsive	unresponsive	JJ	_	6	PRD
8	to	to	IN	_	7	AMOD
9	doxycycline	doxycycline	NN	_	8	PMOD
10	is	be	VBZ	_	0	ROOT
11	unknown	unknown	JJ	_	10	PRD
12	.	.	.	_	10	P

1	It	it	PRP	_	2	SBJ
2	is	be	VBZ	_	0	ROOT
3	conceivable	conceivable	JJ	_	2	PRD
4	that	that	IN	_	2	OBJ
5	the	the	DT	_	7	NMOD
6	integration	integration	NN	_	7	NMOD
7	site	site	NN	_	11	SBJ
8	of	of	IN	_	7	NMOD
9	the	the	DT	_	10	NMOD
10	transgenes	transgene	NNS	_	8	PMOD
11	was	be	VBD	_	4	SUB
12	not	not	RB	_	11	ADV
13	permissive	permissive	JJ	_	11	PRD
14	for	for	IN	_	13	AMOD
15	regulated	regulate	VBN	_	16	NMOD
16	expression	expression	NN	_	14	PMOD
17	.	.	.	_	2	P

1	Screening	screening	NN	_	5	SBJ
2	of	of	IN	_	1	NMOD
3	additional	additional	JJ	_	4	NMOD
4	lines	line	NNS	_	2	PMOD
5	may	may	MD	_	0	ROOT
6	be	be	VB	_	5	VC
7	needed	need	VBN	_	6	VC
8	to	to	TO	_	7	PRP
9	find	find	VB	_	8	IM
10	lines	line	NNS	_	9	OBJ
11	that	that	WDT	_	12	SBJ
12	allow	allow	VBP	_	10	NMOD
13	for	for	IN	_	12	ADV
14	survival	survival	NN	_	13	PMOD
15	and	and	CC	_	12	COORD
16	can	can	MD	_	15	CONJ
17	also	also	RB	_	16	ADV
18	be	be	VB	_	16	VC
19	regulated	regulate	VBN	_	18	VC
20	.	.	.	_	5	P

1	The	the	DT	_	2	NMOD
2	models	model	NNS	_	7	SBJ
3	described	describe	VBN	_	2	NMOD
4	in	in	IN	_	3	ADV
5	this	this	DT	_	6	NMOD
6	communication	communication	NN	_	4	PMOD
7	are	be	VBP	_	0	ROOT
8	important	important	JJ	_	9	NMOD
9	advances	advance	NNS	_	7	PRD
10	over	over	IN	_	9	NMOD
11	the	the	DT	_	14	NMOD
12	previously	previously	RB	_	13	AMOD
13	described	describe	VBN	_	14	NMOD
14	models	model	NNS	_	10	PMOD
15	.	.	.	_	7	P

1	An	an	DT	_	3	NMOD
2	ENU	enu	NN	_	3	NMOD
3	mouse	mouse	NN	_	7	SBJ
4	resembling	resemble	VBG	_	3	NMOD
5	human	human	JJ	_	6	NMOD
6	MSUD	msud	NN	_	4	OBJ
7	was	be	VBD	_	0	ROOT
8	previously	previously	RB	_	7	TMP
9	created	create	VBN	_	7	VC
10	by	by	IN	_	9	MNR
11	disrupting	disrupt	VBG	_	10	PMOD
12	the	the	DT	_	15	NMOD
13	mitochondrial	mitochondrial	JJ	_	15	NMOD
14	BCAT	bcat	NN	_	15	NMOD
15	gene	gene	NN	_	11	OBJ
16	[	[	-LRB-	_	17	P
17	20	0	CD	_	9	PRN
18	]	]	-RRB-	_	17	P
19	.	.	.	_	7	P

1	The	the	DT	_	3	NMOD
2	BCKDH	bckdh	NN	_	3	NMOD
3	activity	activity	NN	_	12	SBJ
4	in	in	IN	_	3	LOC
5	the	the	DT	_	6	NMOD
6	liver	liver	NN	_	4	PMOD
7	and	and	CC	_	6	COORD
8	muscle	muscle	NN	_	7	CONJ
9	of	of	IN	_	6	NMOD
10	this	this	DT	_	11	NMOD
11	mouse	mouse	NN	_	9	PMOD
12	was	be	VBD	_	0	ROOT
13	normal	normal	JJ	_	12	PRD
14	even	even	RB	_	15	ADV
15	though	though	IN	_	12	ADV
16	the	the	DT	_	19	NMOD
17	blood	blood	NN	_	19	NMOD
18	BCAA	bcaa	NN	_	19	NMOD
19	levels	level	NNS	_	20	SBJ
20	were	be	VBD	_	15	SUB
21	markedly	markedly	RB	_	22	AMOD
22	elevated	elevated	JJ	_	20	PRD
23	.	.	.	_	12	P

1	While	while	IN	_	9	ADV
2	this	this	DT	_	3	SBJ
3	is	be	VBZ	_	1	SUB
4	an	an	DT	_	6	NMOD
5	interesting	interesting	JJ	_	6	NMOD
6	model	model	NN	_	3	PRD
7	,	,	,	_	9	P
8	it	it	PRP	_	9	SBJ
9	is	be	VBZ	_	0	ROOT
10	not	not	RB	_	9	ADV
11	a	a	DT	_	13	NMOD
12	true	true	JJ	_	13	NMOD
13	model	model	NN	_	9	PRD
14	of	of	IN	_	13	NMOD
15	MSUD	msud	NN	_	14	PMOD
16	because	because	IN	_	9	PRP
17	the	the	DT	_	18	NMOD
18	mutation	mutation	NN	_	19	SBJ
19	is	be	VBZ	_	16	SUB
20	not	not	RB	_	19	ADV
21	in	in	IN	_	19	PRD
22	BCKDH	bckdh	NN	_	21	PMOD
23	and	and	CC	_	19	COORD
24	the	the	DT	_	25	NMOD
25	levels	level	NNS	_	28	SBJ
26	of	of	IN	_	25	NMOD
27	BCKDH	bckdh	NN	_	26	PMOD
28	are	be	VBP	_	23	CONJ
29	normal	normal	JJ	_	28	PRD
30	.	.	.	_	9	P

1	Furthermore	furthermore	RB	_	7	ADV
2	,	,	,	_	7	P
3	no	no	DT	_	4	NMOD
4	case	case	NN	_	7	SBJ
5	of	of	IN	_	4	NMOD
6	MSUD	msud	NN	_	5	PMOD
7	has	have	VBZ	_	0	ROOT
8	been	be	VBN	_	7	VC
9	described	describe	VBN	_	8	VC
10	attributing	attribute	VBG	_	9	ADV
11	this	this	DT	_	12	NMOD
12	disease	disease	NN	_	10	OBJ
13	to	to	IN	_	10	ADV
14	BCAT	bcat	NN	_	15	NMOD
15	deficiency	deficiency	NN	_	13	PMOD
16	.	.	.	_	7	P

1	In	in	IN	_	13	ADV
2	addition	addition	NN	_	1	PMOD
3	to	to	IN	_	2	NMOD
4	this	this	DT	_	6	NMOD
5	mouse	mouse	NN	_	6	NMOD
6	model	model	NN	_	3	PMOD
7	,	,	,	_	13	P
8	a	a	DT	_	10	NMOD
9	cow	cow	NN	_	10	NMOD
10	model	model	NN	_	13	SBJ
11	of	of	IN	_	10	NMOD
12	MSUD	msud	NN	_	11	PMOD
13	has	have	VBZ	_	0	ROOT
14	also	also	RB	_	13	ADV
15	been	be	VBN	_	13	VC
16	previously	previously	RB	_	15	TMP
17	described	describe	VBN	_	15	VC
18	[	[	-LRB-	_	19	P
19	17	0	CD	_	17	PRN
20	-	-	SYM	_	21	P
21	19	0	CD	_	19	NMOD
22	]	]	-RRB-	_	19	P
23	.	.	.	_	13	P

1	However	however	RB	_	35	ADV
2	,	,	,	_	35	P
3	due	due	IN	_	35	PRP
4	to	to	IN	_	3	PMOD
5	practical	practical	JJ	_	6	NMOD
6	constraints	constraint	NNS	_	3	PMOD
7	imposed	impose	VBN	_	6	NMOD
8	by	by	IN	_	7	LGS
9	such	such	JJ	_	13	NMOD
10	a	a	DT	_	13	NMOD
11	large	large	JJ	_	13	NMOD
12	animal	animal	NN	_	13	NMOD
13	model	model	NN	_	8	PMOD
14	and	and	CC	_	3	COORD
15	due	due	IN	_	14	CONJ
16	to	to	IN	_	15	PMOD
17	the	the	DT	_	18	NMOD
18	observation	observation	NN	_	15	PMOD
19	of	of	IN	_	18	NMOD
20	differences	difference	NNS	_	19	PMOD
21	between	between	IN	_	20	NMOD
22	the	the	DT	_	25	NMOD
23	MSUD	msud	NN	_	25	NMOD
24	cow	cow	NN	_	25	NMOD
25	model	model	NN	_	21	PMOD
26	and	and	CC	_	25	COORD
27	MSUD	msud	NN	_	28	NMOD
28	humans	human	NNS	_	26	CONJ
29	[	[	-LRB-	_	30	P
30	1	0	CD	_	3	PRN
31	]	]	-RRB-	_	30	P
32	,	,	,	_	35	P
33	this	this	DT	_	34	NMOD
34	model	model	NN	_	35	SBJ
35	is	be	VBZ	_	0	ROOT
36	also	also	RB	_	35	ADV
37	of	of	IN	_	35	PRD
38	limited	limited	JJ	_	39	NMOD
39	utility	utility	NN	_	37	PMOD
40	.	.	.	_	35	P

1	In	in	IN	_	11	ADV
2	contrast	contrast	NN	_	1	PMOD
3	,	,	,	_	11	P
4	the	the	DT	_	6	NMOD
5	murine	murine	JJ	_	6	NMOD
6	models	model	NNS	_	11	SBJ
7	described	describe	VBN	_	6	NMOD
8	in	in	IN	_	7	ADV
9	this	this	DT	_	10	NMOD
10	report	report	NN	_	8	PMOD
11	are	be	VBP	_	0	ROOT
12	more	more	RBR	_	13	AMOD
13	valid	valid	JJ	_	11	PRD
14	and	and	CC	_	13	COORD
15	appropriate	appropriate	JJ	_	14	CONJ
16	for	for	IN	_	13	AMOD
17	modeling	model	VBG	_	19	NMOD
18	human	human	JJ	_	19	NMOD
19	MSUD	msud	NN	_	16	PMOD
20	.	.	.	_	11	P

1	The	the	DT	_	4	NMOD
2	most	most	RBS	_	3	AMOD
3	significant	significant	JJ	_	4	NMOD
4	opportunity	opportunity	NN	_	11	SBJ
5	presented	present	VBN	_	4	NMOD
6	by	by	IN	_	5	LGS
7	the	the	DT	_	10	NMOD
8	MSUD	msud	NN	_	10	NMOD
9	mouse	mouse	NN	_	10	NMOD
10	models	model	NNS	_	6	PMOD
11	is	be	VBZ	_	0	ROOT
12	to	to	TO	_	11	PRD
13	test	test	VB	_	12	IM
14	novel	novel	JJ	_	15	NMOD
15	treatments	treatment	NNS	_	13	OBJ
16	such	such	JJ	_	17	PMOD
17	as	as	IN	_	15	NMOD
18	gene	gene	NN	_	26	AMOD
19	[	[	-LRB-	_	20	P
20	38	0	CD	_	18	PRN
21	-	-	SYM	_	22	P
22	41	0	CD	_	20	NMOD
23	]	]	-RRB-	_	20	P
24	and	and	CC	_	18	COORD
25	cell	cell	NN	_	24	CONJ
26	based	base	VBN	_	27	NMOD
27	therapies	therapy	NNS	_	17	PMOD
28	(	(	-LRB-	_	31	P
29	e.g.	e.g.	FW	_	31	NMOD
30	,	,	,	_	31	P
31	hepatocytes	hepatocytes	NNS	_	27	PRN
32	[	[	-LRB-	_	35	P
33	42	0	CD	_	35	NMOD
34	,	,	,	_	35	P
35	43	0	CD	_	31	PRN
36	]	]	-RRB-	_	35	P
37	or	or	CC	_	31	COORD
38	embryonic	embryonic	JJ	_	40	NMOD
39	stem	stem	NN	_	40	NMOD
40	cells	cell	NNS	_	37	CONJ
41	[	[	-LRB-	_	42	P
42	44	0	CD	_	40	PRN
43	]	]	-RRB-	_	42	P
44	)	)	-RRB-	_	31	P
45	.	.	.	_	11	P

1	Relevant	relevant	JJ	_	13	ADV
2	to	to	IN	_	1	AMOD
3	gene	gene	NN	_	4	NMOD
4	therapy	therapy	NN	_	2	PMOD
5	,	,	,	_	13	P
6	recent	recent	JJ	_	7	NMOD
7	problems	problem	NNS	_	13	SBJ
8	with	with	IN	_	7	NMOD
9	gene	gene	NN	_	10	NMOD
10	therapy	therapy	NN	_	8	PMOD
11	in	in	IN	_	7	LOC
12	humans	human	NNS	_	11	PMOD
13	highlight	highlight	VBP	_	0	ROOT
14	the	the	DT	_	15	NMOD
15	importance	importance	NN	_	13	OBJ
16	and	and	CC	_	15	COORD
17	critical	critical	JJ	_	18	NMOD
18	need	need	NN	_	16	CONJ
19	of	of	IN	_	15	NMOD
20	animal	animal	NN	_	21	NMOD
21	models	model	NNS	_	19	PMOD
22	of	of	IN	_	21	NMOD
23	genetic	genetic	JJ	_	24	NMOD
24	diseases	disease	NNS	_	22	PMOD
25	for	for	IN	_	15	NMOD
26	preclinical	preclinical	JJ	_	27	NMOD
27	studies	study	NNS	_	25	PMOD
28	.	.	.	_	13	P

1	The	the	DT	_	2	NMOD
2	testing	testing	NN	_	14	SBJ
3	of	of	IN	_	2	NMOD
4	gene	gene	NN	_	7	AMOD
5	and	and	CC	_	4	COORD
6	cell	cell	NN	_	5	CONJ
7	based	base	VBN	_	8	NMOD
8	therapies	therapy	NNS	_	3	PMOD
9	on	on	IN	_	2	NMOD
10	appropriate	appropriate	JJ	_	13	NMOD
11	animal	animal	NN	_	13	NMOD
12	model	model	NN	_	13	NMOD
13	systems	system	NNS	_	9	PMOD
14	provides	provide	VBZ	_	0	ROOT
15	a	a	DT	_	17	NMOD
16	preliminary	preliminary	JJ	_	17	NMOD
17	method	method	NN	_	14	OBJ
18	of	of	IN	_	17	NMOD
19	establishing	establish	VBG	_	18	PMOD
20	not	not	RB	_	23	COORD
21	only	only	RB	_	20	ADV
22	the	the	DT	_	23	NMOD
23	efficacy	efficacy	NN	_	19	OBJ
24	,	,	,	_	23	P
25	but	but	CC	_	23	COORD
26	also	also	RB	_	25	ADV
27	short	short	JJ	_	32	NMOD
28	-	-	HYPH	_	27	P
29	and	and	CC	_	27	COORD
30	long	long	JJ	_	29	CONJ
31	-	-	HYPH	_	27	P
32	term	term	NN	_	33	NMOD
33	safety	safety	NN	_	25	CONJ
34	.	.	.	_	14	P

1	Success	success	NN	_	5	SBJ
2	with	with	IN	_	1	NMOD
3	animal	animal	NN	_	4	NMOD
4	studies	study	NNS	_	2	PMOD
5	is	be	VBZ	_	0	ROOT
6	expected	expect	VBN	_	5	VC
7	to	to	TO	_	6	OPRD
8	advance	advance	VB	_	7	IM
9	such	such	JJ	_	11	NMOD
10	therapeutic	therapeutic	JJ	_	11	NMOD
11	approaches	approach	NNS	_	8	OBJ
12	and	and	CC	_	5	COORD
13	could	could	MD	_	12	CONJ
14	pave	pave	VB	_	13	VC
15	the	the	DT	_	16	NMOD
16	way	way	NN	_	14	OBJ
17	for	for	IN	_	14	ADV
18	studies	study	NNS	_	17	PMOD
19	in	in	IN	_	18	LOC
20	humans	human	NNS	_	19	PMOD
21	.	.	.	_	5	P

1	In	in	IN	_	10	ADV
2	addition	addition	NN	_	1	PMOD
3	to	to	IN	_	2	NMOD
4	testing	test	VBG	_	3	PMOD
5	various	various	JJ	_	6	NMOD
6	treatments	treatment	NNS	_	4	OBJ
7	,	,	,	_	10	P
8	these	these	DT	_	9	NMOD
9	models	model	NNS	_	10	SBJ
10	should	should	MD	_	0	ROOT
11	also	also	RB	_	10	ADV
12	be	be	VB	_	10	VC
13	very	very	RB	_	14	AMOD
14	useful	useful	JJ	_	12	PRD
15	for	for	IN	_	14	AMOD
16	investigating	investigate	VBG	_	15	PMOD
17	the	the	DT	_	20	NMOD
18	underlying	underlie	VBG	_	20	NMOD
19	pathophysiologic	pathophysiologic	JJ	_	20	NMOD
20	consequences	consequence	NNS	_	16	OBJ
21	of	of	IN	_	20	NMOD
22	the	the	DT	_	23	NMOD
23	disease	disease	NN	_	21	PMOD
24	.	.	.	_	10	P

1	Such	such	JJ	_	2	NMOD
2	studies	study	NNS	_	3	SBJ
3	are	be	VBP	_	0	ROOT
4	very	very	RB	_	5	AMOD
5	difficult	difficult	JJ	_	7	AMOD
6	/	/	HYPH	_	5	P
7	impossible	impossible	JJ	_	3	PRD
8	to	to	TO	_	7	AMOD
9	do	do	VB	_	8	IM
10	in	in	IN	_	9	LOC
11	human	human	JJ	_	12	NMOD
12	patients	patient	NNS	_	10	PMOD
13	for	for	IN	_	9	PRP
14	obvious	obvious	JJ	_	16	NMOD
15	ethical	ethical	JJ	_	16	NMOD
16	reasons	reason	NNS	_	13	PMOD
17	,	,	,	_	3	P
18	and	and	CC	_	3	COORD
19	often	often	RB	_	20	TMP
20	must	must	MD	_	18	CONJ
21	rely	rely	VB	_	20	VC
22	on	on	IN	_	21	ADV
23	autopsy	autopsy	NN	_	24	NMOD
24	tissue	tissue	NN	_	22	PMOD
25	.	.	.	_	3	P

1	Additionally	additionally	RB	_	7	ADV
2	,	,	,	_	7	P
3	the	the	DT	_	6	NMOD
4	intermediate	intermediate	JJ	_	6	NMOD
5	MSUD	msud	NN	_	6	NMOD
6	model	model	NN	_	7	SBJ
7	may	may	MD	_	0	ROOT
8	also	also	RB	_	7	ADV
9	be	be	VB	_	7	VC
10	useful	useful	JJ	_	9	PRD
11	for	for	IN	_	10	AMOD
12	studies	study	NNS	_	11	PMOD
13	to	to	TO	_	12	NMOD
14	test	test	VB	_	13	IM
15	the	the	DT	_	16	NMOD
16	effect	effect	NN	_	14	OBJ
17	of	of	IN	_	16	NMOD
18	thiamin	thiamin	NN	_	17	PMOD
19	.	.	.	_	7	P

1	A	a	DT	_	5	NMOD
2	thiamin	thiamin	NN	_	4	AMOD
3	-	-	HYPH	_	2	P
4	responsive	responsive	JJ	_	5	NMOD
5	form	form	NN	_	8	SBJ
6	of	of	IN	_	5	NMOD
7	MSUD	msud	NN	_	6	PMOD
8	has	have	VBZ	_	0	ROOT
9	been	be	VBN	_	8	VC
10	described	describe	VBN	_	9	VC
11	[	[	-LRB-	_	12	P
12	1	0	CD	_	10	PRN
13	]	]	-RRB-	_	12	P
14	.	.	.	_	8	P

1	The	the	DT	_	2	NMOD
2	phenotype	phenotype	NN	_	6	SBJ
3	of	of	IN	_	2	NMOD
4	these	these	DT	_	5	NMOD
5	patients	patient	NNS	_	3	PMOD
6	is	be	VBZ	_	0	ROOT
7	heterogeneous	heterogeneous	JJ	_	6	PRD
8	and	and	CC	_	6	COORD
9	treatment	treatment	NN	_	17	SBJ
10	with	with	IN	_	9	NMOD
11	a	a	DT	_	13	NMOD
12	wide	wide	JJ	_	13	NMOD
13	range	range	NN	_	10	PMOD
14	of	of	IN	_	13	NMOD
15	thiamin	thiamin	NN	_	16	NMOD
16	doses	dose	NNS	_	14	PMOD
17	has	have	VBZ	_	8	CONJ
18	produced	produce	VBN	_	17	VC
19	limited	limited	JJ	_	20	NMOD
20	success	success	NN	_	18	OBJ
21	[	[	-LRB-	_	22	P
22	1	0	CD	_	18	PRN
23	]	]	-RRB-	_	22	P
24	.	.	.	_	6	P

1	Recent	recent	JJ	_	4	NMOD
2	cell	cell	NN	_	3	NMOD
3	culture	culture	NN	_	4	NMOD
4	studies	study	NNS	_	8	SBJ
5	with	with	IN	_	4	NMOD
6	MSUD	msud	NN	_	7	NMOD
7	cells	cell	NNS	_	5	PMOD
8	have	have	VBP	_	0	ROOT
9	suggested	suggest	VBN	_	8	VC
10	that	that	IN	_	9	OBJ
11	the	the	DT	_	15	NMOD
12	thiamin	thiamin	NN	_	14	AMOD
13	-	-	HYPH	_	12	P
14	responsive	responsive	JJ	_	15	NMOD
15	phenotype	phenotype	NN	_	16	SBJ
16	is	be	VBZ	_	10	SUB
17	dependent	dependent	JJ	_	16	PRD
18	upon	upon	IN	_	17	AMOD
19	the	the	DT	_	20	NMOD
20	presence	presence	NN	_	18	PMOD
21	of	of	IN	_	20	NMOD
22	at	at	RB	_	23	QMOD
23	least	least	RBS	_	27	NMOD
24	one	one	CD	_	23	QMOD
25	E2	e0	NN	_	26	AMOD
26	expressing	express	VBG	_	27	NMOD
27	allele	allele	NN	_	21	PMOD
28	[	[	-LRB-	_	31	P
29	45	0	CD	_	31	NMOD
30	,	,	,	_	31	P
31	46	0	CD	_	9	PRN
32	]	]	-RRB-	_	31	P
33	.	.	.	_	8	P

1	In	in	IN	_	12	ADV
2	light	light	NN	_	1	PMOD
3	of	of	IN	_	2	NMOD
4	these	these	DT	_	6	NMOD
5	newer	new	JJR	_	6	NMOD
6	findings	finding	NNS	_	3	PMOD
7	,	,	,	_	12	P
8	our	our	PRP$	_	11	NMOD
9	intermediate	intermediate	JJ	_	11	NMOD
10	MSUD	msud	NN	_	11	NMOD
11	mouse	mouse	NN	_	12	SBJ
12	provides	provide	VBZ	_	0	ROOT
13	a	a	DT	_	14	NMOD
14	model	model	NN	_	12	OBJ
15	to	to	TO	_	14	NMOD
16	test	test	VB	_	15	IM
17	the	the	DT	_	18	NMOD
18	effect	effect	NN	_	16	OBJ
19	of	of	IN	_	18	NMOD
20	thiamin	thiamin	NN	_	19	PMOD
21	with	with	IN	_	16	ADV
22	respect	respect	NN	_	21	PMOD
23	to	to	IN	_	22	NMOD
24	BCKDH	bckdh	NN	_	25	NMOD
25	activity	activity	NN	_	23	PMOD
26	and	and	CC	_	25	COORD
27	blood	blood	NN	_	30	NMOD
28	amino	amino	NN	_	29	NMOD
29	acid	acid	NN	_	30	NMOD
30	levels	level	NNS	_	26	CONJ
31	at	at	IN	_	16	ADV
32	the	the	DT	_	33	NMOD
33	level	level	NN	_	31	PMOD
34	of	of	IN	_	33	NMOD
35	the	the	DT	_	37	NMOD
36	whole	whole	JJ	_	37	NMOD
37	animal	animal	NN	_	34	PMOD
38	.	.	.	_	12	P

1	Because	because	IN	_	25	PRP
2	of	of	IN	_	1	PMOD
3	recent	recent	JJ	_	4	NMOD
4	interest	interest	NN	_	1	PMOD
5	in	in	IN	_	4	NMOD
6	structural	structural	JJ	_	7	NMOD
7	analysis	analysis	NN	_	5	PMOD
8	of	of	IN	_	7	NMOD
9	multienzyme	multienzyme	NN	_	10	NMOD
10	complexes	complex	NNS	_	8	PMOD
11	[	[	-LRB-	_	18	P
12	35	0	CD	_	18	NMOD
13	,	,	,	_	18	P
14	36	0	CD	_	18	NMOD
15	,	,	,	_	18	P
16	45	0	CD	_	18	NMOD
17	,	,	,	_	18	P
18	46	0	CD	_	1	PRN
19	]	]	-RRB-	_	18	P
20	,	,	,	_	25	P
21	the	the	DT	_	24	NMOD
22	intermediate	intermediate	JJ	_	24	NMOD
23	MSUD	msud	NN	_	24	NMOD
24	model	model	NN	_	25	SBJ
25	may	may	MD	_	0	ROOT
26	provide	provide	VB	_	25	VC
27	a	a	DT	_	29	NMOD
28	valuable	valuable	JJ	_	29	NMOD
29	resource	resource	NN	_	26	OBJ
30	for	for	IN	_	29	NMOD
31	studies	study	NNS	_	30	PMOD
32	of	of	IN	_	31	NMOD
33	structural	structural	JJ	_	34	NMOD
34	biology	biology	NN	_	32	PMOD
35	.	.	.	_	25	P

1	Lastly	lastly	RB	_	16	ADV
2	,	,	,	_	16	P
3	the	the	DT	_	4	NMOD
4	information	information	NN	_	16	SBJ
5	and	and	CC	_	4	COORD
6	knowledge	knowledge	NN	_	5	CONJ
7	gained	gain	VBN	_	4	NMOD
8	from	from	IN	_	7	ADV
9	studies	study	NNS	_	8	PMOD
10	with	with	IN	_	9	NMOD
11	the	the	DT	_	13	NMOD
12	MSUD	msud	NN	_	13	NMOD
13	models	model	NNS	_	10	PMOD
14	described	describe	VBN	_	13	NMOD
15	here	here	RB	_	14	ADV
16	will	will	MD	_	0	ROOT
17	also	also	RB	_	16	ADV
18	be	be	VB	_	16	VC
19	applicable	applicable	JJ	_	18	PRD
20	and	and	CC	_	19	COORD
21	transferable	transferable	JJ	_	20	CONJ
22	to	to	IN	_	19	AMOD
23	other	other	JJ	_	25	NMOD
24	mitochondrial	mitochondrial	JJ	_	25	NMOD
25	disorders	disorder	NNS	_	22	PMOD
26	due	due	IN	_	18	PRP
27	to	to	IN	_	26	PMOD
28	defects	defect	NNS	_	26	PMOD
29	in	in	IN	_	28	LOC
30	multisubunit	multisubunit	JJ	_	31	NMOD
31	enzymes	enzyme	NNS	_	29	PMOD
32	.	.	.	_	16	P

1	Conclusion	conclusion	NN	_	0	ROOT

1	In	in	IN	_	6	ADV
2	summary	summary	NN	_	1	PMOD
3	,	,	,	_	6	P
4	this	this	DT	_	5	NMOD
5	report	report	NN	_	6	SBJ
6	describes	describe	VBZ	_	0	ROOT
7	the	the	DT	_	8	NMOD
8	development	development	NN	_	6	OBJ
9	and	and	CC	_	8	COORD
10	characterization	characterization	NN	_	9	CONJ
11	of	of	IN	_	8	NMOD
12	genetically	genetically	RB	_	13	AMOD
13	engineered	engineer	VBN	_	15	NMOD
14	mouse	mouse	NN	_	15	NMOD
15	models	model	NNS	_	11	PMOD
16	of	of	IN	_	15	NMOD
17	classic	classic	JJ	_	22	NMOD
18	as	as	RB	_	20	ADV
19	well	well	RB	_	20	ADV
20	as	as	IN	_	17	COORD
21	intermediate	intermediate	JJ	_	20	CONJ
22	MSUD	msud	NN	_	16	PMOD
23	.	.	.	_	6	P

1	These	these	DT	_	2	NMOD
2	animals	animal	NNS	_	3	SBJ
3	provide	provide	VBP	_	0	ROOT
4	useful	useful	JJ	_	5	NMOD
5	models	model	NNS	_	3	OBJ
6	to	to	TO	_	5	NMOD
7	further	far	RB	_	6	ADV
8	characterize	characterize	VB	_	6	IM
9	the	the	DT	_	10	NMOD
10	pathogenesis	pathogenesis	NN	_	8	OBJ
11	of	of	IN	_	10	NMOD
12	MSUD	msud	NN	_	11	PMOD
13	,	,	,	_	5	P
14	as	as	RB	_	16	ADV
15	well	well	RB	_	16	ADV
16	as	as	IN	_	5	COORD
17	models	model	NNS	_	16	CONJ
18	to	to	TO	_	17	NMOD
19	test	test	VB	_	18	IM
20	novel	novel	JJ	_	22	NMOD
21	therapeutic	therapeutic	JJ	_	22	NMOD
22	strategies	strategy	NNS	_	19	OBJ
23	,	,	,	_	22	P
24	such	such	JJ	_	25	PMOD
25	as	as	IN	_	22	NMOD
26	gene	gene	NN	_	29	NMOD
27	and	and	CC	_	26	COORD
28	cellular	cellular	JJ	_	27	CONJ
29	therapies	therapy	NNS	_	25	PMOD
30	,	,	,	_	19	P
31	to	to	TO	_	19	PRP
32	treat	treat	VB	_	31	IM
33	this	this	DT	_	36	NMOD
34	devastating	devastate	VBG	_	36	NMOD
35	metabolic	metabolic	JJ	_	36	NMOD
36	disease	disease	NN	_	32	OBJ
37	.	.	.	_	3	P

1	Abbreviations	abbreviation	NNS	_	0	ROOT

1	The	the	DT	_	2	NMOD
2	abbreviations	abbreviation	NNS	_	4	SBJ
3	used	use	VBN	_	2	NMOD
4	are	be	VBP	_	0	ROOT
5	:	:	:	_	4	P
6	MSUD	msud	NN	_	56	NMOD
7	,	,	,	_	6	P
8	Maple	maple	JJ	_	9	NMOD
9	Syrup	syrup	NN	_	11	NMOD
10	Urine	urine	NN	_	11	NMOD
11	Disease	disease	NN	_	6	APPO
12	;	;	:	_	56	P
13	BCKDH	bckdh	NN	_	56	NMOD
14	,	,	,	_	13	P
15	branched	branch	VBN	_	16	NMOD
16	chain	chain	NN	_	18	NMOD
17	ketoacid	ketoacid	NN	_	18	NMOD
18	dehydrogenase	dehydrogenase	NN	_	13	APPO
19	;	;	:	_	56	P
20	BCAA	bcaa	NN	_	56	NMOD
21	,	,	,	_	20	P
22	branched	branch	VBN	_	23	NMOD
23	chain	chain	NN	_	25	NMOD
24	amino	amino	NN	_	25	NMOD
25	acids	acid	NNS	_	20	APPO
26	;	;	:	_	56	P
27	ENU	enu	NN	_	56	NMOD
28	,	,	,	_	27	P
29	N	n	NN	_	31	NMOD
30	-	-	HYPH	_	29	P
31	ethyl	ethyl	NN	_	35	NMOD
32	-	-	HYPH	_	31	P
33	N	n	NN	_	35	NMOD
34	-	-	HYPH	_	33	P
35	nitrosourea	nitrosourea	NN	_	27	APPO
36	;	;	:	_	56	P
37	BCAT	bcat	NN	_	56	NMOD
38	,	,	,	_	37	P
39	branched	branch	VBN	_	40	NMOD
40	chain	chain	NN	_	41	NMOD
41	aminotransferase	aminotransferase	NN	_	37	APPO
42	;	;	:	_	56	P
43	ES	e	NN	_	44	NMOD
44	cell	cell	NN	_	56	NMOD
45	,	,	,	_	44	P
46	embryonic	embryonic	JJ	_	48	NMOD
47	stem	stem	NN	_	48	NMOD
48	cell	cell	NN	_	44	APPO
49	;	;	:	_	56	P
50	TRE	tre	NN	_	56	NMOD
51	,	,	,	_	50	P
52	tetracycline	tetracycline	NN	_	54	NMOD
53	responsive	responsive	JJ	_	54	NMOD
54	element	element	NN	_	50	APPO
55	;	;	:	_	56	P
56	MEF	mef	NN	_	4	PRD
57	,	,	,	_	56	P
58	mouse	mouse	NN	_	60	NMOD
59	embryonic	embryonic	JJ	_	60	NMOD
60	fibroblast	fibroblast	NN	_	56	APPO
61	.	.	.	_	4	P

1	Competing	compete	VBG	_	2	NMOD
2	interests	interest	NNS	_	0	ROOT

1	The	the	DT	_	2	NMOD
2	author	author	NN	_	6	SBJ
3	(	(	-LRB-	_	2	P
4	s	s	AFX	_	2	NMOD
5	)	)	-RRB-	_	6	P
6	declare	declare	VBP	_	0	ROOT
7	that	that	IN	_	6	OBJ
8	they	they	PRP	_	9	SBJ
9	have	have	VBP	_	7	SUB
10	no	no	DT	_	12	NMOD
11	competing	compete	VBG	_	12	NMOD
12	interests	interest	NNS	_	9	OBJ
13	.	.	.	_	6	P

1	Authors	author	NNS	_	3	NMOD
2	'	'	POS	_	1	NMOD
3	contributions	contribution	NNS	_	0	ROOT

1	GEH	geh	NNP	_	2	SBJ
2	designed	design	VBD	_	0	ROOT
3	and	and	CC	_	2	COORD
4	produced	produce	VBD	_	3	CONJ
5	the	the	DT	_	7	NMOD
6	mouse	mouse	NN	_	7	NMOD
7	models	model	NNS	_	2	OBJ
8	,	,	,	_	2	P
9	coordinated	coordinate	VBN	_	2	CONJ
10	experiments	experiment	NNS	_	9	OBJ
11	,	,	,	_	9	P
12	interpreted	interpret	VBN	_	9	CONJ
13	data	datum	NNS	_	12	OBJ
14	,	,	,	_	12	P
15	and	and	CC	_	12	COORD
16	helped	help	VBN	_	15	CONJ
17	draft	draft	VB	_	16	VC
18	the	the	DT	_	19	NMOD
19	manuscript	manuscript	NN	_	17	OBJ
20	.	.	.	_	2	P

1	KS	k	NNP	_	2	SBJ
2	conducted	conduct	VBD	_	0	ROOT
3	much	much	JJ	_	2	OBJ
4	of	of	IN	_	3	NMOD
5	the	the	DT	_	6	NMOD
6	characterization	characterization	NN	_	4	PMOD
7	of	of	IN	_	6	NMOD
8	the	the	DT	_	11	NMOD
9	intermediate	intermediate	JJ	_	11	NMOD
10	MSUD	msud	NN	_	11	NMOD
11	model	model	NN	_	7	PMOD
12	.	.	.	_	2	P

1	CF	cf	NNP	_	2	SBJ
2	assisted	assist	VBD	_	0	ROOT
3	with	with	IN	_	2	ADV
4	production	production	NN	_	3	PMOD
5	of	of	IN	_	4	NMOD
6	the	the	DT	_	8	NMOD
7	mouse	mouse	NN	_	8	NMOD
8	models	model	NNS	_	5	PMOD
9	,	,	,	_	4	P
10	data	datum	NNS	_	11	NMOD
11	collection	collection	NN	_	4	CONJ
12	,	,	,	_	11	P
13	analysis	analysis	NN	_	11	CONJ
14	,	,	,	_	13	P
15	and	and	CC	_	13	COORD
16	interpretation	interpretation	NN	_	15	CONJ
17	.	.	.	_	2	P

1	SW	sw	NNP	_	2	SBJ
2	directed	direct	VBD	_	0	ROOT
3	the	the	DT	_	5	NMOD
4	immunohistochemistry	immunohistochemistry	NN	_	5	NMOD
5	experiments	experiment	NNS	_	2	OBJ
6	.	.	.	_	2	P

1	HSP	hsp	NNP	_	2	SBJ
2	conceived	conceive	VBD	_	0	ROOT
3	of	of	IN	_	2	ADV
4	the	the	DT	_	6	NMOD
5	knockout	knockout	NN	_	6	NMOD
6	model	model	NN	_	3	PMOD
7	,	,	,	_	2	P
8	interpreted	interpret	VBN	_	2	CONJ
9	data	datum	NNS	_	8	OBJ
10	and	and	CC	_	8	COORD
11	drafted	draft	VBD	_	10	CONJ
12	the	the	DT	_	13	NMOD
13	manuscript	manuscript	NN	_	11	OBJ
14	.	.	.	_	2	P

1	All	all	DT	_	2	NMOD
2	authors	author	NNS	_	3	SBJ
3	contributed	contribute	VBD	_	0	ROOT
4	to	to	IN	_	3	ADV
5	composing	compose	VBG	_	4	PMOD
6	and	and	CC	_	5	COORD
7	editing	edit	VBG	_	6	CONJ
8	the	the	DT	_	9	NMOD
9	manuscript	manuscript	NN	_	5	OBJ
10	and	and	CC	_	3	COORD
11	have	have	VBP	_	10	CONJ
12	read	read	VBN	_	11	VC
13	and	and	CC	_	12	COORD
14	approved	approve	VBN	_	13	CONJ
15	the	the	DT	_	17	NMOD
16	final	final	JJ	_	17	NMOD
17	version	version	NN	_	12	OBJ
18	.	.	.	_	3	P

1	Pre-publication	pre-publication	NN	_	2	NMOD
2	history	history	NN	_	0	ROOT

1	The	the	DT	_	3	NMOD
2	pre-publication	pre-publication	JJ	_	3	NMOD
3	history	history	NN	_	7	SBJ
4	for	for	IN	_	3	NMOD
5	this	this	DT	_	6	NMOD
6	paper	paper	NN	_	4	PMOD
7	can	can	MD	_	0	ROOT
8	be	be	VB	_	7	VC
9	accessed	access	VBN	_	8	VC
10	here	here	RB	_	9	ADV
11	:	:	:	_	7	P

1	Acknowledgements	acknowledgement	NNS	_	0	ROOT

1	The	the	DT	_	2	NMOD
2	authors	author	NNS	_	3	SBJ
3	would	would	MD	_	0	ROOT
4	like	like	VB	_	3	VC
5	to	to	TO	_	4	OPRD
6	thank	thank	VB	_	5	IM
7	Frank	frank	NNP	_	8	NMOD
8	Kist	kist	NNP	_	6	OBJ
9	,	,	,	_	8	P
10	Jodi	jodi	NNP	_	11	NMOD
11	Dagget	dagget	NNP	_	8	CONJ
12	,	,	,	_	11	P
13	Edward	edward	NNP	_	14	NMOD
14	Mallick	mallick	NNP	_	11	CONJ
15	,	,	,	_	14	P
16	Brian	brian	NNP	_	17	NMOD
17	Sloat	sloat	NNP	_	14	CONJ
18	,	,	,	_	17	P
19	and	and	CC	_	17	COORD
20	Judith	judith	NNP	_	21	NMOD
21	Rodda	rodda	NNP	_	19	CONJ
22	for	for	IN	_	6	PRP
23	expert	expert	NN	_	25	NMOD
24	technical	technical	JJ	_	25	NMOD
25	assistance	assistance	NN	_	22	PMOD
26	,	,	,	_	6	P
27	and	and	CC	_	6	COORD
28	Dr.	dr.	NNP	_	30	NMOD
29	Susan	susan	NNP	_	30	NMOD
30	Hutson	hutson	NNP	_	27	GAP
31	for	for	IN	_	30	PRP
32	the	the	DT	_	33	NMOD
33	gift	gift	NN	_	31	PMOD
34	of	of	IN	_	33	NMOD
35	E2	e0	NN	_	36	NMOD
36	antiserum	antiserum	NN	_	34	PMOD
37	.	.	.	_	3	P

1	This	this	DT	_	2	NMOD
2	work	work	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	supported	support	VBN	_	3	VC
5	by	by	IN	_	4	LGS
6	National	national	NNP	_	7	NMOD
7	Institutes	institute	NNPS	_	17	NMOD
8	of	of	IN	_	7	NMOD
9	Health	health	NNP	_	8	PMOD
10	Grants	grant	NNPS	_	17	NMOD
11	DK51960	dk0	NN	_	17	NMOD
12	,	,	,	_	17	P
13	DK57386	dk0	NN	_	17	NMOD
14	,	,	,	_	17	P
15	DK57956	dk0	NN	_	17	NMOD
16	,	,	,	_	17	P
17	AA10422	aa0	NN	_	5	PMOD
18	,	,	,	_	17	P
19	the	the	DT	_	25	NMOD
20	Scott	scott	NNP	_	22	NMOD
21	C.	c.	NNP	_	22	NMOD
22	Foster	foster	NNP	_	25	NMOD
23	Metabolic	metabolic	NNP	_	24	NMOD
24	Disease	disease	NNP	_	25	NMOD
25	Fund	fund	NNP	_	17	CONJ
26	,	,	,	_	25	P
27	and	and	CC	_	25	COORD
28	the	the	DT	_	32	NMOD
29	MSUD	msud	NNP	_	32	NMOD
30	Family	family	NNP	_	31	NMOD
31	Support	support	NNP	_	32	NMOD
32	Group	group	NNP	_	27	CONJ
33	.	.	.	_	3	P

